var title_f3_42_3744="Demand pulsed oxygen delivery";
var content_f3_42_3744=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F69597&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F69597&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Demand pulsed oxygen delivery",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 417px; height: 269px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The demand module is interposed between the pressurized oxygen source and the patient. As the patient inhales, inspiratory airflow is detected by pressure changes in the nasal cannula. A solenoid in the module is rapidly opened and closed, enabling a pulse of oxygen to be delivered at the beginning of inhalation.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Tiep BL. Electronic pulse oxygen. In: Portable Oxygen Therapy: Including Oxygen Conserving Methodology, Tiep BL (Ed), Futura Publishing, Mt Kisco, New York, 1991.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_42_3744=[""].join("\n");
var outline_f3_42_3744=null;
var title_f3_42_3745="Ultrasound of first extensor compartment wrist";
var content_f3_42_3745=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F85861&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F85861&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 610px\">",
"   <div class=\"ttl\">",
"    Ultrasound of the first extensor compartment of the wrist",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 590px; height: 260px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAEEAk4DASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwDvo/DFo67p2GfrT/8AhFNMxy7H/gVcympamWKvIAuehpst/eI24ztn2oA6d/CVqBmAkfjVG90J4ozsbBHrWUvia6iXDTtx7VBc+K55QU2FvegCKewuVJ3FSPrVb+zwTzIVaq11eT3H3pCi+gNUirg5V5G/GgDVfTYurXDk/Wq0y2kA/eTMT6bqrGcbSHlYH0NRLHbs253U/wC9QBIbyEHMO/HuaRtVY8CENTnEJXEbqo+lNRRFyGDe2KAIpNVeP7kDA1GNTv5TlHZB7mrqRlvmYcemM0+K0DtltzD0xQBVWXUJFyZSw9M0zfcJkszp75NbS6cCuY9yGo2tTn9/l19qAMxJpDyJXb1606e7lCfIXP1rQ+yxgZibYPTFSRqDwQD7kUAc60twzZ2tn6mnp5zHM28D0zXQPbZXJwB7VXEajJ3Kw9DQBQjUsPlO0D1qZXkQYRi341YUK7EZCiniBmOFxt9qAKqys5+ZsH2NPAlxw+fY1fh05c5dMe9WFtY843MfbFAGN5FzKfvN+dSLpk7D77A+oatk2xPyotAs7gcKAo9c0AYElrcQnDXL1E0k0XPns2O1dEbTn99IKik0+Hlt+4fSgDDgumlbEhYCrXmDHyNJ+Zq/9ljYYUbfwpVeGH5GI/KgDKIkckF2A+tSx2wxgs271q/ILZ+jZP8As0LDMeIUG31brQBRbT5h8xnYr6VC77DhNxNbMcMwz5mDUElr5hyG2H0xQBn+XLIvzhsfWqU9q4OYmf8AFq0ZrSZG+eRivtTVRW4ZGx60AZRa5T7rufpT11i4hG1kYn61q+Si/cb5fSqs1vADncVP0oApnULyU7vmVfrVmLWEiwJA7H607fbhCgyx96pyW7OSVRQPWgDch11QmYkkDfWpB4lvwPl5X/aNYH+qUKNu73NIJHYkSA49qAOusvFd0w8skZ7nNbVrqiOgafO415i2RJ8jlfetGzvZo8K0wYe9AHZ6hLHcn90c/jWeJ7i1bMGePWsdrx8/eXNRyTXzH91KXHoKAOut/EhjTF3b5PqKh1DWoLtNkdpgHuRXLSzaioAMJ+ppYrqdvlmwtAF2bB/1WCT2JqsIZScNhQanhWJWBaQZpl1aiY7o7j8KAGtYsFJVw2fU1l3Gl3MjnyX59mqyEjRtsszfgav2zW9vhgzUAc8dG1FTlxI6+xqOSxdOsMoP412w1lNu2OIt7kVatpEuFJmVQD7UAeX3E8tuxBikaq/9pSBuI5B7GvVhb2rSkOqlfcVJJo2kTjLjb9AKAPK1u53OVicipllnb/l3kJxXoF14dsypNq+2suTR5kDGKbkA9RQB89AvuPzt1PenqX/vN+dPEeHbp94/zqVI/wAq9aMDichi7/77fnTxv/vt+dSiPipBHxyK0VMjmIMvzhm/Ot7wYzrrSZdsFSOprKEftW34RIj161JHBJB/KscVD9zL0NsNL97H1PY9H3YCMeGGcit2zD5SIM25gT16VjaLhpuV4HAA710OmrtuNxOX3cfSvk5s+ohsRyJIBy5y77eOhHrVPgQlBuZ1DLuz0NaV6pDRtnI8xicDgYrJnDBphHwuCwB71g2bQMu4aSMKzMQ5HzDPArivEMkqFsbsKx6N612epsX2uBj5QD9K4XxZKFtp9v3imAPU1rSV5IwrOyZ5temR7ty7OGySeevNV2L/AN9vzqaOMtlmbdxilZOK+sw9Llpq58vVnebKbF/77fnUTNJn77fnVtkqB19qqUCVIg3P/fb86fbbzIcu/TsxpGWprQfvT/u1zygaqR9GX9/JHIwUqwB61CryTLu8049qzZJCC22Els/xGljmdeX+Qe1cZ0FqVlXlpGJ+lEJWQfICxHtUcMzTHjYwHrW9p0tvHGd8Koe+KAMqCObzCDAT+FXDZzHBETD14rUTUrNGILAf71a+l6jpzsBJcRgelAHLwaWksmXXn3FX20SzKnKqD7V2M40po9wni/AisqQaeGzHIjD0zQBzC6fZxybWGR9K1bPTLJ48pGD9anuoI5BmMRp75ql5qW44uPyoAsNpxQ4jiRV96kit/K6CMGsyTWIc4ebcPQGp4Lq0nHLFB6k0AXpNrDa7ID7U2PSvPOU496EfTY0y9wrN7mqt3rqxKRbuOOm2gDVTSo4wBMit71LJZW2wALGB9a5Q3t5egnz5QPSmLFdZyZXHuTQB0kltbKNrINp9Kry2Omqn+q5Pc1kr9qUZaU7R3NVLzVreJcTXS7hQBtx2VgnOFx7moJ7rTbZsYBI9K4bUfEHmMUgcketU7eaWeXBdhmgD0D+1LaUbYxke9VrjUoouQ4X2FYEFrJGmQT9a0NPitHO2bcze4oAlm1jdzExz7UseqyMMNvq9Hb2qn93Ao92qtqMkkSHy4IyPUUAVDeEsSXYfWplup2TEbA1lGa6nbbs2A9wKbHZXRkxHI9AF2VrkHMk2we1PgRpBzKGHqang0qXbuupC2O2amEVpbfMx/A0ARLaMp3RyjPpRK94owoGPUGny6paquBCv4VTNwZ3PlkoPrQBK99PEh3qWI71R/wCEhZXw0YappIC+VMx+lYuq2EkK7oyTQB0cWswzAZOw+hFXPNRxwVOfavOYbi4DbT0962bG8eNh+/IPoaAOoltZpEJAUL7VjXDSQOVZNw96e2p3JXbxg9xUtvvfmQK2aAK8UckrAhAq+9XhACuGP4Co5hLggbFFRxpIpyjj86AK1zaQiTkPSQwlH4J2e9XGDAbpGBI7VSkZZGJORj0oAnuI0Zc5CgVRMsW8jcCR7U4qzgrDux/tVXMDxk7wF96ALEMru+FUNVk3MtsmY2VW9KpwW0so3RHB9jV6CwBAM3LehNAEJ1fUZ/lVcj2FOhR5nzcuVPoRiujsGjs4wPLU/QVdMdvermWNc9sCgDng1rbqCTk/nSoUuDhRtB71p3+hEQl448L9axrECK4KEfMD0NAGi+ho8QcTYaqTafPCQQwkA7A1rsJ5kClAq+oNSWtvDBzIXI9aAOdub1ol2lDG30rLl1adGH79j7Cut1aGxkTKBmeuUvbdk58naPUigCzb+ImXAILt6mp21yZz/cFc0SzyFYlBb2FI7XELfOrH8OKAOnPiOWMYjUE/Wli1y9uM/wCrUehrlRM+MtGKfEFbJaRl9hQB56sXzNx3P86lWKp0Tn8anVPQV9ConlORXWL2p6xjPvVxY+mAMU4RYI6Yq7CuVViPatDQkKatauOgf+lBiwo2g/XpVzSoyuoWoJOBIOKwxKvSl6M1oO1SPqj17w1l1QkfOxGBW/bptZplG5kYk49BxXP+FlDFImB2xJkn1Oa6RF8q3yM4b+IDtjvXw9R6n2FPYbIRLYFlIVo8t+f/ANasK8cm4VRkHaucVvwQlrecDAHytjHbHSsW5jC3kuew59+e1ZGy0MXWyEUkH0wMdOa8w8Z3RERQ53udo55Bzz+leia9MDFKBnOdykdq8r8UOZrmBP4ud3513YOHPNI4MbLlgzGSPZEo68ZqNxV6RcDAHAqs619ly2Vj5W92VXWoHWrbrUDrWUolJlRhxT7QfvT/ALtOdfrS2w/en6VhKJrFnu1xZPHuaR269qz5AMHAdvrWxd3z7mV4dwz1FUUCSkliUPoK8s7SlbyyQuSBgVNNclxkysv0qS4t5QMqfl9azHjuHfigBlxM/JDuw96qfaY0OWkcH0rT+y3jJ9xcVSn0G4uDncoPpQA06syrhS2PrUaatPv4ldR9aVfDF+xwqb/fNX7Xwpc5USxtnvQBBLqd2ygrcSfi1C390Y8O5I+tdNB4PPlBsEn0NSp4dePgogHvQBy0UdzM48pWcHuK3LbR7oxhppSo9Ca27HTZbXnagFXJIht3zOOO1AGLBoayjKbmb2NX4NOuLZTuhUgetRyeIEsZNiR8eoFTHXzOud4A9DQBLb3AD7W+Q+mKW+1VbdDvCYHc1y2vayUOYpRu9q5G/vprrmWcn2BoA6XWfE8shMdtIAK5wyzTyFpnBqpAkfBJY1ZLIvCIc0AWoFhMignv6V1enJaMgCJvf1rD0u0eVA4A+la6S/ZR8wCn6UAaREy8RxDHoTSxi5DfNEie4qnb6naMcPKwNaS3EDx5E5K0ATLChTdLI1C+QD8sjfjUP3x8ky496ytSRkBYzjjsDQBoXmpLbcbI3qqNawpKR7a5ea6LsRhmx3zUKiViSGIHuaAOsk1NpY+JmFUHQyZeWdmUds1T0SC51TUEsLQLJOys2GkWNQFUsxLMQAAqk8ntVqCw+1XRtrC60m6kEElw/wBn1a1kWKKMAu7sshCKAc5Yjv6GgBFa3cFYt4b3pYYZQ5Z3IHqDT7fQtR82VpDaxW8dst4bhr2BYPJZtokEpfYVLcZDdat3tgLIpHczIHkiWaMpKrrIjDKurKSGU9iCRQBBJdQqAoc7h3qreXRaMkMXH0qBdgmIDK340l6s+3MRAX0oAxLmXbMWOSKns75d4BBz71WnBd/nXn1pvmJGfu5/GgDo0vFK7QwBPrTzdSD7nJ9jWFHdK64ZPyqxAoblS60Aa51GJU/e79/1qCPUcMWUH25qq6kj93hj3Jqq8kCna4O/60AbKak8rcxjA9TUxuXlOIokJFc+JUUgAkA+prUtbJpIvMjmAz70AXRKchZiqfQ1NJbSmPMXzj3rnrppIJcOu/HerEGvy2y7fKO2gC9G80EmGBT8as+ZG3LM+71rGn1Y3Zyy7B61Mk5MXyODQBqS37wR48zj1NVjrd2RmObGOwrEuppmbDfpTV3AglttAGxJrOoSrtE8x9s8VWjmvDJkkhj3NRx3hhHzHJ7YFatjq9qgH2m2Zx6igCJv7XkA8uWQjsFNaOkT3EEu3VvNWP1Y1dt/EFiB+5gKHtmqGs6pDeIFlbGOgFAHVR3egFBibLDvVG8GmztkTllPauLFs+zdbcg1b0fUHsZybq1Mi+9AGrdDSbMb4iEb3Fc/qGtRyNsjRCo710up3unalagSWyRD16Vyn9jWEs5/f7E+tAFKSd5jk4C+1VZZ1HGHq1rOm2tnHutLwyt/dBrMQSGPlsH3oAzEXn8anQHIBxzSRDnkd+tWUXkH07V9NY8clSMBQMfU1KkY3AfKSevtTokOM7Rt9PWrUMKkZzz6VLKRGtuSF2ruPr2qxaQql7C5P3XBwetWERiQqhuB83PWpYoiJIm5bawPIrmrv93L0ZvQX7yPqejaApW33yHllJOPU118SA2jKjBVK7QfT3rm9BOy2iQockjt+v6V1Mce61k+bhwSwA6V8RUep9fBaEenqXjkLABWLDPcEDmuc1uIoZGGOFIz710UDOjGJASr/Nj+73IrJ8TKFj8zdtRgDj3rG5rbU878RPmDIOAF+Yf0rzG8YXOoowYlVX9a7vxXceXHIjPt3HO4dcnpXB2ELGMu4+Ytx9P8mvdymleaZ4mZ1LRsNlX1FVnSr8qcEYqq6nv3719S0fPFKRc1C61bdagkXFZyRSZTcUWq/vT9KkdeOKLVcyn6VhNGsWe4pcBpGHQZqCdpQ+V5X2FTTtaWgd9xJB6Gs641+JEPlJuxXjHoF9PMuV27wo9DT/su0cnP0rkLjxIZGI8rZ7g1TbX3GQk8i0Ad/bwTFsb12+hrUt7aOPJlZMeua8gm16Qt/r5D7ZqSLVp5h/r2QfXrQB7B/aWm22VMvPtUf9u27HZbtk+9eYW9xvXHmbmq1CDu+ZmB9qAPSl1STyyzSc1k3uvMh+Zi2O1cyrzrys52+hNXbYwTgfaGwO5oA0x4lLjasTL71FNdtdjCeYCe/Nb2if2KkXyzwt/vVPea7pNjkR+W5/2VoA5R9NO0vPcgexrB1aU26MIZc4q54q1pb+Xdb7UUDHHFctNcsykGQE+lAFaW8lL4lJKmnGQ7f3aD8TVSSVg24pkCmNdI4+ZWX6UAaNrvkcjn6Cr0kIiQM+5TVDRL5Leb5TnP94V1ElzFdQfvNmMUARaTetFHhJgvsaty307HBUSD1xXMTTxW0+Yjuwelel+AtWGn6NFf3MunWkOo3q6fM15fw2hNoq7rgp5jqWPzRL8vTNAGJaR29wPnjxJ7UssUlsCyBtnpXVW80nh3w5BBc6/caT9h8RNDcvALhmutkJ+UJCrbwcBtr4UjrWX4l1qS80/w7dRxSW1pd3Osyx2z8bY/PtjGGA4yFbHtkigDjrnU7hpSE3Lio5r+4kj2MhHua257m0RN6Qh5PpWLeaoZsqY0Qeg60AVgTtO1juPal81EU+Yrk/WlW5PlnYmT9Kz5bi5aXBjP0xQB2Hw5v7O38Uxy3P2eGEWt0pa7mEURzbyAB3JUKCSBnI69RV/R9Ss7Wz1cau/haG0OgX6NbaLqavLJmHaE8xricKxztU7eS3RsYrhQz8Z3L+FaNv5zoACWX6UAdxYaqlzo+sxXEWh2trDpkVnY2N/qOInP2pZWaSYmDcxJLYBX7uO/OD4tnttT1LTns7qwub+PT0iuxp03m2lvsdxHHGwZhkqdxG9uSTnmsxYpVcbUByauyW9ykO5ocDHUGgDPSCWNszDj1FXUkiiTMjk/WqDX4hB82TGOxFZN5rPnMU2ZX2oAsatdwvL+6kB9hVePDkFgp+pqgEjc7gjVNC8cTZ2sfrQBsJINuBGPwNSQ3jqdoTI9KoxPv+5Ea0rW2lIyAB9KAI5biZ+IkK5qIWT3DjzCQx710Frpokw3mBTWrFaRRqNxRiO5oA5uPQGZeuB6k0jabcWxxFOSPQV08mm+au6OXA9AabbaXFnMkr5FAHJXAulO0Kze5FVvJZv9aGz6V6PA+lWj4ncFv9qs/WrnRroFI3VW9RxQBy9pZ2/BnyB7mrjaTayj/Rp/m9M1TnSCOUhJQy/7RqeK6t4h95QfagBW0uWLl8Y9Qc0x7VVGSC5ps+pL0EhIqs95xlCc0ATvhFyUIxUSgSHjgfWnxymVPm4PvTSpY7Tx+FACyWc23dExYe1MglUfK6kN/tVagv5LQhXUOlSS3thMwZkKN9KALGnRhpB/pIQGti7sHeIeRMrt7mufDQykbJFA9a1LRIdmBcHd7GgCC50HVJ48hVI/3qzZNG1WBDmIFfrWrctqMWTBJL5fasybVNSZTGJWDdKAMCdmikKzRlT6VGpikb+PPpVuaw1KRi7qWPq1TaNcSaZdCS7tUdB6igDHVGLD9BV2BBnkE1BENznk9a0LdO4znua+nbPGRLH04HHcYq6oPACj5hyfSktYdwxzWhDATgbfm6ZNZSaNUiK3hcj5iFzVyOACSMtw24YxVqCAlRkgHt/WppY9sYO0khgQc5zXHiJe5L0OmhH34+qO20dljjjOHdguDg8DJrqbMCV2R/lbDEj/AD+Nc9pMaxMoOQjqo47mt2E+XMxjHLqRt9SB618VUep9dTRVt3ZLmNsAtErKwH8QGR/Ks2/kNxpcxaPDrg7Sc49a1dvlzzK2Mvtb6g+lY13KYbe5QcMG6Y7VknqatHjfiuQtvdADlgADzyD2rIggCWyqFweSfrmrmuOXuHxJtjSQFge5z0qdomWCPeADjPTHWvrcpjyps+WzKXNKxjTxkdiDVCRMZ71sTJgHnk9Kz5lr20eSzPdarSD0q/IMLjFU3GKloaKci9aLcfvT9KkkX2pLYZlP0rGSLiegaxK7zON/y5POayTlASSD9KW6k3SP5rAYJ71Tkk+QqGGPavDPTEl8qUnOFqswVQQDxS5XHzDH1oRPMZY4wXLHAAGST6CgCnNGcEr+dRwI+ck9PWu68c+G7DQoLN9JnmuAkklhfGRlYJexBDIq4Awvz8ZJPytzxXJJGCCdnzelADoJuQA4AHpW9Y3SgcShj6GsCNSM5RVq3bBScbVPvQB1MMlowzMw3emaoXtwhkxDkx+xrP8Asq9ULE+1WY1Cx4kU/gKALFsxTkNt+tLqM5MfyOoNVGnRVwD+BqpK6t1IBoArXBkOSzD6CmR4I5QfXNEx5w5yPaot8Sfd4PvQBMYx1LDHoKrS+WM/LirAZ5FwjqT6VYttKNzwx5oAyNhDAhj7VsabbpIB50zD2Bq6nh4Rjc74/GrFvYRI3yzfnQBLHplmQCjBj7mrL2jP5G4O6wIyRKZCVjVjlgq9BkgE464qMlY/lxk+uKlW5eKMbSCKAJpjNdPma4vZWEvn4luHcb9gj3YJxkIAo9BwKtx6lqFnAsUer6zawqSRHZ6hNbpk99qOBn3rJk1GQ8BT9RUU0zPHukYqPegCaWT90FhR9o/ikYux+pOST7mqSwoxOVyfUioxfbM7WL49arXmvMilUjUmgBl/O1ucIwH0rLe/mJyCSfWobm4knfe64HtTFjaQcMFFAF2HVbuMjjf7EVfTV75wNsap9axoz5DZ81SfQ0S37HgKPrmgDaOo6hwWkUD/AGaJNZuPKw90/wBM1gG+lCnoRVZ7kuemDQBpT30shIB3D3qJSD0+U+9VRJuUAqR70vOcA5oA0Y5lUbd+PerKsi43tuFZYjbGXBI9qeMDorEUAdBBImAVLYrZs7yJF5bb+FchDfDhSGAFXBdqy/u+v1oA7uwexlO53Zj7cVenm09E+WOQke9edJeSAfeKfQ0NfXII8uVm+tAHcprqWr4WHC+5rH1zxjMwZLfZGPXHNcrd3s7r+8DfgazpbgsMYGfegCW81aeeQmSWQ1Ua7x1d/rmoJc5yN2faoSpY5ZmH4UAaMN9kbdxHuTV6G+2YDYcetYRUDrgj1qxHhUyFLUAbr3avjadv0qaCZnXCuCfesGOUgcoB7GrdvdBPuqQaANX7Y1scsxb2pBrBL4cFQfWs64vHxlox9TUNuguCTnn0NAG/Hexg7vNz7U55llG4px61lLZ+WMgKc+9PXehAIYj0zQBZNyASEY/QUsN3NEwMbSKaktTDuyYDmteMLJHhdin0NADrDWrjZsuZCUIxUwlCS+ZAwb2PNZU9rNu5YFfQU61aW3kDJGx9jQBqX2u7YdpQ7vpWPbXttLPm9ZvL/u1tTXkE8GLm0Ctj72K5q4s42lLQ/d9DQBLCgz0ye1atvDgA+v8AOqcC/NgDpWnboPXk19JJnkJF23XGGyc9MVpW8Dc/OBn1qpbJkDqMDvWvapuUHoR+Z+lc82bRJ7W3BIweOp4qa4jVIV3D7rDPHXmrVnCr4GPm+tX5LNPJVpQdoYfzrixEvcl6HZQXvx9TV0zbKkZIO3APP6flW0Im27VYEgZB9qzNGAnAYcIoxiugWHzC38JYYVgOg718fPc+qp6K5n3qK4DnO9VwT6YrkPENyI2nBBz/AJ611moOY0yAMupXA71wPiBxK8xlz8yEcDkelKCuy5uybPMI4vt+u+W2TF5hlOO2OgrZu48rkHOe1M0CzS41W7mZQCvAUHOD1NaV7BsJA7V9lgVy00fIYt3mzmLhMNj1rOmUZPtW3dR8njisqZACT+lemmcDRlyr39aqSDHatGVSfpVSZRz602SUJBSWw/en6VLIKbbj96c+lZSRpFli7mlMzDHc1EOWG52Bp858uR2YEnJqLzQyk4rwD1CwJSSB8pA7mtPQNUTSNbstRkt47sWsomEBfYrsvKgnB4zjPHI4rDibJ4XNSbiGHQCgDp7rxXqOoeG7zTNVjs7mS4uIrtJoba3tPJmBYSORFEvmFldh8xznBz1B58sUA2EmkUQMw3OSTVyKJOzKfQUAVYyWOWXIq4mdnyoKmSydjwMD2q9BpakcuQfSgDPhmnhHyE4q0k80y/MSD9K17XS4sZ6n3qS58u1Qlgg/CgDDVCTloyT602WJ8ZWECrEl4ZCSiKB61TmvXHBHPqKAI3yv31UfWqcqwyHC9amZ3kyXT8aryfKDtQmgBoCwsMc/Q1o2c8gbKAj8ayAwZxuytbFmUwoJBH1oA0BdTuPmIxTo7gBv3gH4UgitiOXK/Q1Nb29vuyjFj70ASeZHKvyu2fpUbEDrJg1bkYxrgIoHqKz5HZmwFyfegBJHKZxIGrPubl2+Vula0dq7jLRZHtVS7EZG0JhvcUAY8juinZGTWe4lkkyVK/hW60RPXAHtStJDChDqCaAMGRXjwWPFRS3B24UZq1fPFKT5Z2/Ws91AB6UAMyS3MefxpGODymB9aFIHYn8akSFpW+X9aAIyy7flyKfCARkjJq2NOm28AUv2IgcghvpQBCjBT85wKUsp+5inm2l6AMfwp6WkrDPl0ANSRiMbwKnU7R8mSaa1q6jLRkUqo6LlcgUAO2MwywH0qRHKfeiXbUBjkIypJ+ppqvsPzqc+9AE0t2A3yrTTckjkFQe4NDyB1PCZqm5UHDZFAEjySZO2Qke9Rlx/Gc01skfKwC1GEIOetAG54P1Cz07xRpl1qdrDd6fHOv2iGVA6tGeG4PfBJHocGt7xPoY8I6Fq9ndxwzX13qpsrSV1Vj9mg+d5kJHG/fCMjHBYeorh2B4+UA1o694g1bXprN9ZvHu/sdutpbhlVfLiXoPlAyemSck4HPFAFBVRjlulSbgOEz+FR5DLgAj2qVEG35uKAGDdvyAfxq1Cynhhtb1piqv8JzSoSrc4IoAsqkbNhnLD0p+FiP7tMe9VGmJOFUD3FRyXBxhs0AaiXS/x7aDcAn92P1rG84g5KgCp4rtcEBR9aANu3lc8MwWr8CRnky7jXNQSb3JyT7VqW6M6/KjCgDRlnkU4TpTra7kXoCW96ovG6L91/wA6jhuWVsEc+9AGu91JIdrqDSrCFGRnPpUaOjRZxzRGpYZ3N+dAEluv7wYHWta1Xn096zbVe5zmti1xhTnFfRyPJiaFnGCFOD1rbsIATliPYVl24xjAJ9K3dOUAcZ59eTXNNnRFGvYW67VAAHual1jdbWBJyyllXHv16V4vrnGt6hjp9ok/9CNUa+Tr5y3zQ5PLf/gH6jhOAeaEKv1jdJ/B8/5j6T0aHZbwjAHAO3sOK6FAETAGC3FfJdFeR9Y1vY9f/U3S3tv/ACX/AO2PpTWQAGYZ3IcsDXn3iSPbFOYz/CcZ7HGa8soojX5XexUuD7q3tv8AyX/7Y7TwbAxLSHgSnf8Ad9ulT6nEA7cEc8Vk+Al3atcEEgrbMQfT5lrd1FfmPUD+f0r7HK6/t6Klax+ZcRZX/ZeLeH5+bRO9rb/NnL3a9RgYrJuFAOa37xR+VY92vB45zXsxZ85JGPP7VSlA71oXAHU1RlAI5rQzKUgptvxKfpUknQ0yD/Wn6VnJFxCS4DSMsi9zTv3TLwBmmXJ/eMMENk9qgK8gnJ+lfPHqltAEBMa5NRyBj8xjFLGsqj5FbmrlvYzzckH8DQBmrJvO04QVagjYEbJc1rJpqrjzIMn3qytoq4Hl7B9KAKsM7xJhyamj1ER9HzTpIAnIOc1B9kjkO6Q/lQBNNrFwFxGxFZs17dOSXcN9TUWo4Q4Vzj0qorRFeWOaAJGnkc5d8ewpgckY8xhSBMHKkEfWklC/j7UAPjnZeDIcVID5nzK7Z96qgbhw1OQ44LHFAGjAvmcOo+tbFjoRucGFjk+9c9bzIjADdit6x1JYsbCwPtQBv2nhqSMjzEY/Q1rJpVtCo8wE+1Ycev3SqFjdiPertvrxi5mw7d6ANUWViy/dKmq8tpZIcg8+9QvrcNyvyjY3uKq72mbL7WX60AWGuooPlVlPvVa5K3CEmNGPtTJ4YcYdCPpSWlrE8gEbOnvQBnm3lclVtj+ApF8P397IFhhIz6jiu4srWGKMEOWb3rXtdQS3X5wePSgDhrL4ValdsplljRT+daqfB3YP3lwH+ldLP41NpxHCWxWbdfES7wfLhCD3oAr23wosgfnZxV5PhbpSkFjJ+Brnrrx9qeSyzKufasi7+IGrHI+18H0FAHcy+AtHtRkSEEf3mqldado1kh3vEce4rzK/8U39y2ZLt/esme+eVixmZj7mgD0K8uNLJIgVfyrJm8o5MbJj0Ncd9okIz5u32FENxIG+VwfqaANy8VyDyB7isnY6E5kB9qlE5PVix9qR2L9YuaAKhWQN1IzTJVkIwNxPvVwoQMswWlikCsMsG/CgDPFu5GWRx709IJWOFRmH0rdiv4SAhGD64qwsO5d8M6/SgDAFizKS0TL+FQ/ZWUnHUdjW+zTAkMcikW0Enzb8E0AYPktty4poUDpxWlfWVwnKkMtZbxzlsMvFADlZc4DZp4yB1496IYRt4wD70oTL43YoAci7+4A9aayybwqgNVhImI4UMau20EwH+qx70AVoLUqu6RQDQyRHIb+Vav2ZyBuOPpTJI4ohyMn3oAwXt/mPlkEe9V5AVYBgK3J3AXEaKCe9ZMincxfGaAEhJRsjgetaEN5JnBcke1ZYLDPpV7T7pAdrbcUAbEUkhQbXJ9jU0Uxjb54VJ9aq/K3MTYNSROy43MGPpQBpw3kDH97EBVpby2b5RGAKq29unDzbfpVxYoZBhPl/CgCK3HtWta424Hc96yoDg9zWvYgn5mAHoDX0UjyYmta4J6kc9u9dFpWQ7ZJI6j65rDslP3Qa6HTw6lQpGB94DrXLUOmBXbwFpN/fSTz3N6slw5kIV0ABY5xyvrUOtfDnSLPUtNs7W5vmkuEZ5N8icAHAx8n+NdzpDF5FHlndjA9qfLZm78YTzMo/0SFLcAno3Vv518/jcLQhFy5Vc+swOfZk5KCrOyOZg+E2imMmW71HcBnKyJj/ANApyfCfQTndeamB/wBdI/8A4ivQJm8uI9MHioppGVFxt3ZAAPc14UoRXQ9v+2ce/wDl6zzbUfhjo1um6K61Bh23Oh/9krjPEnhyx0rSmuY5bhpQw4ZlIx3PQV7brX+r8xc4PQD1ryT4hgGwjCklWkI2t/e7Z+tXRpRlNJomrnmPjTbVVi+BtKjhtbjUP3hlyYMEjaR8rZxjNWdRALsevoK2tCh8vw7BkgmQb+mN3bJrL1EDLcYr7DB0o0oKMFY+Ix+MrYyq6teXNLuzmL1RjNYl0vHvW7enPUVh3XGa9GB5cjJuBnJrPlGDWlP0rPlGeBWxkUpOKbb8zH6VJKOTimW+PNOfSs5FRHNIolfcCxyaWNJZWyij8RVwo/mkRRjJJ6ir8MRWPMuAfavnj1iC0tZSuDtb2rYtIY7f7ylTWS13DAxJZvwqT/hI4I1xsMh9xQBv4SfAQndSS2UqjkkmubfxPJ/yxjEf0FV5PEV7IDl8CgDqEsieZGT8TVa/ezgUg7SfauMn1aZ3I8xvrmmC7cg8lvcmgCzfXVq0mFDGqc00IH7vNVnkctkhSPpTfMVuNozQBYeVSvyYFR+bxyWJqLev3cZNOCDblmIoAUyN2yBSl+OXNRMQOhzTWclCMUAWYw4IZH/OtCC4mGBhW+lZMG443HI9K1baNiM7do9aANGB7k84C1OkzKx8xgKpRo3GxyT71Y+fHzlRQBfgdpTiKQE+9TOlxENzSKo+tYjXRhbAP4gVDcXkrnqzL70AbM2qSoNobfimR63cIuFwDWC9xsX+IVXa7J6Ag+tAHXx69duMGfbTJNXuXPN2wH1rjvtLhsszEVciuRMAqgZ9TQBuSX07HidmFU57mds5LFfrVdUKjLy4+hqKa7hjG0uSfagCVnyNxcnHaq8ku4/N0+lVWvETJUkg1Xe/ZiQuMUAW5jEy/JnPvVYJIDkkCovtHPX5vpUUt1JnkigC787ehpHDfxcD2qqkoxnBBpjzFm64H1oAtLNJH9xvzqVb+VDl6zQ/oB9TSMzZwTQBqG98w5dhVuK4QKMt+lc/l8jA4qYvIFAWgDfS7B4XaPqKcNxcES4z6Vz8TvuHODWlbvLwS60AbUSTdQ3HvUm2XOXyR7VVtpnIwzrinTNK3yo/y0AXobwBvLOAPerD2iXBCrty3fpWNE4jba4DH1q2JtgHYfrQB0lr8PLm7jDi/hjU84Jq3/wglraqBdXyEjqRWLY6q8a4WdwP7pNWTrEkjbXXPuTQBqL4f0aJeZyzD0NUbyeztAUgXco7mqs9xGPmMmD6VlTTozEl/wBKAJ7y+jdTsABrJkuC5y7cD2qWRxngjH0qpPK4PyLx7igB6XEeeSeKZM0U3Qiq5zIPmXH0FQ+SSSU5I7GgCSaFQB1A9RTIv3Z+QBvwpryTgYKcVGPNY/Jx7UAbdtdhQBIh/KtO3kik5JQD9a5uHco+c4PuatwTFOd0Z9qAOg82JOVcmpI7pZGwSce1ZVteBv8AWIqr61qW80J/1bRk/WgC5AcEGte0Pp1rHgbkVqWrEMOwr6OR5MToLE7dvbmuhsRtdNm4jvXM2rk7ecVv2crfLgnj9fauSojogdfYXJtYGnkG4kBUQfxN2FaulW7woWmO6aQlnb+8T1Nc/ocBvL0Fh8kLYHHVu/8AhXahCrHoRj0r5nMKvPPkWyPosBS5Ic73Zn6luFtuU8Kc46UkfzIHOXJGc+lXJ4lmDIyjFUcOCVVQdvUZ6Y9q8qSPUi7qxm6pKXiYIeMZI681558Q4RJpVtcgAhLhd+P7vSu+1QiOUuCSSM89CK5PxLZrf6BqdtGcFo/MU/7Q5zV0XyzTIrR5oNF2zliOiwCLBAU4z9awNSfzNxC/SpvCFy114SspJTuOCOn55qDUG2gjHPoK+xo7I+SqbmBej5Scc1g3Y5atu+bqQaxLvgmu6ByyMq4B5qjL71emOQaoy8mtTIpzDnH6VHbf60+uKklPPSo7fmU/SoZUTp4YCJHPBbJ71R1PzYySVIH+zUNzf7JGwfLOTzVOfUfMUjzyT7188eqUbq9boY+PU1nSPJksGAFWp3Bzk5B9KpSgDkHA96AGeaxP3zmjzivViabtTvn8KcgQngfnQA5JAeoAFKzKPulsU1gAe340jOemRj2oAcuO2SfQ0q7zxkCgc8oPxpwDueP5UAMdWQ5H506Ik8Ek1J8q/eJz6ConlDcDIoANjK3ApzKwwQc+1R7h3JpVY5+Q5+tAE6OR3wfYVoW11JgKoyfestSSeXANWEaROd4NAHR2oZgDNtH0qad4AuQQTWNYXkW7E44HvVy4ktXTMI596AEfZKMsu0DvVOd1C/JlqinuGVdoOPpVbzyVwfl96AFkLyDkYFKqpt+9z713HizwXa6LD4n+wa1c3U3h6eKC6FzYrAkhkcIPKYSvuOSOGC8ZIzg1zWpeGdZtraG4aKzuoJbhbRX0+9gvB5zAlYz5LthiAcA4zg4oAw5go5Lk/SojuB/dnAruYvAUsNvp63dubzUrrVl04WdlqdtknYSULjeI5NwA+fp3Fc3ZeGdVv9NmvrBLKSGKKSeSFNRt2uEjQnexh3+ZgYJzt6c9OaAMsyuBh5CajMgPBwa2PGOlW+jTaOtu80gvNLt72QysDh5ASQMAYHHHU+9aujfDrWr/AFfSrK7W0s4r25t7eRzdwPLbCbBUyQ+YHUleQrBS3AHJFAHGsyim70PbmtjWPCuqaYskpjtrm2W6FmJrS7huV80glVPlO2CQCcH0I7Gt278A30Gl6TDBbzSeIbjUL6yuLZZo2jj+zrExO4cDG99zFsAL2waAOJbBHU5pgIB+YH61058JanaXE8d7YfaP+JdNfxSWl/CYjGgOZRIu9JFXa2VU5OCMg1btPBV5D4d1vVNYRbf7Lp0d7bQi7h84l54UUyQ5MioUkZgSq5+XnsQDkiy7ec1ENzH5cflShgDlmx7Cl91JzQA0Ek4IxT1/2hmkBPRhk08FOhGKAG+ZtYDBxUqxyOcpnmlVUXHGRUitg5XIHvQA5YZQRnFW0DKnzY/Cq4weSCaljkXIwjDFAFyCQrjHJ9DWpBIGUeYqA1keZ8vC8+9Rr5rE4BFAG1J5YfJIH0pcKzfuwWP0rMjllTCyAGrsF0yuMA7fYUAXo7XJDMRV4GCIAbhu9zWZNcl1+UiqokjdvmBLUAbLxNLypTFU7mMIDvKg+1RRXBX5URhSNG8rfMQPrQBGijB2tzU0YHAZgR6Uwo0AzvQj3qOSZiMqoz6igC3M6IoCqorPn8sHLnGf7tI26QZlPT0qL90QRhjQBNBHazNhpGUVauNKt/K3W92N3vWWo2PwQV9KuQyRnOQEP1oAybm2liY7mLinQADnp7Gr08hY4Vs/hUW+KM4cEn6UATQiSYhQVxVpNNZGD5/75NUECs2Y3K1dWaWPHzlvxoA6aAkYrUgYDGOh5rIgbp6mtGBiK+kkeQjatpDkY4/GtmymEbZYEheetc5AeRitzSf317bxn+NwD9M1y1moxcux00lzSUe5614SsTb6bEzj94w3n6nmtpyRu4xjvTLFfLtUHtzSykn1z1r4qbvqz6yK6IiO0g1WuUKl5Qcnbgn071b5YelRyo2GwPwrFm8XZnLawxCsxxjGRWDCwCKP4GGMHuK6TVhtZlZcZ/LFcfJlFmXOWjfOB6Zoii2YPgNzBZarpzZ32V5JGBnoDhh+hqe9bt1P1rL052s/HHiGAbdtwkVwPrjFWr2TO7nv1FfX4J81NM+SxS5akkZV23Xp/hWLcknPvWpctwSaxrhyT7V6MTikUZs8iqMpPNXJT19apTZJNamZTkyKZb/64/SnyjBplvnzT06VEhoJfLMzgbicmoxa+Y3+r/Or6QSGVjEAvJ61aFnPty7qB7Gvnj1TCuLEqp4C/jWfKCgwxU1vXkewHdPWLceWc8596AKLEscBhinoMfxLQyxD3puEB+XNAErIW6gVGYjnjpQDg9CRUqv2VaAGhgPlyQKlR5AuIyMe9DICuf5UsOwcYJoAbh2OWcE+lTRGMDDDn3pB5ZblSKniiic4IIzQBXkjD52lcVED5XBGRWhJY45iNVJ45AOQMCgCFRubdjIqzGyHA4zVdGOOBge9NLkNkA8e1AF5gv8AC4U0z5h1mFVxIWPzIaGKY54+tAFgy5HzMpqtM7MMHA/Gm/IO+ahZkB4oA9T8V/EWz8Xaj4gg1+LVr3Qprz7fpUbyDzbWRRtCYL4EbrkEA/L94DOQbU/xG0LTGV9E0+cJFrVnqUFsdMtbSOKGAyfujJG7SSt84w755yQF5z5CGOOHqJ/9o5/GgD0jwx4r8M+G7nQBYtrd6llrMep3MtxbRRMyqhUqqiVstk9SRn2qXw9468NaPo9uiWVzDeDTru1uEi0y2laaeWOVFl+1O/mIoDqCiADg8sOD5YVx1BxUbOAeOPqKAOm8Xa3ba1JpDWyTRiz0u2spPNAGXjUhiME/LzxnB9q7KT4gaHb3ek3iw3urXtlqFldxzXun2tvPBHAQWT7RExecsAqguowBXlEZGeWGaV8Z5waAPVPAvibRvD+p+Kby1mN3pK2ovbaLU444JXvklBt9kayPuKsxyQfulyQOhzvDnj2wsvD1hpepw3sxb+1Ir+aPbu8u8ijTfGSfmcFGYggA9M85HnW1McA5puPf8KAPR4/GejadYppmnpqU9hBot/Yxz3EUccss9yD8xQOwSNflGAzHqe+KTUvFug3lr4ovU/tZtZ12yhtjAbaJbe3ZZYHbEnmFmXEPHyLjpg9R5w2T3pwDBRzigCfK59DQXweCKg6DOM0inPYCgC0ZGI7YpUJJ4fn3qBZMDBzSgZ5BzQBcXd0ODUhMa9SfwqBNu372DQGB44NAF5JV2YBBpqyMG5bAqqpIPCVMDuHzELQBO8qLyck+uamt73aMAE1VTZ0J3UoEYPAIoA0kvFPLRjNKLh5D8p2j0rOU846inh2z8v3aANDLfxEfnU0DSK/yqoHqapI3HAH41MiyP/EoFAGkzyOPkdc03ZcN95k/GoYysY+YjPrTo8NnJz+NADjbAAmV/wAjU0EcRBUMTUJCE4YH8KkVVU5VWFAFgQqgO1Sw96rTLzhFVfrUxlc8K+Kcsbvjc6mgCgbPPLOM+lIbEt0PPtWnsKdV3CpFkVB8sbA/SgDKj06YnAfB9CKm/s2cjDrn3xWkJ1xl4yT60wX6oSoDbaAM8abcRNlApHvUN5FKMfLhvatE3Cs3yu4FOVY5G5fn1JoA0YTwD7Cr8DcisuJuKuwuMda+lZ46NiBuRXQeGmzrFn/v1y9u/AzW7oU3lalat6OK4sWv3M/RnbhP4sfVH0BaDMKe44HpSSZDdqdpw3WoY9cAUrKGbGOa+Ma0PqU7MYo5J/WlKnqOvapFQAKexpluxk8z/ZbbWdh36nPeI4D5RccYFcFMxW9mRxneuRivT9ZQNZSggcV5tqEPk6qrDuOQaImyd0cBqTmD4gQMMkXNgRn/AHTV26lBPqTWP40fyPEOm3f8MM5gJ/2WP/16tztg/Mfavqssd6KPmcxVqzKty2ScnrWXO+MgCrtyxz6j2rNmbnrXqxPNkU5jkk9aqSnrViYjcapSHvVkEMvWmQH98fpRIeDTYD+8P0rOTKRLcaj5sjhV2nJ6Gs+e8uMkeY+PTNQSyqsj4OTk01XVjyW/CvAPUF813OCGJNMNpOWyAce9XLeQbuEJHvWtAQ4AZMCgDCFm5HCjNRyQNH/rP0FdpbQ6co3SD5qtCGzk5W3yPU0AeeiLdnG78aEtpWbCZxXd3EenRj54Rn2FZ7xwyEmGHC0Ac+ljKBktxQ+I+FTB9a1pom+6iHFV3t4h/rTt9qAM8Lu5LEn0FSbHIwgI+tWHaGMfusZ9aas4cckE0AR7XRfnkNRPcKvYsfepJJADyuahYKeVUE0AQu+852EfSkeQoAe1PaQjhlP4VAzAn7uaAA3AbuRUbOW4Dg0knXkVGQAcnj8KAHFcdWxSFGb+IflQJFUc9Kcs6EYYUAJGiL3zTZioG4AUjzovTBqqzlzkg49qAFd2kPBwKYQc/MQaVsEfdIqM4H3etACkBckUqPzyMim/N/ERiplAC5HFAB8p6Eg0g2jvk00ZzkHNODjuAKAFY7l44qEhuMnIqUhR0bBpgBzywNACjJ6MQKViw6OMUoYDjNKVVuVINACR88k5qQHn5iMU6PIH3eKlG3oVzQBCVXOQaliK44Umn+ShGcfhTlAX2+tACAMc84FJg565HpUjcjAameW/ocUASIhY9cVMURBkgmoo4z1OQakJAPXP1oAcrhiAq4q2quF+UgCoISD1AFSZJ+7JzQBINwHzMDQoZTkNgfWoyWH313fSpI2AHyxEigC3DuI+U7x71bSFXOTwfQVWgmiyN0bA+1aKyJ5fyDBoAiWMqDtO39actu5+YS4NTopYZLAH3FPMZIzvXigCm8dznGVx60+ONlGWOT7VYAbBBw3403yW55xQAqTsMBj9DUjevmZHtVVoGBOXxSeWU5d8+woAuxlHGFJJqGe3AGQQp96hVpF5RdopSAw3TSY9s0ARYaNsFgfwpVMWfmUk01mjDZSUY96Rpo24D80AasTdKtxN0z1rNibircb4x1zX0zPHRrQSrkKcZPQVtaIwk1G0UnhpVz+dcykpKgYAPrWnp05iuoJc8pIG/UVz14c1OSXZnRQlyzi/NH1Dpn/HgoPJJGTVi4QArznjtVLQpTLZL9Af0q5NnfgdexNfEL4T6qXxsqSsUjgBxliBxTNPm3wyFADmRiTnjrwKzfEt+tkkbH7yOOB684A+pqzo0bQ6bbwMRv25fHXceT/Os+p0cvuXJrmNmjOeR3964HxNAY5S4zwhIPvXochEjfKconHHt2rjfGUYCOQO3NK1mVB6HjPj2z/c6lH/AMtEg+0xn/aG0/0NVhci4gimUjbIgbj3Fdd42tVXXNPL8Q3NuUYexBH9a840KZl0lIGOXt2aBj7qcfyxX0OTzveJ4ebQs1Iuzueg5rPnY9emalmkPPPU1Snck4PNe+jw2QTH5uvWqspFSyN2zVaRs0MkidqbAf3h+lNkORSW5/eH6VlJloy5WAlfIx8xpyyjHyk5pJmRZX3HuaaHDH5Tgewrwj0y2odxkZBqxDM0f3nOfeqcLRocl2JqyCknTk0AaVvck/ewRUwmeQlRKyj0FZSxlOSDj2NXYLu2jXDBgaAHzxqPvTOaijlEZwGf86l+0wytiLk+4qO4gBGWJH0FADbm62DIY5qpM7zrkHNO8qMnALMfepo0EQxwPagDKkhn6iojDL16e+a2iWc/cyKZIAo5jUD60AYx3J1LE0u9j3YGrkrR4OAAar7k65zQAwltvLk/Sot4JwAc1Y3AjpxTDJg8KuKAImUmoihz9/inzygHpzVbcxJKj9aAHuAf4iTTCDtyWxSeY5yCAPeo2cd3BoAQv6EflR5p7U0yIR0oD8dBQApLt2pmB3XmjLA52mgqzHIyKAFwD2xTgFwQWpAh7ZzTtrd1B/GgBFABO0Gl3AHlOaBnoq4pwQgZPJoAbjPJAFNZff8AIVIc5zt/Wmlsfw0AIrADBGRSnaTkZ/AU0Bc8k1IpC9BmgB8bAD72DUyDPcGmLtxztFAVRyH/ACoAsouTzmphgdRmqsTc4BJ+tT7j6GgCzGFYdAPwp/lxgctzVeP5u5BqVQw6jIoAmWDcPllGKX7JgdNxpqq+MrgU4b88uaAFW0Y9gKP7Nk6+ZinqrMOS350/59uAWoAYLKbH+szSpFMh2kE+4o2N3kcGom+1bsI5IoAuxQBvvsVPvUmwRniYn6VnNHcMuSTmmK0yHG4mgDYE/QFmIq7DMmz7hNYAlzwCd1TxXBjGWJP0oA6GK7tl/hAPvUVxdM3+qjGPWsRr1n4UL+NAumAw5K/SgC+bg7/3oINNeR8ZSQD8KorcQk/MzE024jaUAwyHHpQBYkklYYY/kartvAOWP0zTI4JF+9JmpRCGOd5/KgCAMB94E09GYcou361ZVATtAP1NLNbEcjJoA0om6VPG9UkPHWplfpX06PGNGJiQKuQSYHBrKic9zVuF+aiSLiz6Z+HV6brw9ZyOfmaNc/liuolP7wHocd64P4VMW8OWBP8Azy/qa72XhCfXtXw1Vcs5RXRs+vi7xjLujzr4iavb6XqFpJfOEgNxCN56A5OP1rptJuvOlZgMKVBHPrXj/wC0mHbSLSTkR/aApHqMHFXfgprWo3WnWdrNMJo1jGXfllHQDPpgVMaPNS9ouht7ZKoqL6o9q8vbCET5c/M1c94mtvMgbgnKnBrfWRmVg+CTwMdhWfrG1rcIOWHcnr71lJLoVC6ep5P4yxL/AMI/NLx5fmRvj025H8q8htjs1vW4B91bgOPxFerfFG6it7O3kkbbFHdxliDxjnP6V41ocjTre38mQ13Ozj6dq9jKE3UTPMzdpR5TUmI21TlPFSyvkVVcknP6V9MfOMhkbPY1Wc+tSu2KryNUtghkhptsw80/7tNc0WxBlP0rGTNEjNmid5X/AHR+8aFtyOcke1dNBaoZmEj8ZPNW5dOswu7z1z6ZrxT0TlY1I+7GT+FL+8VshNtbk0sUAwrKfoKoTT+b90AfhQBAs8p6lcVIQrj5pB+FRscjBKmoypByoOaALMMogfKAmrTapIRtIQD6Vmhn75qJpWDfd596ALzXBJzknPoKRLhlPXJ96gW4+Xn9BSo3OVX8zQBPNNcbenHtVT7Sw4K5P1qSSWUjHAFUyMH1NADmkyc7MVGZOckA0SE45x+dQMODgYoAleYkcYxULHcOTimcjo1DTKg5PNACblGf60xmLdMCgtv6Y5prgp6UAIw4+8aj4B5FOOOozSdeooAbtHUnH0o4zxz9aceB8opu/sev0oAd+lO69+KapOenFIQc54NAClR3ZqFVQeGNC7vSn7TjJGKADKj+KlDDt3qPAB6Zpx244BFADiFB6nNNPJ+9R8+O2KUIx6tigByA9ABTsbT1FKY8DJYmnxqe2KAGqM9Tj8KcvyHrn8KVkA7kmlUMOhyKAJVY9wKliBY9QKjUrjHGakWFzyvAoAcYWVtwPSpEmGNrD8qaC6jBG6lEL4LDIoAl8wpyvSnLLnkNz6VDGZBwRmkeJgdy4oAmeRs/Mamhn+XGcVSV5M4bbinMM8gZ/GgC47u3CkGo18zPJIqKMMBwAPxpwZicbjmgCQ3BXgncfU1G8pfqdtK698c0eWXGdwoAIQvQyU6Xyx3J+lRlAPu9acq8/MSooAaAWPygkVKeBjdj605FA+4240SRk8senpQBCYmPO+nRSupx94VIpToxJ+op/wC6OAufwoARZWJwFwakjaXdyAaeqyAfKmR61GzOGwFP1AoAnAZvvKR9DU0Z2n5pSPY1AobjIapTIhHPX6UASq3NTqRVRD71MjV9MmeOXIyCTVqOTFZ6Nipkbvmkxo+k/hKf+KWsSe6Z/DJrvZ5YxGF3Hn0FeffCs7fCunb/APnkOK7e4YYH7v6c18LWf7yfq/zPs6cPch6I8h+P1uLjwheMuGEbJMpH+y3P6GuR+BF4+9I0J+UFW+gP/wBevRPjFEv/AAieo5AAMDkr+FeZ/AgiCwNy4wHnaLdjuVBAqqUuWhOL/rb/ACFUp3xEH5f1+Z9HRyK0WevHPasfWJyIGG75cdfSrEN2qwg7duR/FXKeLtQ8jT7ltwQYJLE8Aetci10OtrlueG/GnWTdTW2nQPkZ8xwPU8AVj26i2tYoV/5ZoB+NU9cU3GvWTybv3+66AbrsHCfoM/jVl25r6vKqSjTufLZlVc6oPIeearu/HFK5x16VA7cV6jZ5oxyagc09mqBzzWcmUkMc5FLbH96fpUb+5oteZT9KwkzRGncNmR84IyelVSik5P8AOn3HmGRgAo5NQDcPvAY+teSd5LsHHAxS/Jj5Qaru5PCkfnUJdwwywx9aALT5HIRSaiZifvAj6UzzMn71KHC9eSaAG7lJ53VIfLx1P0NRtM7H5QPyoEmB+8HNADSxzhVqOU467ifapgjMchgB9aVoWxksMUAVN56Fjj0oLAfdP505ymcEEn1qP5QMsKAEYg8sOfambsnhaVmX+FD+NNZiBzxQA1lPXAqEg55UVMWDLzzUZVD6/gaAGHAPUj6UMFI4Yn60u1VGRk/WmAbiSARQAm3H8XFSFVC5JGaRUz1alb5BwM0ARtz3wKYNinqTSSSeopVJIyFFAD85HyjP1pAGPO0U4A57UjcHnP4UAKS3QACl5A+Y0g24wASacuemMUAJtA5ORQOD8rfnTipH3Rk+9LsbHzL+VAB8wNJuyenNOCD1bNTxxgrzQBEvX5m/AVJ5e/pxSmEE8NUyIyDHWgCP7OAuck0zAB7irQQ+9PSPHJXNAFaM4PA/OptzDqcCnMFJxjH1pGQqOCCKAHgrjJJoFywbHO36UxS/YrU8LD+M5/CgBdyt8wJpGdm7cUORu+Vacp287R+dADAsZ4dSKcVRV+UkClJDHOaVjvwvFAEfl7jkHNP4QZGKk2Y6L+tNDEnGwfhQA+E7l6inqmGyF/HNRSRuvPanoAoyS30NAEzDpkCnR/Zx99GJqNgCAV609QxGSMe4oAmBt84VDTlhgJ5DCqg3FvvE/hSsHB4ZgaALj28Q5DY+tQsqDtu/3RSRSFR++GamEsbfdJX8KAFguAnG1se4qw9x/wA8wv5VCqk/8tF+lQz/AGqPkAEewoAtmYuNuzP1FRM+zgorD2qOBzKcEtmpjmPqAR6igCsrc1KrVVVqkU19GmeRYtq5zUytweapq3NTI1O4I+ofhsFj8K6Uw53W6Z/KuruHjP3i4P1rifhXcg+DNNkkICiLbuPbBxXXXdzaiNWL9R2r4Sv7tSS82fcUtYRfkjz74ogz+H9SBZtot5Op4+7XGfAFPO0ExlfljnMn1bAA/Lmun+K10B4N1iZGz+4Iz9SBWd8BLTyvB8Ur8GaV2/DOKE/3T9Ql/GV+x6q4UxjI6eteZfE+4VtKa2Vh/pEqQkj0LDP6Zr025cLAwHPFePeNLhJvE1lEx/dWyvdSZ6HaOP1NZ017xVR6M8r8TTrdePdQaMAQ20YhQDpgDFQOwx14rN0+Zrm6v7xjzPMSPpVpmr7DBQ5KKR8hip89VscWzxULmhm4qFm9a6WzBIRjUDNinMw5qBzWUmUkDtRan96e3FRM3pS2p/en6VjJmsUXJifMf58jcajJTGAMn60h2NI5APU1FJtU/drzDsGtlCTgfnTN+4/MufpUisnT+dRsvPyNigB4CYyFP50xpCOEGKbg4O8k1G2f4c4oAlLHqSc+1NZ27kEe9MBI7Nil4PJoAlG0rwSDTH3AfeOaTIx1pjFenNADg+Bg8n6U3j1pFJHRTihi56YAoAC0nYjFREkfeBNS7F6k80oIxjNAEXLD5RxSbSo6flUu3J5GR7U7EYH3WzQBUYDOSppu0H+I1cO0jhSKjAbPAx9aAIdpXoQajdWPU1YcEnlgKDFkcfrQBX8oEdM0AMvTpU+wL1am7gDxQAiuTxjmlxxx1pTgjkgGgdR3oAYMjnnNLuY9QcVNlQBwTTAGLZCkUAOABXvQFccqeKf2+YZo4z0xQAqfMcNgVMqhev60zC7eCM0whs4IzQBMMZ6inhxnPWmLHkdBTihXoaAJftGRgDiovOXPRs0wlgOmKehLj5eDQBIGRuSSD70hIY/MciotkgbLHipdm4cgCgBQVzgAj6U7kdF/GmqjKODzUiM5IDHAoAcgB+8xzSMgB6EmlZAGyDmnDHYkGgCIYH3jgegqZPJH3c596BESc7waTyyG4oAVnKn5WP0IpQz4ztx9Kcdw7ipEK93yfagCJeeG3AVKqpwctVgRllzvAFKm4cdR9KAIndCAFH6UwSFTgNxVkIG4ZMD1qEogfAQ49TQA+JuuwYPc08Etndz9ajwkRyTwfSmzOpIIJI9KAJhzwpX6VHI2OGx+FMLRkcIQfY1JFKijhTn35oAgcHqhI+oqe3kuMYLj6GpDKCnIB/CiJl6upX6UASGVujhQPbipVlRV+VgT6Gq0nlsMKhJ9aiRHUEhcH3oAhB5qVTxVVWqRWr6BM8totK1So3PNVFapFancSR9H/CR0m8EacM5ZXZfyNeoX/lNbBvKXcF7CvDfgVqiyabcac7fNBP5oH+yw/wARXtdzIBbYNfI4qPJWmvM+xoSVShTa7HkXxoKxfD7V5eFLOkXHHVhVj4Mso8GacE4+U5z9a5n42Xv9q3mm+FLQnzru5FxPj+CJRwfzz+VegeEtPi0+wjitztWNAgBPUDpXNPSml3ZovfqtrZKxt6lJsgJHSvAfH+qmGLxHfowyESwib1ZjlgPoK9n8R38cNjNI8qqqqSfX8K+UtT1CTXtcuAzn7DHO8yRjoSeM/jitcHRdSdkc2OrezhqTWEfkWMSY5CgmpHakd/Soi1fWxXKkkfLPV3FZuKiYnmhmqJmpNjSEdveoWNK7VC7GsZMtIRjTrVv3p57VCxp1of3p/wB2sZM1SLk24yvsxjJ6Uwk9GOD61HPIwdwOOTTANwyxNcB0kjbPcmmHC9D+FNBQAgnikyucDNAAX684pvP8JNBP+zj3pOMffNACl3xgkUKMjJb8KAcdBmgnjpQAhds4HSmy7j7/AEFKQAclSKC3vgUAM3MBg5NICO/H41LsB+YNTOSccfXFAC/u8c5oXb2Qn60oBHcGjDHqOKAAyOvGQBSFnI+Q5p3loOSCTTjIoGNhFAEX7wjqM0bj/E1PJXHHU0wq/quKAFBB5OCaQlgucjFNwehIFL5QI+8KAIwcnoKeuzuvNKqKhznNPBJ/hzQBGQO6nFGfROKlwccDNGB3HNAES53ckip/4OtBiZl7CmBHQ9CaAGDG47gxqRWA4C4pxR3HDc0mzy/v5oAcWA6pmgvn1WkLK/8AFikKZAwc0AToQeM7qa6hT0NRgbRxkGpImfHJz9aAHBuMFT9aVUIGUIpgmYHG2pYlkY5BAoAYDIrfNUj5ADdakKOOrDNORyDhkzQAyOUE8YB96tBEcAl1BqLcmeIwDT0Kt0UA0AOeMY+8OKYmRxwafvKkKwBHtT2dNvYUARgN1RAKRlkyGOPwqVJdo+X5qcr7jz8hoAaA57ce9JjnhcVIUyeGJpql0PGB9aAJ0BUZzn2NMMrE4MgWoy7seRTJI2JyWU+1AEpdlOS28UjPu5DAUzaQBsBpQuTyvWgCXgqMgN+NIY0C5KHNOSGPrg8dealQuv3cbRQBEi7+Ao49alETAdAKGmUn5Uy3tThI78OhUetAECYMmGGDUxTY3IDUjQrnKymnrFGR85ZjQA9ERfmPyj2NPLDPy/MPemC3Q8ElR6ZqRY4lHB3UAc+G5qRWqsG5/E1IG44zXtRkec0WVb3qRWqsGp6tWikKxv8AhnXbrQNWh1CyI3pwyHo69wa9WvPjMstkI9P0i5luyvEZYbQfr6V4arV3fgq3SLR5r0qGmkfYv4dB+fNeZmNOnye0ktdj1MtqVXP2UXpuafgSzvtT8T6hrmuENfSjaAOkY9B+gr1RLxLK0JdgvFYHh2yFrEsh6kZb3PrXK/FTxWmk6ewhIa4k+SJff1P0r56d6s7I95NUabbOU+KvjZ7qeXSNNbLOcSyDt/siuJ021FpBg/6xuW/wqvpduwLXdyS00hLZPXnvV5mr6PA4ZUY8zPmsXiZVpDmb3qMtSFsc1GWPau1s47DmaoXbmhmqJ2rNyLSEdvyqJmpXb3qFjWMpFpAx44p9of3px6VCTT7Q/vT9KxcjRI2pLGJpGzuJye9MNpGOMtj60UVym5HJZx56sKgFuqtwzUUUAP8Asyt1Z/zp6WkZ6lqKKAFa0jHQtTRaoT1b86KKAHLZx55LH8aVrKIHjdRRQA02kZ7t+dH2VFXgtRRQA1bZCcktUht0x3oooAZ9mTPVqR7VMfef86KKAFjtIyv8VKbSP/a/OiigCNrWPceWpn2WMN1aiigB0dpGTyWoa2QcAsKKKACO3XP3mqRrSMc5bNFFADobZCeS351NLaJgfM/50UUARLaRjJy+frTHt1Lcs1FFADltY8d6DapnhmH0NFFACpbKP4m/Op4bSMtyWoooAsGxhA/iqrNbIj/KWH40UUAEMClxlmP41aNuoI5aiigBfsyEjk1L9iiKg5fP1oooAT7Kingt+JpVs4icndmiigCVLOLGeaZJbIDwWoooAQQjH3mqQ2kbLli2frRRQBF9mXH3n/OnrZRZBy350UUALJaovIZ/zqJIQZMFm/OiigCxLbKF4ZvzojhXaBk4NFFAEhtY4/mTcCadFGHB3M1FFADUiG4jJxU0USknOaKKAJ/s6OMNnHtQtjCoJG4fjRRQByv2ZM9W608WyerUUV6iOFj1t09Wp4t19WoorRCHi3X1au38EpvtEiZjsjlJUe5xRRXFmP8AB+Z35Z/G+R6VuZLXCk4214F44Laj4yaO5dmSLCoo6AdaKK8fCL94etmL/djDbpgHLUxrZPVqKK+mZ8yMNsnq1Rm2T1aiioZSGG3X+81RNbJnOWoorORaI2tkz1ao2tU9WoorCRaGNax+rU+1tE8w4Zxx7f4UUVkyz//Z);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This ultrasound image shows the first extensor compartment. The image was obtained with an ultrasound probe placed at the site of the red mark in the photograph.",
"    <div class=\"footnotes\">",
"     APL: abductor pollicis longus; EPB: extensor pollicis brevis.",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Blake Boggess, DO.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_42_3745=[""].join("\n");
var outline_f3_42_3745=null;
var title_f3_42_3746="Patient information: Medicines for attention deficit hyperactivity disorder (ADHD) (The Basics)";
var content_f3_42_3746=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?11/32/11778\">",
"         Patient information: Attention deficit hyperactivity disorder (ADHD) (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?37/47/38641\">",
"         Patient information: Learning disabilities (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?34/53/35668\">",
"         Patient information: Treatment of attention deficit hyperactivity disorder in children (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Medicines for attention deficit hyperactivity disorder (ADHD) (The Basics)",
"    </div>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H81464113\">",
"      <span class=\"h1\">",
"       What do ADHD medicines do?",
"      </span>",
"      &nbsp;&mdash;&nbsp;These medicines",
"      <strong>",
"      </strong>",
"      help children with ADHD pay attention and concentrate better. The most common medicines to treat ADHD are called &ldquo;stimulants.&rdquo; Stimulants do not cause children to be more active or excited. Instead, these medicines help different parts of the brain to work together.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H81464130\">",
"      <span class=\"h1\">",
"       Does my child need medicines for ADHD?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Some parents wonder whether their child needs medicine for ADHD. It is something that all parents need to discuss with their child&rsquo;s doctor. But it&rsquo;s important to know that many studies show that ADHD medicines are very good at helping children to pay attention and concentrate better.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H81464145\">",
"      <span class=\"h1\">",
"       Medicines to treat ADHD",
"      </span>",
"      &nbsp;&mdash;&nbsp;There are 2 main kinds of medicines to treat ADHD: stimulants and nonstimulants. Stimulants work faster and cost less than nonstimulants. But some children get side effect from stimulants, so they cannot take them. Plus, children with certain medical problems should not take stimulants. Your doctor or nurse will work with you to choose the safest medicine for your child. &nbsp;",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        <a class=\"drug drug_patient\" href=\"UTD.htm?7/43/7863?source=see_link\">",
"         Methylphenidate",
"        </a>",
"        <strong>",
"         (sample brand names: Ritalin&reg;, Methylin&reg;)",
"        </strong>",
"        - These are stimulant medicines and are given as a tablet, capsule, or liquid. They come in different formulas that work on the body in different ways. Short-acting formulas are usually started with 1 dose per day. They later go up to 2 doses per day. Long-acting formulas are usually taken once per day. A child can also get a methylphenidate patch (brand name: Daytrana&reg;). The child wears the patch on the skin for up to 9 hours per day.",
"       </li>",
"       <li>",
"        <strong>",
"         Amphetamines (sample brand names: Dexedrine&reg;, Adderall&reg;,",
"        </strong>",
"        <strong>",
"         Vyvanse&reg;)",
"        </strong>",
"        - These are different types of stimulant medicines that also come in short-acting and long-acting formulas.",
"       </li>",
"       <li>",
"        <a class=\"drug drug_patient\" href=\"UTD.htm?6/2/6182?source=see_link\">",
"         Atomoxetine",
"        </a>",
"        <strong>",
"         (brand name: Strattera&reg;)",
"        </strong>",
"        &ndash; This is a non-stimulant medicine that a child can take if he or she should not take stimulants. Atomoxetine comes as a capsule that is usually taken once or twice per day. &nbsp;",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H81464162\">",
"      <span class=\"h1\">",
"       How soon will I notice a change in my child&rsquo;s behavior?",
"      </span>",
"      &nbsp;&mdash;&nbsp;The immediate-release stimulants usually start to work in 30 to 40 minutes. But doctors often start children on a low dose, which might be too small to make a difference in your child&rsquo;s behavior. Your child&rsquo;s nurse or doctor will tell you if you should give your child a higher dose.",
"     </p>",
"     <p>",
"      If your child takes atomoxetime, it will probably take at least 1 week before you notice changes in your child&rsquo;s behavior.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H81464177\">",
"      <span class=\"h1\">",
"       What if my child needs to take ADHD medicine at school?",
"      </span>",
"      &nbsp;&mdash;&nbsp;If your child needs to take medicine at school, you should give your child&rsquo;s school nurse or faculty member a separate bottle of your child&rsquo;s medicine. That way, the person can give your child a dose at the right time. Do not let your child keep the medicine in his or her school bag or desk.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H81464192\">",
"      <span class=\"h1\">",
"       What if my child has have side effects?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Some of the most common side effects include:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Not feeling hungry",
"       </li>",
"       <li>",
"        Trouble sleeping",
"       </li>",
"       <li>",
"        Weight loss",
"       </li>",
"       <li>",
"        Motor tics &ndash; These are unusual movements that a child cannot control, such as blinking, shrugging the shoulders, or jerking the head.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Most of these side effects are mild and go away after a few weeks. Some can be avoided by changing the way the medicine is given. Rarely, ADHD medicines can have more serious side effects. Your child&rsquo;s doctor or nurse will discuss these with you before your child starts the medicine.",
"     </p>",
"     <p>",
"      For more detailed information about your medicines, ask your doctor or nurse for information from Lexicomp available through UpToDate. The Lexicomp hand-outs explain how to use and store your medicines. They also list possible side effects and warn you if your medicines should not be taken with certain other medicines or foods.&nbsp;",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H81464209\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?11/32/11778?source=see_link\">",
"       Patient information: Attention deficit hyperactivity disorder (ADHD) (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?37/47/38641?source=see_link\">",
"       Patient information: Learning disabilities (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?34/53/35668?source=see_link\">",
"       Patient information: Treatment of attention deficit hyperactivity disorder in children (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 14, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?3/42/3746?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 85728 Version 2.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-217.117.136.88-094BD8D684-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_42_3746=[""].join("\n");
var outline_f3_42_3746=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H81464113\">",
"      What do ADHD medicines do?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H81464130\">",
"      Does my child need medicines for ADHD?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H81464145\">",
"      Medicines to treat ADHD",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H81464162\">",
"      How soon will I notice a change in my child&rsquo;s behavior?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H81464177\">",
"      What if my child needs to take ADHD medicine at school?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H81464192\">",
"      What if my child has have side effects?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H81464209\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?11/32/11778?source=related_link\">",
"      Patient information: Attention deficit hyperactivity disorder (ADHD) (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?37/47/38641?source=related_link\">",
"      Patient information: Learning disabilities (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?34/53/35668?source=related_link\">",
"      Patient information: Treatment of attention deficit hyperactivity disorder in children (Beyond the Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f3_42_3747="MacConkey agar";
var content_f3_42_3747=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F63042%7EID%2F58979%7EID%2F71759&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F63042%7EID%2F58979%7EID%2F71759&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    MacConkey agar",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 364px; height: 240px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Because of the abundant normal flora present in stool, detection of enteric pathogens requires culture on selective and differential media. MacConkey agar inhibits the growth of gram-positive bacteria and differentiates between gram-negative bacteria that ferment lactose (pink to red colonies on this medium) and those that do not (colorless). Neither Salmonella nor Shigella can ferment lactose on this medium.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Harriet Provine.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Salmonella-Shigella agar",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 240px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Salmonella-Shigella agar is another selective and differential medium for stool culture. Like MacConkey, this medium inhibits the growth of gram-positive bacteria and differentiates lactose-positive from lactose-negative, gram-negative rods. In addition, growth of E. coli is suppressed, and production of hydrogen sulfide can be detected when black-centered colonies are produced.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Harriet Provine.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Serologic grouping by agglutination with antisera",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 343px; height: 240px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Isolates of Salmonella and Shigella can be presumptively identified by agglutination with appropriate antisera. A positive agglutination is on the left, a negative agglutination on the right.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Harriet Provine.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_42_3747=[""].join("\n");
var outline_f3_42_3747=null;
var title_f3_42_3748="Calcium carbonate and simethicone: Patient drug information";
var content_f3_42_3748=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Calcium carbonate and simethicone: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/51/27446?source=see_link\">",
"     see \"Calcium carbonate and simethicone: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F144457\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Gas Ban&trade; [OTC];",
"     </li>",
"     <li>",
"      Maalox&reg; Advanced Maximum Strength [OTC];",
"     </li>",
"     <li>",
"      Maalox&reg; Junior Plus Antigas [OTC];",
"     </li>",
"     <li>",
"      Titralac&reg; Plus [OTC]",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10021048\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691304",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used for bone growth.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691408",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to lower high phosphate levels.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691593",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to ease too much gas in the stomach.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691873",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat heartburn and upset stomach.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10021047\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701691",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to calcium, simethicone, or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10021052\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696895",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take other drugs within 1 hour of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10021053\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696432",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Bad taste in your mouth. This most often goes back to normal.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697978",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Hard stools (constipation). Drinking more liquids, working out, or adding fiber to your diet may help. Talk with your doctor about a stool softener or laxative.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10021055\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699019",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699014",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very hard stools (constipation).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699105",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any bruising or bleeding.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10021050\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695112",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If calcium is used as an aid, take with food.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694604",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Chewable tablet: Chew or crush well. Mix crushed tablet with food. Do not swallow it whole.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10021051\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696540",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Many times this drug is taken on an as needed basis.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10021056\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10021057\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11303 Version 34.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-2.133.93.82-3DA446CC7F-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_42_3748=[""].join("\n");
var outline_f3_42_3748=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F144457\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021048\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021047\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021052\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021053\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021055\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021050\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021051\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021056\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021057\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?26/51/27446?source=related_link\">",
"      Calcium carbonate and simethicone: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f3_42_3749="Acrokeratosis paraneoplastica hand";
var content_f3_42_3749=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F66625&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F66625&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Acrokeratosis paraneoplastica (Bazex's syndrome)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 323px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Erythematous, scaly papules are present on the hands.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_42_3749=[""].join("\n");
var outline_f3_42_3749=null;
var title_f3_42_3750="Paliperidone: Patient drug information";
var content_f3_42_3750=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Paliperidone: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?43/43/44728?source=see_link\">",
"     see \"Paliperidone: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?35/51/36663?source=see_link\">",
"     see \"Paliperidone: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F3981432\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Invega&reg;;",
"     </li>",
"     <li>",
"      Invega&reg; Sustenna&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F5941023\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Invega&reg;;",
"     </li>",
"     <li>",
"      Invega&reg; Sustenna&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10023611\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700570",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       There is a higher chance of death in older adults who take this drug for mental problems caused by dementia. Most of the deaths were linked to heart disease or infection. This drug is not approved to treat mental problems caused by dementia.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10023613\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2692053",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat schizophrenia. It may take 6 weeks to see the full effect.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10023612\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702668",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to paliperidone, risperidone, or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10023617\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697197",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have high blood sugar (diabetes), talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698422",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check your blood sugar as you have been told by your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697130",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have a family history of high blood sugar (diabetes), talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697268",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have high cholesterol or triglyceride levels, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697258",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have heart disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697282",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697060",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are overweight, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697320",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have Parkinson's disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697340",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have seizures, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696611",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid beer, wine, mixed drinks, or other drugs and natural products that slow your actions.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696701",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Be careful in hot weather. Drink lots of fluids to stop fluid loss.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10023618\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698205",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You may see the tablet shell in your stool.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698060",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling lightheaded, sleepy, having blurred eyesight, or a change in thinking clearly. Avoid driving and doing other tasks or actions that call for you to be alert or have clear eyesight until you see how this drug affects you.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698051",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling dizzy. Rise slowly over a few minutes when sitting or lying down. Be careful climbing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698139",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       High blood sugar. This most often goes back to normal when drug is stopped.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698392",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Weight gain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698279",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Nervous and excitable.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698162",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not able to sleep.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698182",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Irritation or swelling where the shot was given.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10023620\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698706",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are planning to harm yourself or the want to harm yourself gets worse.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698623",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Chest pain or pressure or a fast heartbeat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699023",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad dizziness or passing out.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699057",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Big change in balance.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699055",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Shakiness, trouble moving around, or stiffness.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698963",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       More trips to the bathroom, more thirst, or weight loss.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699062",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       A big weight gain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699112",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very nervous and excitable.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698997",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Erection that lasts more than 4 hours.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698670",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       For women, if you get pregnant while taking this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10023615\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705490",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Oral:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695914",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with or without food. Take with food if it causes an upset stomach.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695714",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Swallow whole. Do not chew, break, or crush.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694818",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Drink lots of noncaffeine liquids unless told to drink less liquid by your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694865",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Follow the diet and workout plan that your doctor told you about.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705429",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Shot:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695985",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is given as a shot into a muscle.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10023616\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705490",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Oral:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705429",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Shot:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696445",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Call your doctor for an office visit.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10023621\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705564",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Tablet:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705429",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Shot:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699585",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       The shot will be given to you in a hospital or doctor's office. You will not store it at home.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10023622\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10920 Version 34.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-89.32.226.102-E9F4F161E5-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_42_3750=[""].join("\n");
var outline_f3_42_3750=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3981432\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5941023\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023611\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023613\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023612\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023617\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023618\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023620\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023615\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023616\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023621\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023622\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?43/43/44728?source=related_link\">",
"      Paliperidone: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?35/51/36663?source=related_link\">",
"      Paliperidone: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f3_42_3751="Oblit bronchiolitis BMT II";
var content_f3_42_3751=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F65164&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F65164&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Bronchiolitis obliterans following bone marrow transplantation",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 373px; height: 245px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Photomicrographs of a completely obliterated bronchiole in a patient who has received an allogeneic bone marrow transplant. Left: Hematoxylin and eosin stained section shows complete replacement of a bronchiole by a collagenous scar associated with a scant inflammatory infiltrate and so-called cholesterol clefts, a nonspecific finding. Right: An elastic tissue stain is helpful in outlining the elastic layer of the same bronchiole pictured on the left and shows complete replacement of the bronchiole lumen by scar tissue.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Jeffrey L Myers, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_42_3751=[""].join("\n");
var outline_f3_42_3751=null;
var title_f3_42_3752="Mannitol: Drug information";
var content_f3_42_3752=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Mannitol: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?28/34/29221?source=see_link\">",
"    see \"Mannitol: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?42/60/43975?source=see_link\">",
"    see \"Mannitol: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F12595457\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F191286\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Aridol&trade;;",
"     </li>",
"     <li>",
"      Osmitrol",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F191287\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Osmitrol&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F191316\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Diagnostic Agent;",
"     </li>",
"     <li>",
"      Diuretic, Osmotic;",
"     </li>",
"     <li>",
"      Genitourinary Irrigant",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F191289\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      Assessment of bronchial hyper-responsiveness:",
"     </b>",
"     Inhalation: Administer in a stepwise fashion (measuring FEV",
"     <sub>",
"      1",
"     </sub>",
"     in duplicate after each administration) until the patient has a positive response or 635 mg of mannitol has been administered (whichever comes first).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     <i>",
"      Positive test:",
"     </i>",
"     15% reduction in FEV",
"     <sub>",
"      1",
"     </sub>",
"     from baseline or 10% incremental reduction in FEV",
"     <sub>",
"      1",
"     </sub>",
"     between consecutive doses",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     <i>",
"      Negative test:",
"     </i>",
"     Administration of full dose (635 mg) without reduction in FEV",
"     <sub>",
"      1",
"     </sub>",
"     sufficient to meet criteria for a positive test",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Administration should be as follows:",
"    </p>",
"    <table border=\"1\" frame=\"border\" rules=\"all\">",
"     <caption style=\"text-align:center;\">",
"      Stepwise Administration Schedule",
"     </caption>",
"     <col align=\"center\" width=\"100\">",
"     </col>",
"     <col align=\"center\" width=\"100\">",
"     </col>",
"     <col align=\"center\" width=\"150\">",
"     </col>",
"     <col align=\"center\" width=\"150\">",
"     </col>",
"     <thead valign=\"middle\">",
"      <tr>",
"       <th align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Dose #",
"        </p>",
"       </th>",
"       <th align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Dose (mg)",
"        </p>",
"       </th>",
"       <th align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Cumulative Dose (mg)",
"        </p>",
"       </th>",
"       <th align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Capsules/Dose",
"        </p>",
"       </th>",
"      </tr>",
"     </thead>",
"     <tbody>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         1",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         0",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         0",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         1",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         2",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         5",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         5",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         1",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         3",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         10",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         15",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         1",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         4",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         20",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         35",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         1",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         5",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         40",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         75",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         1",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         6",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         80",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         155",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         2 x 40 mg caps",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         7",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         160",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         315",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         4 x 40 mg caps",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         8",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         160",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         475",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         4 x 40 mg caps",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         9",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         160",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         635",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         4 x 40 mg caps",
"        </p>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Increased intracranial pressure, cerebral edema (unlabeled dosing):",
"     </b>",
"     I.V.: 0.25-1 g/kg/dose; may repeat every 6-8 hours as needed (Adelson, 2003; Bratton, 2007); maintain serum osmolality &lt;300-320 mOsm/kg (Adelson, 2003; Rabinstein, 2006)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Reduction of intraocular pressure:",
"     </b>",
"     I.V.: 0.25-2 g/kg administered over 30-60 minutes 1-1.5 hours prior to surgery",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Reduction of intraocular pressure (traumatic hyphema):",
"     </b>",
"     I.V.: 1.5 g/kg administered over 45 minutes twice daily for IOP &gt;35 mm Hg; may administer every 8 hours in patients with extremely high pressure (Crouch, 1999)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Severe traumatic brain injury (unlabeled use):",
"     </b>",
"     I.V.: ~1.4 g/kg as initial management prior to neurosurgery with concurrent fluid replacement (Cruz, 2001; Cruz, 2002; Cruz, 2004)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Kidney transplant:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Donor: 12.5 g (with adequate hydration) prior to nephrectomy; may repeat (Morris, 2008)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Recipient: 50 g before kidney revascularization (Sprung, 2000; Tiggeler, 1984; van Valenberg, 1987; Weimar, 1983)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Transurethral irrigation:",
"     </b>",
"     Topical: Use 5% urogenital solution as required for irrigation.",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F191303\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?42/60/43975?source=see_link\">",
"      see \"Mannitol: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Assessment of bronchial hyper-responsiveness:",
"     </b>",
"     Inhalation: Children &ge;6 years: Refer to adult dosing.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Increased intracranial pressure (unlabeled dosing):",
"     </b>",
"     I.V.: 0.25-1 g/kg/dose; repeat as needed to maintain serum osmolality &lt;300-320 mOsm/kg (Adelson, 2003; Broderick, 2007; Hegenbarth, 2008)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Reduction of intraocular pressure:",
"     </b>",
"     1-2 g/kg or 30-60 g/m",
"     <sup>",
"      2",
"     </sup>",
"     administered over 30-60 minutes 1-1.5 hours prior to surgery",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Reduction of intraocular pressure (traumatic hyphema):",
"     </b>",
"     1.5 g/kg administered over 45 minutes twice daily for IOP &gt;35 mm Hg; may administer every 8 hours in patients with extremely high pressure (Crouch, 1999)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Additional indications:",
"     </b>",
"     I.V.: Children &ge;12 years: Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F191290\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing. Consider initiation at lower end of dosing range.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F854601\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Contraindicated in severe renal impairment. Use caution in patients with underlying renal disease. May be used to reduce the incidence of acute tubular necrosis when administered prior to revascularization during kidney transplantation.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F854602\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No adjustment required.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F191267\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution: 20% [200 mg/mL] (250 mL, 500 mL); 25% [250 mg/mL] (50 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Osmitrol: 5% [50 mg/mL] (1000 mL); 10% [100 mg/mL] (500 mL); 15% [150 mg/mL] (500 mL); 20% [200 mg/mL] (250 mL, 500 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution [preservative free]: 25% [250 mg/mL] (50 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Powder, for oral inhalation [capsule/kit]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Aridol&trade;: 0 mg (1s) [empty], 5 mg (1s), 10 mg (1s), 20 mg (1s), 40 mg (15s) (19s)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, genitourinary irrigation: 5% [50 mg/mL] (2000 mL)",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F191253\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes: Excludes powder for inhalation",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F191270\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     I.V.: Vesicant; avoid extravasation. Do not administer with blood. Crenation and agglutination of red blood cells may occur if administered with whole blood.  Inspect for crystals prior to administration. If crystals are present, redissolve by warming solution. Use filter-type administration set for infusion solutions containing mannitol &ge;20%. For cerebral edema or elevated ICP, administer over 20-30 minutes.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Inhalation (Aridol&trade;): Administer using supplied single patient use inhaler; do not puncture capsule more than once; do not swallow capsules.  A nose clip may be used if preferred.  The patient should exhale completely, followed by a controlled rapid deep inspiration from the device; hold breath for 5 seconds and exhale through the mouth.  Measure FEV",
"     <sub>",
"      1",
"     </sub>",
"     in duplicate 60 seconds after inhalation; repeat process until positive response or full dose (635 mg) has been administered.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Irrigation: Administer using only the appropriate transurethral urologic instrumentation.",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F191322\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stable in D",
"     <sub>",
"      5",
"     </sub>",
"     W, D",
"     <sub>",
"      5",
"     </sub>",
"     NS, LR, NS, R.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Y-site administration: Compatible:",
"     </b>",
"     Allopurinol, amifostine, amphotericin B cholesteryl sulfate complex, aztreonam, bivalirudin, cisatracurium, cladribine, docetaxel, doripenem, etoposide phosphate, fenoldopam, fludarabine, fluorouracil, gallium nitrate, gemcitabine, hetastarch in lactate electrolyte injection (Hextend&reg;), idarubicin, linezolid, melphalan, ondansetron, oxaliplatin, paclitaxel, palonosetron, pemetrexed, piperacillin/tazobactam, propofol, remifentanil, sargramostim, telavancin, teniposide, thiotepa, vinorelbine.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Cefepime, doxorubicin liposome, filgrastim, pantoprazole.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F191268\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Injection: Reduction of increased intracranial pressure associated with cerebral edema; reduction of increased intraocular pressure; promoting urinary excretion of toxic substances; genitourinary irrigant in transurethral prostatic resection or other transurethral surgical procedures",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Note:",
"     </b>",
"     Although FDA-labeled indications, the use of mannitol for the prevention of acute renal failure and/or promotion of diuresis is not routinely recommended (Kellum, 2008).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Genitourinary irrigation solution: Irrigation in transurethral prostatic resection or other transurethral surgical procedures",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Powder for inhalation: Assessment of bronchial hyper-responsiveness",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F12963311\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Improve renal transplant function",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F191324\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Osmitrol&reg; may be confused with esmolol",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F191314\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Inhalation:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Cardiovascular: Chest discomfort (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Central nervous system: Headache (adults 6%; children 3%), dizziness (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Gastrointestinal: Nausea (adults 2%; children 3%), throat irritation (2%), retching (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Respiratory: Cough (2%), pharyngolaryngeal pain (adults 2%; children 4%), rhinorrhea (2%), dyspnea (1%), wheezing (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     &lt;1% (Limited to important or life-threatening): FEV",
"     <sub>",
"      1",
"     </sub>",
"     decreased, gagging",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Injection:",
"     </b>",
"     Frequency not defined:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Cardiovascular: Chest pain, CHF, circulatory overload, hyper-/hypotension, peripheral edema, tachycardia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Central nervous system: Chills, convulsions, dizziness, fever, headache",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Dermatologic: Bullous eruption, urticaria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Fluid and electrolyte imbalance, dehydration and hypovolemia secondary to rapid diuresis, hyperglycemia, hypernatremia, hyponatremia (dilutional), hyperosmolality-induced hyperkalemia, metabolic acidosis (dilutional), osmolar gap increased, water intoxication",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Gastrointestinal: Nausea, vomiting, xerostomia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Genitourinary: Dysuria, polyuria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Local: Pain, thrombophlebitis, tissue necrosis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Ocular: Blurred vision",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Renal: Acute renal failure, acute tubular necrosis (adult dose &gt;200 g/day; serum osmolality &gt;320 mOsm/L)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Respiratory: Pulmonary edema, rhinitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Miscellaneous: Allergic reactions",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F191273\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Injection: Hypersensitivity to mannitol or any component of the formulation; severe renal disease (anuria); severe dehydration; active intracranial bleeding except during craniotomy; progressive heart failure, pulmonary congestion, or renal dysfunction after mannitol administration; severe pulmonary edema or congestion",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Genitourinary irrigation solution:  Anuria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Powder for inhalation: Hypersensitivity to mannitol, gelatin, or any component of the formulation; conditions that may be compromised by induced bronchospasm or repeated spirometry (eg, aortic or cerebral aneurysm, uncontrolled hypertension, recent MI or cerebral vascular accident)",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F191257\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Fluid/electrolyte loss: Excess amounts can lead to profound diuresis with fluid and electrolyte loss; close medical supervision and dose evaluation are required. Watch for and correct electrolyte disturbances; adjust dose to avoid dehydration.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Nephrotoxicity: May cause renal dysfunction especially with high doses; use caution in patients taking other nephrotoxic agents, with sepsis or pre-existing renal disease. To minimize adverse renal effects, adjust to keep serum osmolality less than 320 mOsm/L. Discontinue if evidence of acute tubular necrosis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cerebral edema:  In patients being treated for cerebral edema, mannitol may accumulate in the brain (causing rebound increases in intracranial pressure) if circulating for long periods of time as with continuous infusion; intermittent boluses preferred. Cardiovascular status should also be evaluated; do not administer electrolyte-free mannitol solutions with blood. If hypotension occurs, monitor cerebral perfusion pressure to ensure adequate.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Dosage form specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &bull; Powder for inhalation (Aridol&trade;): Bronchospasm:",
"     <b>",
"      [U.S. Boxed Warning] Use may result in severe bronchospasm; use only for bronchial challenge testing. Testing should only be done by trained professionals. Not for use in patients with asthma or very low baseline pulmonary function.  Medications (eg, short-acting inhaled beta-agonist) and equipment for the treatment of severe bronchospasm should be readily available.",
"     </b>",
"     Use with caution in patients with conditions that may increase sensitivity to bronchoconstriction (eg, severe cough, ventilatory impairment, spirometry-induced bronchoconstriction, hemoptysis of unknown origin, pneumothorax, recent abdominal, thoracic, or intraocular surgery, unstable angina, active upper or lower respiratory tract infection).  Patients who have &ge;10% reduction in FEV",
"     <sub>",
"      1",
"     </sub>",
"     on administration of the 0 mg capsule, patients with a positive response to bronchial challenge testing, or patients who develop significant respiratory symptoms should receive short acting inhaled beta-agonist; monitor until full recovery to baseline.  Bronchial challenge testing should not be performed in children &lt;6 years of age as these patients are unable to provide reliable spirometric results.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Adequate renal function: Should not be administered until adequacy of renal function and urine flow is established; use 1-2 test doses to assess renal response.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299644\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F191261\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alfuzosin: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amifostine: Antihypertensives may enhance the hypotensive effect of Amifostine.  Management: When amifostine is used at chemotherapy doses, antihypertensive medications should be withheld for 24 hours prior to amifostine administration. If antihypertensive therapy can not be withheld, amifostine should not be administered.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antihypertensives: May enhance the hypotensive effect of other Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Diazoxide: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Hypertensive Properties): May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Hypotensive Properties): May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hypotensive Agents: May enhance the adverse/toxic effect of other Hypotensive Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the orthostatic hypotensive effect of Orthostatic Hypotension Producing Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methylphenidate: May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pentoxifylline: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phosphodiesterase 5 Inhibitors: May enhance the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prostacyclin Analogues: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     RiTUXimab: Antihypertensives may enhance the hypotensive effect of RiTUXimab.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Phosphates: Diuretics may enhance the nephrotoxic effect of Sodium Phosphates. Specifically, the risk of acute phosphate nephropathy may be enhanced.  Management: Consider avoiding this combination by temporarily suspending treatment with diuretics, or seeking alternatives to oral sodium phosphate bowel preparation. If the combination cannot be avoided, hydrate adequately and monitor fluid and renal status.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Yohimbine: May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F191263\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F854599\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Reproduction studies have not been conducted.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F191294\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/use caution",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16323360\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Mannitol Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5% (1000 mL): $12.37",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10% (1000 mL): $17.29",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     15% (500 mL): $20.86",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     20% (250 mL): $17.56",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     25% (50 mL): $2.17",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Osmitrol Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5% (1000 mL): $20.96",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10% (500 mL): $20.78",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     15% (500 mL): $24.79",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     20% (250 mL): $24.28",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Resectisol Irrigation)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5% (2000 mL): $10.58",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F191265\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Renal function, daily fluid I &amp; O, serum electrolytes, serum and urine osmolality; for treatment of elevated intracranial pressure, maintain serum osmolality &lt;300-320 mOsm/kg.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Bronchial challenge test: Standard spirometry prior to bronchial challenge test; FEV",
"     <sub>",
"      1",
"     </sub>",
"     in duplicate 60 seconds after administration of each step of test",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F2869390\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Anol (TW);",
"     </li>",
"     <li>",
"      Ardeaosmosol MA (CZ);",
"     </li>",
"     <li>",
"      Aridol (AU, CH, FI, FR, GR, NO, PT, SE, SG);",
"     </li>",
"     <li>",
"      D-Mannitol (KP);",
"     </li>",
"     <li>",
"      Demanitol (PE);",
"     </li>",
"     <li>",
"      Diurecide (PE);",
"     </li>",
"     <li>",
"      Feng Hai Lu (CL);",
"     </li>",
"     <li>",
"      Infusan M20 (ID);",
"     </li>",
"     <li>",
"      Isotol (IT);",
"     </li>",
"     <li>",
"      Kratol (IN);",
"     </li>",
"     <li>",
"      Mannisol (HN);",
"     </li>",
"     <li>",
"      Mannisol B (PL);",
"     </li>",
"     <li>",
"      Mannit (AT);",
"     </li>",
"     <li>",
"      Mannit-Losung (DE);",
"     </li>",
"     <li>",
"      Mannitol (KP, PL);",
"     </li>",
"     <li>",
"      Mannits (EE);",
"     </li>",
"     <li>",
"      Osmitrol (IN, NL, NZ, SG);",
"     </li>",
"     <li>",
"      Osmofundin (SG);",
"     </li>",
"     <li>",
"      Osmofundina (PT);",
"     </li>",
"     <li>",
"      Osmofusin-M (BG);",
"     </li>",
"     <li>",
"      Osmohale (DK, IT);",
"     </li>",
"     <li>",
"      Osmosteril (NL);",
"     </li>",
"     <li>",
"      Otsu-manitol (ID);",
"     </li>",
"     <li>",
"      Photoderm Max Bio (MX);",
"     </li>",
"     <li>",
"      Pu Ke (CL)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F191256\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Produces an osmotic diuresis by increasing the osmotic pressure of glomerular filtrate, which inhibits tubular reabsorption of water and electrolytes and increases urinary output . Mechanism of action in reduction of intracranial pressure (ICP) is controversial. However, it is thought that mannitol reduces ICP by reducing blood viscosity which transiently increases cerebral blood flow and oxygen transport. This in turn reduces cerebral blood volume and ICP. Furthermore, mannitol reduces ICP by withdrawing water from the brain parenchyma and excretes water in the urine (Allen, 2009; Bratton, 2007; Miller, 2010).",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F191272\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: Diuresis: Injection: 1-3 hours; Reduction in intracranial pressure: ~15-30 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Duration: Reduction in intracranial pressure: 1.5-6 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: 34.3 L; remains confined to extracellular space (except in extreme concentrations); does not penetrate the blood-brain barrier (generally, penetration is low)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Minimally hepatic to glycogen",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability: Inhaled: 59% (relative to oral administration: 96%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: Terminal:  4.7 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak, plasma: Inhaled: 1.5 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine (~55% to 87% as unchanged drug)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Adelson PD, Bratton SL, Carney NA, et al, &ldquo;Guidelines for the Acute Medical Management of Severe Traumatic Brain Injury in Infants, Children, and Adolescents,&rdquo;",
"      <i>",
"       Pediatr Crit Care Med",
"      </i>",
"      , 2003, 4(3 Suppl):40-4.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Allen CH and Ward JD, &ldquo;An Evidence-Based Approach to Management of Increased Intracranial Pressure,&rdquo;",
"      <i>",
"       Crit Care Clin",
"      </i>",
"      , 1998, 14(3):485-96.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Badjatia N, Carney N, Crocco TJ, et al, &ldquo;Guideline for Prehospital Management of Traumatic Brain Injury 2nd Edition,&rdquo;",
"      <i>",
"       Prehosp Emerg Care",
"      </i>",
"      , 2008, 12(Suppl 1):1-52.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?3/42/3752/abstract-text/18203044/pubmed\" id=\"18203044\" target=\"_blank\">",
"        18203044",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Brain Trauma Foundation, American Association of Neurological Surgeons, Congress of Neurological Surgeons, &ldquo;Guidelines for the Management of Severe Traumatic Brain Injury,&rdquo;",
"      <i>",
"       J Neurotrauma",
"      </i>",
"      , 2007, 24(Suppl 1):1-106.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?3/42/3752/abstract-text/17511534/pubmed\" id=\"17511534\" target=\"_blank\">",
"        17511534",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Brain Trauma Foundation,\"Guidelines for the Field Management of Combat-Related Head Trauma,\" 2005. Available at file://www.braintrauma.org",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bratton SL, Chestnut RM, Ghajar J, et al, &ldquo;Guidelines for the Management of Severe Traumatic Brain Injury. II. Hyperosmolar Therapy,&rdquo;",
"      <i>",
"       J Neurotrauma",
"      </i>",
"      , 2007, 24(Suppl 1):14-20.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?3/42/3752/abstract-text/17511539/pubmed\" id=\"17511539\" target=\"_blank\">",
"        17511539",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Broderick J, Connolly S, Feldmann E, et al, &ldquo;Guidelines for the Management of Spontaneous Intracerebral Hemorrhage in Adults: 2007 Update: A Guideline From the American Heart Association/American Stroke Association Stroke Council, High Blood Pressure Research Council, and the Quality of Care and Outcomes in Research Interdisciplinary Working Group,&rdquo;",
"      <i>",
"       Stroke",
"      </i>",
"      , 2007, 38(6):2001-23.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?3/42/3752/abstract-text/17478736/pubmed\" id=\"17478736\" target=\"_blank\">",
"        17478736",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Crouch ER Jr and Crouch ER, \"Management of Traumatic Hyphema: Therapeutic Options,\"",
"      <i>",
"       J Pediatr Ophthalmol Strabismus",
"      </i>",
"      , 1999, 36(5):238-50.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?3/42/3752/abstract-text/10505828/pubmed\" id=\"10505828\" target=\"_blank\">",
"        10505828",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Cruz J, Minoja G, and Okuchi K, &ldquo;Improving Clinical Outcomes from Acute Subdural Hematomas With the Emergency Preoperative Administration of High Doses of Mannitol: A Randomized Trial,&rdquo;",
"      <i>",
"       Neurosurgery",
"      </i>",
"      , 2001, 49(4):864-71.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?3/42/3752/abstract-text/11564247/pubmed\" id=\"11564247\" target=\"_blank\">",
"        11564247",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Cruz J, Minoja G, and Okuchi K, et al, &ldquo;Major Clinical and Physiological Benefits of Early High Doses of Mannitol for Intraparenchymal Temporal Lobe Hemorrhages With Abnormal Pupillary Widening: A  Randomized Trial,&rdquo;",
"      <i>",
"       Neurosurgery",
"      </i>",
"      , 2002, 51(3):628-38.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?3/42/3752/abstract-text/12188940/pubmed\" id=\"12188940\" target=\"_blank\">",
"        12188940",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Cruz J, Minoja G, Okuchi K, et al, &ldquo;Successful Use of the New High-Dose Mannitol Treatment in Patients With Glasgow Coma Scale Scores of 3 and Bilateral Abnormal Pupillary Widening: A Randomized Trial,&rdquo;",
"      <i>",
"       J Neurosurg",
"      </i>",
"      , 2004, 100(3):376-83.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?3/42/3752/abstract-text/15035271/pubmed\" id=\"15035271\" target=\"_blank\">",
"        15035271",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Expert Panel Report 3, &ldquo;Guidelines for the Diagnosis and Management of Asthma,&rdquo;",
"      <i>",
"       Clinical Practice Guidelines",
"      </i>",
"      , National Institutes of Health, National Heart, Lung, and Blood Institute, NIH Publication No. 08-4051, prepublication 2007. Available at",
"      <a href=\"file://www.nhlbi.nih.gov/guidelines/asthma/asthgdln.htm\" target=\"_blank\">",
"       file://www.nhlbi.nih.gov/guidelines/asthma/asthgdln.htm",
"      </a>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gadallah MF, Lynn M, and Work J, &ldquo;Case Report: Mannitol Nephrotoxicity Syndrome: Role of Hemodialysis and Postulate of Mechanisms,&rdquo;",
"      <i>",
"       Am J Med Sci",
"      </i>",
"      , 1995, 309(4):219-22.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?3/42/3752/abstract-text/7900744/pubmed\" id=\"7900744\" target=\"_blank\">",
"        7900744",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hegenbarth MA, &ldquo;Preparing for Pediatric Emergencies: Drugs to Consider,&rdquo;",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2008, 121(2):433-43.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?3/42/3752/abstract-text/18245435/pubmed\" id=\"18245435\" target=\"_blank\">",
"        18245435",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kellum JA, Cerda J, Kaplan LJ, et al, &ldquo;Fluids for Prevention and Management of Acute Kidney Injury,&rdquo;",
"      <i>",
"       Int J Art Organ",
"      </i>",
"      , 2008, 31(2):96-110.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?3/42/3752/abstract-text/18311727/pubmed\" id=\"18311727\" target=\"_blank\">",
"        18311727",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      <i>",
"       Kidney Transplantation: Principles and Practice",
"      </i>",
"      , 6th ed, Morris PJ and Knechtle SJ, eds, Philadelphia, PA: Saunders, 2008.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kochanek PM, Carney N, Adelson PD, et al, &ldquo;Guidelines for the Acute Medical Management of Severe Traumatic Brain Injury in Infants, Children, and Adolescents -- Second Edition,&rdquo;",
"      <i>",
"       Pediatr Crit Care Med",
"      </i>",
"      , 2012, 13(Suppl 1):1-82.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?3/42/3752/abstract-text/22217782/pubmed\" id=\"22217782\" target=\"_blank\">",
"        22217782",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Leuppi JD, Brannan JD, and Anderson SD, &ldquo;Bronchial Provocation Tests: The Rationale for Using Inhaled Mannitol as a Test for Airway Hyperresponsiveness,&rdquo;",
"      <i>",
"       Swiss Med Wkly",
"      </i>",
"      , 2002, 132(13-14):151-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?3/42/3752/abstract-text/12070787/pubmed\" id=\"12070787\" target=\"_blank\">",
"        12070787",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Leuppi JD, Tandjung R, Anderson SD, et al, &ldquo;Prediction of Treatment-Response to Inhaled Corticosteroids by Mannitol-Challenge Test in COPD: A Proof of Concept,&rdquo;",
"      <i>",
"       Pulm Pharmacol Ther",
"      </i>",
"      , 2005, 18(2):83-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?3/42/3752/abstract-text/15649849/pubmed\" id=\"15649849\" target=\"_blank\">",
"        15649849",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Miller RD, Fleisher LA, Wiener-Kronish JP, et al, eds, Miller&rsquo;s Anesthesia, 7th ed, Philadelphia: Churchill Livingstone, 2009.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Palmquist KL, Quattrocchi FP, and Looney LA, &ldquo;Compatibility of Furosemide With 20% Mannitol,&rdquo;",
"      <i>",
"       Am J Health Syst Pharm",
"      </i>",
"      , 1995, 52(6):648,50.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?3/42/3752/abstract-text/7606581/pubmed\" id=\"7606581\" target=\"_blank\">",
"        7606581",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Procaccio F, Stocchetti N, Citerio G, et al, &ldquo;Guidelines for the Treatment of Adults With Severe Head Trauma (Part II). Criteria for Medical Treatment,&rdquo;",
"      <i>",
"       J Neurosurg Sci",
"      </i>",
"      , 2000, 44(1):11-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?3/42/3752/abstract-text/10961491/pubmed\" id=\"10961491\" target=\"_blank\">",
"        10961491",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Rabinstein AA, \"Treatment of Cerebral Edema,\"",
"      <i>",
"       Neurologist",
"      </i>",
"      , 2006, 12(2):59-73.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?3/42/3752/abstract-text/16534443/pubmed\" id=\"16534443\" target=\"_blank\">",
"        16534443",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Sprung J, Kapural L, Bourke DL, et al, \"Anesthesia for Kidney Transplant Surgery,\"",
"      <i>",
"       Anesthesiol Clin North America",
"      </i>",
"      , 2000, 18(4):919-51.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?3/42/3752/abstract-text/11094698/pubmed\" id=\"11094698\" target=\"_blank\">",
"        11094698",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Tiggeler RG, Berden JH, Hoitsma AJ, et al, \"Prevention of Acute Tubular Necrosis in Cadaveric Kidney Transplantation by the Combined Use of Mannitol and Moderate Hydration,\"",
"      <i>",
"       Ann Surg",
"      </i>",
"      , 1985, 201(2):246-51.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?3/42/3752/abstract-text/3918517/pubmed\" id=\"3918517\" target=\"_blank\">",
"        3918517",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      van Valenberg PL, Hoitsma AJ, Tiggeler RG, et al, \"Mannitol as an Indispensable Constituent of an Intraoperative Hydration Protocol for the Prevention of Acute Renal Failure After Renal Cadaveric Transplantation,\"",
"      <i>",
"       Transplantation",
"      </i>",
"      , 1987, 44(6):784-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?3/42/3752/abstract-text/3122381/pubmed\" id=\"3122381\" target=\"_blank\">",
"        3122381",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Weimar W, Geerlings W, Bijnen AB, et al, \"A Controlled Study on the Effect of Mannitol on Immediate Renal Function After Cadaver Donor Kidney Transplantation,\"",
"      <i>",
"       Transplantation",
"      </i>",
"      , 1983, 35(1):99-101.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?3/42/3752/abstract-text/6401883/pubmed\" id=\"6401883\" target=\"_blank\">",
"        6401883",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9587 Version 37.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-61.234.146.186-FF4A722CD6-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_42_3752=[""].join("\n");
var outline_f3_42_3752=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12595457\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F191286\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F191287\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F191316\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F191289\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F191303\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F191290\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F854601\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F854602\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F191267\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F191253\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F191270\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F191322\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F191268\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12963311\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F191324\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F191314\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F191273\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F191257\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299644\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F191261\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F191263\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F854599\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F191294\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16323360\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F191265\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2869390\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F191256\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F191272\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9587\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9587|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?28/34/29221?source=related_link\">",
"      Mannitol: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?42/60/43975?source=related_link\">",
"      Mannitol: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f3_42_3753="Treatment and prevention of Fusarium infection";
var content_f3_42_3753=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Treatment and prevention of Fusarium infection",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?3/42/3753/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/42/3753/contributors\">",
"     Marcio Nucci, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/42/3753/contributors\">",
"     Elias Anaissie, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?3/42/3753/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/42/3753/contributors\">",
"     Carol A Kauffman, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?3/42/3753/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/42/3753/contributors\">",
"     Anna R Thorner, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?3/42/3753/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jul 19, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H472773620\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fusarium species cause a broad spectrum of infections in humans, including superficial infections such as keratitis and onychomycosis, as well as locally invasive and disseminated infections [",
"    <a class=\"abstract\" href=\"UTD.htm?3/42/3753/abstract/1\">",
"     1",
"    </a>",
"    ]. Invasive and disseminated infections occur almost exclusively in severely immunocompromised patients, particularly among those with prolonged and profound neutropenia",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    severe T cell immunodeficiency. Among patients with hematologic malignancy, the infection predominates during periods of neutropenia, typically among patients with leukemia receiving induction chemotherapy.",
"   </p>",
"   <p>",
"    Fusarium species may also cause allergic diseases such as sinusitis in immunocompetent individuals [",
"    <a class=\"abstract\" href=\"UTD.htm?3/42/3753/abstract/2\">",
"     2",
"    </a>",
"    ], and mycotoxicosis following ingestion of food contaminated by toxin-producing Fusarium species [",
"    <a class=\"abstract\" href=\"UTD.htm?3/42/3753/abstract/3\">",
"     3",
"    </a>",
"    ]. Fusarium species are also important plant pathogens that cause various diseases on cereal grains [",
"    <a class=\"abstract\" href=\"UTD.htm?3/42/3753/abstract/3\">",
"     3",
"    </a>",
"    ], and occasionally cause infection in animals [",
"    <a class=\"abstract\" href=\"UTD.htm?3/42/3753/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The treatment and prevention of fusariosis will be reviewed here. The mycology, pathogenesis, epidemiology, clinical manifestations, and diagnosis of fusariosis are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/18/6439?source=see_link\">",
"     \"Mycology, pathogenesis, and epidemiology of Fusarium infection\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/29/10712?source=see_link\">",
"     \"Clinical manifestations and diagnosis of Fusarium infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H596312049\">",
"    <span class=\"h1\">",
"     SPECIES PREVALENCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;More than 100 species of Fusarium have been identified, but only a few cause infections in humans [",
"    <a class=\"abstract\" href=\"UTD.htm?3/42/3753/abstract/5\">",
"     5",
"    </a>",
"    ]. Fusarium solani is the most frequent cause of invasive disease (in approximately half of all cases), followed by F. oxysporum, F. moniliforme (previously F. verticillioides), and F. proliferatum [",
"    <a class=\"abstract\" href=\"UTD.htm?3/42/3753/abstract/6\">",
"     6",
"    </a>",
"    ]. Other species that rarely cause infections in humans include F. dimerum, F. chlamidosporum, F. sacchari, F. antophilum and others.",
"   </p>",
"   <p>",
"    Fusarial keratitis is most commonly caused by F. solani [",
"    <a class=\"abstract\" href=\"UTD.htm?3/42/3753/abstract/7\">",
"     7",
"    </a>",
"    ], whereas fusarial onychomycosis is most commonly caused by F. oxysporum [",
"    <a class=\"abstract\" href=\"UTD.htm?3/42/3753/abstract/8-10\">",
"     8-10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H346085910\">",
"    <span class=\"h1\">",
"     ANTIFUNGAL SUSCEPTIBILITY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fusarium species are relatively resistant in vitro to most antifungal agents. Although antifungal susceptibility testing results have varied in different studies, the following general patterns have been observed [",
"    <a class=\"abstract\" href=\"UTD.htm?3/42/3753/abstract/1,5,11-23\">",
"     1,5,11-23",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Most Fusarium isolates have higher",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/53/43863?source=see_link\">",
"       amphotericin B",
"      </a>",
"      minimum inhibitory concentrations (MICs) than do Aspergillus species.",
"     </li>",
"     <li>",
"      F. solani and F. moniliforme (previously F. verticillioides) have higher azole MICs than other Fusarium species.",
"     </li>",
"     <li>",
"      However, compared with F. solani, the MICs for F. oxysporum and F. moniliforme are lower for",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/53/43863?source=see_link\">",
"       amphotericin B",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/38/17002?source=see_link\">",
"       voriconazole",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/60/33737?source=see_link\">",
"       posaconazole",
"      </a>",
"      .",
"     </li>",
"     <li>",
"      Older azoles, such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/15/20730?source=see_link\">",
"       itraconazole",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/12/16586?source=see_link\">",
"       fluconazole",
"      </a>",
"      , have high MICs to Fusarium.",
"     </li>",
"     <li>",
"      The echinocandins (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/15/10486?source=see_link\">",
"       caspofungin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?43/31/44532?source=see_link\">",
"       micafungin",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/51/20276?source=see_link\">",
"       anidulafungin",
"      </a>",
"      ) lack activity against Fusarium spp.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The clinical relevance of these in vitro data has not been established. Interpreting the MICs of antifungal agents for molds is difficult with no established breakpoints for defining susceptibility or resistance [",
"    <a class=\"abstract\" href=\"UTD.htm?3/42/3753/abstract/6\">",
"     6",
"    </a>",
"    ]. Differences in testing methods are likely responsible for the differences in susceptibility testing results [",
"    <a class=\"abstract\" href=\"UTD.htm?3/42/3753/abstract/14,16,17,19\">",
"     14,16,17,19",
"    </a>",
"    ]. Because of these limitations, we cannot recommend routine in vitro susceptibility testing. When testing is performed, the results must be interpreted with caution, and treatment decisions should be based mostly upon the individual patient&rsquo;s response to therapy. Among immunocompromised patients with invasive disease, identification of Fusarium isolates to the species level may be clinically useful given the known variable susceptibility of different Fusarium spp to antifungal agents.",
"   </p>",
"   <p>",
"    Certain antifungal agents, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/22/33120?source=see_link\">",
"     terbinafine",
"    </a>",
"    and the echinocandins, have little in vitro activity alone, but appear synergistic with other antifungal agents in vitro when tested in combination. However, their role in the treatment of invasive disease is not clear. (See",
"    <a class=\"local\" href=\"#H420415669\">",
"     'Combination therapy'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Antifungal susceptibility testing is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/21/29018?source=see_link\">",
"     \"Antifungal susceptibility testing\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H420415640\">",
"    <span class=\"h1\">",
"     ANTIFUNGAL AGENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;As discussed above, different Fusarium species exhibit variable in vitro susceptibility to antifungal agents, and the clinical relevance of these data is not known. This section describes what is known about the clinical use of antifungal agents for Fusarium infections; most data come from case reports and observational studies in immunocompromised patients with invasive fusariosis.",
"   </p>",
"   <p>",
"    Treatment recommendations based upon the immune status of the host and the site(s) of infection are presented below. (See",
"    <a class=\"local\" href=\"#H472773634\">",
"     'Treatment'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H420415648\">",
"    <span class=\"h2\">",
"     Amphotericin B",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lipid formulations of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/53/43863?source=see_link\">",
"     amphotericin B",
"    </a>",
"    have been successful in the treatment of some patients, and have been used most extensively for invasive fusariosis [",
"    <a class=\"abstract\" href=\"UTD.htm?3/42/3753/abstract/24,25\">",
"     24,25",
"    </a>",
"    ]. In the Collaborative Exchange of Antifungal Research database, 28 of 3514 patients developed fusariosis and were treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/27/18871?source=see_link\">",
"     amphotericin B lipid complex",
"    </a>",
"    either as primary or salvage therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?3/42/3753/abstract/25\">",
"     25",
"    </a>",
"    ]. Of the 26 evaluable patients, 12 (46 percent) were cured or improved and three (12 percent) stabilized after receiving therapy. Patients with normal absolute neutrophil counts at the end of therapy had better outcomes than those who did not, regardless of neutrophil status at baseline.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H420415655\">",
"    <span class=\"h2\">",
"     Azoles",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/38/17002?source=see_link\">",
"     Voriconazole",
"    </a>",
"    is fungicidal for filamentous fungi, including Fusarium spp, and is approved in many parts of the world, including the United States, Europe, and Brazil, for the treatment of Fusarium infections in patients who are not responding to or are intolerant of other therapies. This recommendation was based upon a series of only 11 patients [",
"    <a class=\"abstract\" href=\"UTD.htm?3/42/3753/abstract/26\">",
"     26",
"    </a>",
"    ]. Additional publications have since extended the observations of the use of voriconazole among patients with fusariosis. These include a review of 102 cases [",
"    <a class=\"abstract\" href=\"UTD.htm?3/42/3753/abstract/27\">",
"     27",
"    </a>",
"    ], and a composite review of 73 cases from the Pfizer database and the French National Reference Center for Mycoses database [",
"    <a class=\"abstract\" href=\"UTD.htm?3/42/3753/abstract/28\">",
"     28",
"    </a>",
"    ]. In the latter study, the overall response rate (complete or partial) was 47 percent, and it was 52 percent when data were limited to those patients who received at least five days of therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?3/42/3753/abstract/28\">",
"     28",
"    </a>",
"    ]. The response rate did not differ among different species. The most significant parameter that predicted success was resolution of neutropenia; a 63 percent response rate was observed among patients whose neutropenia resolved, compared with only 5 percent among patients who remained neutropenic. None of the four patients with brain lesions caused by Fusarium spp survived. &nbsp;",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/60/33737?source=see_link\">",
"     Posaconazole",
"    </a>",
"    possesses in vitro activity against Fusarium spp, although results differed among studies; as noted with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/38/17002?source=see_link\">",
"     voriconazole",
"    </a>",
"    , the susceptibility pattern is species-dependent [",
"    <a class=\"abstract\" href=\"UTD.htm?3/42/3753/abstract/11\">",
"     11",
"    </a>",
"    ]. The clinical experience using posaconazole salvage therapy is somewhat limited. In a retrospective analysis, 21 patients with proven or probable invasive fusariosis who were not responding to or were intolerant of other therapies received oral posaconazole salvage therapy at 800 mg orally per day in divided doses [",
"    <a class=\"abstract\" href=\"UTD.htm?3/42/3753/abstract/29\">",
"     29",
"    </a>",
"    ]. Most patients (76 percent) had an underlying hematologic malignancy. A 48 percent complete or partial response to posaconazole was seen. Case reports have also suggested that posaconazole is effective for fusariosis [",
"    <a class=\"abstract\" href=\"UTD.htm?3/42/3753/abstract/30\">",
"     30",
"    </a>",
"    ]. On the other hand, cases of disseminated fusariosis have been reported in patients receiving posaconazole prophylaxis [",
"    <a class=\"abstract\" href=\"UTD.htm?3/42/3753/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Because older azoles (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/15/20730?source=see_link\">",
"     itraconazole",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/12/16586?source=see_link\">",
"     fluconazole",
"    </a>",
"    ) do not have activity against Fusarium species, they do not have a role in the treatment of invasive fusariosis [",
"    <a class=\"abstract\" href=\"UTD.htm?3/42/3753/abstract/22,32\">",
"     22,32",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H420415662\">",
"    <span class=\"h2\">",
"     Echinocandins",
"    </span>",
"    &nbsp;&mdash;&nbsp;The echinocandins (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/15/10486?source=see_link\">",
"     caspofungin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?43/31/44532?source=see_link\">",
"     micafungin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/51/20276?source=see_link\">",
"     anidulafungin",
"    </a>",
"    ) should",
"    <strong>",
"     not",
"    </strong>",
"    be used to treat invasive infection with Fusarium spp because they lack activity against these pathogens [",
"    <a class=\"abstract\" href=\"UTD.htm?3/42/3753/abstract/23\">",
"     23",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H346085910\">",
"     'Antifungal susceptibility'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H420415669\">",
"    <span class=\"h2\">",
"     Combination therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because of species&ndash;dependent variability in in vitro susceptibility profiles of Fusarium spp and the poor prognosis of fusariosis in immunocompromised hosts, particularly those with disseminated disease, some have recommended combination antifungal regimens initially in such settings in order to ensure activity of at least one agent [",
"    <a class=\"abstract\" href=\"UTD.htm?3/42/3753/abstract/33,34\">",
"     33,34",
"    </a>",
"    ]. A small number of in vitro studies have suggested that certain antifungal combinations may be synergistic (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/38/17002?source=see_link\">",
"     voriconazole",
"    </a>",
"    plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/22/33120?source=see_link\">",
"     terbinafine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?3/42/3753/abstract/35,36\">",
"     35,36",
"    </a>",
"    ] or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/53/43863?source=see_link\">",
"     amphotericin B",
"    </a>",
"    plus voriconazole [",
"    <a class=\"abstract\" href=\"UTD.htm?3/42/3753/abstract/35,36\">",
"     35,36",
"    </a>",
"    ]), although possible antagonism remains a potential concern, particularly with the latter combination.",
"   </p>",
"   <p>",
"    The clinical significance of these in vitro data is unclear. Single case reports have described successful outcomes using the following combinations:",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/53/43863?source=see_link\">",
"     amphotericin B",
"    </a>",
"    plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/38/17002?source=see_link\">",
"     voriconazole",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?3/42/3753/abstract/33,37-39\">",
"     33,37-39",
"    </a>",
"    ], amphotericin B plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/22/33120?source=see_link\">",
"     terbinafine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?3/42/3753/abstract/40,41\">",
"     40,41",
"    </a>",
"    ], or amphotericin B plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/15/10486?source=see_link\">",
"     caspofungin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?3/42/3753/abstract/42\">",
"     42",
"    </a>",
"    ]. However, potential publication bias limits the usefulness of these findings. In a retrospective review of 73 patients with invasive fusariosis treated with voriconazole, 13 received another agent (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/4/1096?source=see_link\">",
"     liposomal amphotericin B",
"    </a>",
"    , terbinafine, caspofungin, or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/60/33737?source=see_link\">",
"     posaconazole",
"    </a>",
"    ) in combination with or immediately following voriconazole; the response rate among these patients was similar to that reported with voriconazole monotherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?3/42/3753/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H472773634\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because Fusarium species exhibit limited and species-dependent susceptibility to antifungal agents and because of the lack of randomized trials, the optimal treatment of fusariosis is not well established [",
"    <a class=\"abstract\" href=\"UTD.htm?3/42/3753/abstract/43\">",
"     43",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/53/43863?source=see_link\">",
"     Amphotericin B",
"    </a>",
"    has been the most commonly used agent for invasive disease, but",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/38/17002?source=see_link\">",
"     voriconazole",
"    </a>",
"    is used with increasing frequency.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5520169\">",
"    <span class=\"h2\">",
"     Localized disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Localized disease, such as keratitis and onychomycosis, are the most common manifestations of Fusarium infection in immunocompetent patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H346085004\">",
"    <span class=\"h3\">",
"     Keratitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fusarial keratitis may develop following the traumatic inoculation of Fusarium-contaminated soil or plant material or related to poor hygiene practices in soft contact lens wearers. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/18/6439?source=see_link&amp;anchor=H420413563#H420413563\">",
"     \"Mycology, pathogenesis, and epidemiology of Fusarium infection\", section on 'Keratitis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The treatment of Fusarium keratitis is challenging because of the limited and variable susceptibility of Fusarium spp to antifungal agents, the poor tissue penetration of topical antifungal agents and the potential seriousness of infection by this pathogen, which can result in corneal perforation and even endophthalmitis.",
"   </p>",
"   <p>",
"    First-line therapy for fusarial keratitis includes a topical antifungal agent either alone or in combination with systemic antifungal medications. We favor a combination of topical plus systemic therapy in immunocompromised patients and in those with severe infections.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/39/43634?source=see_link\">",
"     Natamycin",
"    </a>",
"    suspension (5",
"    <span class=\"nowrap\">",
"     mg/mL)",
"    </span>",
"    has been the traditional drug of choice for topical therapy, although",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/53/43863?source=see_link\">",
"     amphotericin B",
"    </a>",
"    drops (1.5",
"    <span class=\"nowrap\">",
"     mg/mL)",
"    </span>",
"    have also been used [",
"    <a class=\"abstract\" href=\"UTD.htm?3/42/3753/abstract/7,44\">",
"     7,44",
"    </a>",
"    ]. Topical",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/38/17002?source=see_link\">",
"     voriconazole",
"    </a>",
"    is increasingly favored among ophthalmologists [",
"    <a class=\"abstract\" href=\"UTD.htm?3/42/3753/abstract/45,46\">",
"     45,46",
"    </a>",
"    ]. Topical agents should initially be applied hourly with subsequent modification based upon response.",
"   </p>",
"   <p>",
"    The addition of systemic therapy with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/38/17002?source=see_link\">",
"     voriconazole",
"    </a>",
"    is commonly used particularly in severe cases [",
"    <a class=\"abstract\" href=\"UTD.htm?3/42/3753/abstract/44,47\">",
"     44,47",
"    </a>",
"    ]. In hospitalized patients, the loading dose of voriconazole is 6",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    IV every 12 hours for two doses, followed by 4",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    IV every 12 hours. For outpatients, oral voriconazole may be given as a loading dose of 400 mg orally every 12 hours for two doses, followed by 200 mg orally twice daily. Oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/60/33737?source=see_link\">",
"     posaconazole",
"    </a>",
"    has been used successfully in three patients who did not respond to systemic",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    topical voriconazole [",
"    <a class=\"abstract\" href=\"UTD.htm?3/42/3753/abstract/48\">",
"     48",
"    </a>",
"    ]. Small case series have reported success with the addition of intracorneal (intrastromal) injections of voriconazole in patients who responded poorly to topical and systemic therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?3/42/3753/abstract/49,50\">",
"     49,50",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The total duration of antifungal therapy depends upon the patient&rsquo;s response, which should be assessed frequently by ophthalmologic examinations. Many patients require several months of therapy. In a retrospective study of fungal keratitis, Fusarium was the most common pathogen, occurring in 29 of 78 eyes (37 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?3/42/3753/abstract/51\">",
"     51",
"    </a>",
"    ]. The average duration of therapy was 81 days (range 20 days to 1 year). The time to healing, defined as resolution of infiltrate and epithelial healing, was a mean of 57 days but ranged from 8 to 300 days.",
"   </p>",
"   <p>",
"    Patients who do not respond to antifungal therapy usually require corneal transplantation. Patients with keratitis should be managed by an ophthalmologist with expertise in corneal infections.",
"   </p>",
"   <p>",
"    The management of endophthalmitis caused by molds is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/55/2937?source=see_link&amp;anchor=H634314713#H634314713\">",
"     \"Treatment of endophthalmitis due to molds\", section on 'Treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H346085011\">",
"    <span class=\"h3\">",
"     Onychomycosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fusarium onychomycosis is difficult to treat, with high failure rates even after long courses of systemic antifungal or topical therapy, with or without nail avulsion [",
"    <a class=\"abstract\" href=\"UTD.htm?3/42/3753/abstract/52\">",
"     52",
"    </a>",
"    ]. Despite limited in vitro activity, oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/15/20730?source=see_link\">",
"     itraconazole",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/22/33120?source=see_link\">",
"     terbinafine",
"    </a>",
"    are commonly used as therapy for fusarial onychomycosis, and have been observed to be effective in immunocompetent patients in some [",
"    <a class=\"abstract\" href=\"UTD.htm?3/42/3753/abstract/53-55\">",
"     53-55",
"    </a>",
"    ], but not all reports [",
"    <a class=\"abstract\" href=\"UTD.htm?3/42/3753/abstract/56\">",
"     56",
"    </a>",
"    ]. Because the newer triazoles,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/38/17002?source=see_link\">",
"     voriconazole",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/60/33737?source=see_link\">",
"     posaconazole",
"    </a>",
"    have greater in vitro activity against Fusarium spp than itraconazole, we recommend the use of oral voriconazole in immunocompromised patients with onychomycosis caused by Fusarium spp. Voriconazole is administered as a loading dose of 400 mg orally every 12 hours for two doses, followed by 200 mg orally twice daily. Adjunctive nail avulsion with topical",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/53/43863?source=see_link\">",
"     amphotericin B",
"    </a>",
"    can be used in patients who do not respond to systemic antifungal therapy, but it is usually avoided in severely immunocompromised patients. The infection often requires months of therapy and the duration depends on the patient&rsquo;s overall state of immunosuppression and the response to therapy. (See",
"    <a class=\"local\" href=\"#H5520317\">",
"     'Duration'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The management of onychomycosis in immunocompetent patients is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/8/5258?source=see_link&amp;anchor=H16#H16\">",
"     \"Onychomycosis\", section on 'Indications'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/8/5258?source=see_link&amp;anchor=H9#H9\">",
"     \"Onychomycosis\", section on 'Yeast onychomycosis'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/8/5258?source=see_link&amp;anchor=H10#H10\">",
"     \"Onychomycosis\", section on 'Mold onychomycosis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H472773641\">",
"    <span class=\"h2\">",
"     Invasive disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because Fusarium infections are almost always invasive in immunocompromised hosts, and are often disseminated, treatment should be multifaceted; although systemic antifungal agents represent the cornerstone of therapy, surgical debridement of infected tissues",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    removal of infected foreign bodies should be performed when possible. Therapy usually starts without knowing the infecting species because identification to the species level and susceptibility testing are typically performed only at reference laboratories, and results may not be rapidly available to the treating clinician.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H472773663\">",
"    <span class=\"h3\">",
"     Choice of antifungal therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The optimal treatment strategy of patients with fusariosis remains unclear because of the lack of clinical trials and the critical role that immune reconstitution plays in the outcome of this infection. Successful outcomes have been reported with various antifungal agents including",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/53/43863?source=see_link\">",
"     amphotericin B",
"    </a>",
"    deoxycholate [",
"    <a class=\"abstract\" href=\"UTD.htm?3/42/3753/abstract/57\">",
"     57",
"    </a>",
"    ],",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/4/1096?source=see_link\">",
"     liposomal amphotericin B",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?3/42/3753/abstract/57\">",
"     57",
"    </a>",
"    ],",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/27/18871?source=see_link\">",
"     amphotericin B lipid complex",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?3/42/3753/abstract/25\">",
"     25",
"    </a>",
"    ], and the triazole antifungals,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/38/17002?source=see_link\">",
"     voriconazole",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?3/42/3753/abstract/26,28\">",
"     26,28",
"    </a>",
"    ] and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/60/33737?source=see_link\">",
"     posaconazole",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?3/42/3753/abstract/29\">",
"     29",
"    </a>",
"    ]. Combination antifungal therapy has also been described in single case reports and a retrospective study, as discussed above. (See",
"    <a class=\"local\" href=\"#H420415669\">",
"     'Combination therapy'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Studies of salvage therapy have shown better overall outcomes than studies of primary therapy, suggesting a selection bias; in other words, patients treated with salvage regimens may have a better prognosis simply due to the fact that they survived long enough to receive a second treatment regimen [",
"    <a class=\"abstract\" href=\"UTD.htm?3/42/3753/abstract/58\">",
"     58",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A lipid formulation of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/53/43863?source=see_link\">",
"     amphotericin B",
"    </a>",
"    (3 to 5",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    IV once daily) is usually the preferable first-line therapy. A combination of a lipid formulation of amphotericin B and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/38/17002?source=see_link\">",
"     voriconazole",
"    </a>",
"    (6",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    IV every 12 hours for two doses, followed by 4",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    IV every 12 hours) is often used because of the variable susceptibility of Fusarium spp to antifungal agents and the need to ensure that at least one active antifungal agent is given. Combination therapy with a lipid formulation of amphotericin B and voriconazole should be considered in cases of severe immunosuppression",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    severe disease. We favor a lipid formulation rather than amphotericin B deoxycholate because the latter agent is likely to result in more severe toxicities. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/41/15001?source=see_link\">",
"     \"Pharmacology of amphotericin B\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/5/38998?source=see_link\">",
"     \"Amphotericin B nephrotoxicity\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A switch from IV to oral therapy with either",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/38/17002?source=see_link\">",
"     voriconazole",
"    </a>",
"    (200 to 300 mg orally twice daily) or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/60/33737?source=see_link\">",
"     posaconazole",
"    </a>",
"    (200 mg orally four times per day) may be considered upon achievement of a significant response provided that the patient is compliant and is able to absorb oral medications. Monitoring serum drug concentration is recommended during oral therapy. This is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/4/36938?source=see_link&amp;anchor=H28#H28\">",
"     \"Pharmacology of azoles\", section on 'Voriconazole'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/4/36938?source=see_link&amp;anchor=H30#H30\">",
"     \"Pharmacology of azoles\", section on 'Posaconazole'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5520317\">",
"    <span class=\"h3\">",
"     Duration",
"    </span>",
"    &nbsp;&mdash;&nbsp;The duration of antifungal therapy depends upon the site and extent of the infection, the patient's underlying disease and immune status, the need for continuous immunosuppression, and the response to therapy. The most important factor in outcome is resolution of neutropenia. Antifungal therapy is generally continued until all signs and symptoms of the infection have resolved, radiographic abnormalities have stabilized, and significant immune reconstitution has occurred. For severely immunosuppressed patients, antifungal therapy may continue for months or longer in some cases.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H472773691\">",
"    <span class=\"h3\">",
"     Adjunctive therapies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because a recovering immune system is essential for the successful outcome of fusariosis, every effort should be made to enhance immunity; this includes decreasing the dose of immunosuppressants when possible and the use of adjunctive immunotherapy such as granulocyte or granulocyte-macrophage colony-stimulating factors (G-CSF or GM-CSF), G-CSF-stimulated granulocyte transfusions, or interferon-gamma adjunctive therapies. The efficacy of these therapies for fusariosis has not been established [",
"    <a class=\"abstract\" href=\"UTD.htm?3/42/3753/abstract/59,60\">",
"     59,60",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Additional strategies include surgical debridement of infected tissues (eg, sinuses, soft tissues, lung nodules) [",
"    <a class=\"abstract\" href=\"UTD.htm?3/42/3753/abstract/61\">",
"     61",
"    </a>",
"    ], particularly in immunocompromised patients with localized disease, and removal of central venous catheters in patients with possible catheter-related fusariosis [",
"    <a class=\"abstract\" href=\"UTD.htm?3/42/3753/abstract/62\">",
"     62",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H472773698\">",
"    <span class=\"h1\">",
"     PREVENTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because of the poor prognosis associated with fusariosis and the limited susceptibility of Fusarium species to antifungal agents, preventing this infection is important, when possible.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H524570891\">",
"    <span class=\"h2\">",
"     Primary prophylaxis",
"    </span>",
"    &nbsp;&mdash;&nbsp;General preventive measures that should be employed in patients at significant risk of invasive fusariosis, such as patients with hematologic malignancies undergoing induction chemotherapy or hematopoietic cell transplantation, include [",
"    <a class=\"abstract\" href=\"UTD.htm?3/42/3753/abstract/1,63-65\">",
"     1,63-65",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Avoidance of activities associated with skin breakdown.",
"     </li>",
"     <li>",
"      Avoidance of contact of areas of skin breakdown with tap water.",
"     </li>",
"     <li>",
"      Careful examination for and treatment of onychomycosis and paronychia and surgical debridement of infected wounds prior to commencing anti-cancer therapies. (See",
"      <a class=\"local\" href=\"#H346085011\">",
"       'Onychomycosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Delaying severely immunosuppressive therapies until areas of skin breakdown are healed, when possible.",
"     </li>",
"     <li>",
"      Following appropriate air and water precautions during periods at risk. These include use of a high efficiency particulate air filter and positive pressure isolation rooms, avoiding contact with reservoirs of Fusarium spp, such as tap water, and having showers cleaned thoroughly prior to use by high-risk patients. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?2/59/3001?source=see_link&amp;anchor=H875811313#H875811313\">",
"       \"Prophylaxis of infection during chemotherapy-induced neutropenia in high-risk adults\", section on 'Infection control precautions'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H524570898\">",
"    <span class=\"h2\">",
"     Secondary prophylaxis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Secondary prophylaxis involves the use of antifungal therapy during periods of increased risk for relapsing fusariosis, such as following chemotherapy or hematopoietic cell transplantation (HCT) or when immunosuppression is significantly increased for the management of graft-versus-host disease (GVHD). Among patients with a history of invasive Fusarium infection, the following measures should be taken [",
"    <a class=\"abstract\" href=\"UTD.htm?3/42/3753/abstract/1\">",
"     1",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Evaluation of residual infection prior to starting immunosuppressive therapy: blood cultures, imaging with CT, others as indicated.",
"     </li>",
"     <li>",
"      Prophylaxis with an antifungal agent active against the Fusarium species previously isolated (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/38/17002?source=see_link\">",
"       voriconazole",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/60/33737?source=see_link\">",
"       posaconazole",
"      </a>",
"      , or a lipid formulation of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/53/43863?source=see_link\">",
"       amphotericin B",
"      </a>",
"      ). (see",
"      <a class=\"local\" href=\"#H472773663\">",
"       'Choice of antifungal therapy'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      Application of less immunosuppressive therapies when possible (eg, dose reduction of the antineoplastic regimen, reduced intensity rather than myeloablative conditioning regimen for HCT).",
"     </li>",
"     <li>",
"      Careful selection of donors in allogeneic hematopoietic cell transplantation to decrease the immunosuppressive effects of GVHD, graft failure, or cytomegalovirus reactivation.",
"     </li>",
"     <li>",
"      Consideration of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/13/23767?source=see_link\">",
"       granulocyte colony-stimulating factor",
"      </a>",
"      (G-CSF) plus dexamethasone-elicited granulocyte transfusions during periods of expected neutropenia [",
"      <a class=\"abstract\" href=\"UTD.htm?3/42/3753/abstract/59,60\">",
"       59,60",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Documentation of GVHD before empirical therapy with glucocorticoids, when possible, and prompt therapy of GVHD with the lowest immunosuppressive regimen possible and a careful approach to glucocorticoid tapering.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5519506\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The prognosis of fusariosis is directly related to the patient&rsquo;s immune status, with very high mortality rates in persistently immunocompromised patients. The overall mortality rate from disseminated Fusarium infection is 60 to 80 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?3/42/3753/abstract/1,24,66-68\">",
"     1,24,66-68",
"    </a>",
"    ]. In a series of 84 patients with fusariosis and an underlying hematologic malignancy, the 30- and 90-day survival rates were 50 and 21 percent, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?3/42/3753/abstract/57\">",
"     57",
"    </a>",
"    ]. Persistent neutropenia and recent glucocorticoid therapy were the only independent factors associated with poor outcome; no patient who had adverse prognostic factors survived, whereas the survival rate was 67 percent among patients who had neither of these factors.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H472773705\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Fusarium species cause a broad spectrum of infections in humans including superficial infections such as keratitis and onychomycosis, as well as locally invasive and disseminated infections. Invasive and disseminated infections occur almost exclusively in severely immunocompromised patients. (See",
"      <a class=\"local\" href=\"#H472773620\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Fusarium solani is the most frequent cause of invasive disease, causing approximately 50 percent of cases, followed by F. oxysporum, F. moniliforme (previously F. verticillioides), and F. proliferatum. Fusarial keratitis is most commonly caused by F. solani, whereas fusarial onychomycosis is most commonly caused by F. oxysporum. (See",
"      <a class=\"local\" href=\"#H596312049\">",
"       'Species prevalence'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Fusarium species are relatively resistant in vitro to most antifungal agents, with F. solani being more resistant than other Fusarium species. (See",
"      <a class=\"local\" href=\"#H346085910\">",
"       'Antifungal susceptibility'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients suspected of having Fusarium keratitis should be evaluated and treated urgently. Treatment usually involves a combination of topical and systemic antifungal therapy. For patients with Fusarium keratitis, we suggest initial therapy with a topical antifungal agent in combination with systemic",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/38/17002?source=see_link\">",
"       voriconazole",
"      </a>",
"      (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Appropriate topical agents include",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/39/43634?source=see_link\">",
"       natamycin",
"      </a>",
"      , voriconazole, and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/53/43863?source=see_link\">",
"       amphotericin B",
"      </a>",
"      . Among these, voriconazole is generally favored by ophthalmologists. Topical agents should be used every hour initially. (See",
"      <a class=\"local\" href=\"#H346085004\">",
"       'Keratitis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For immunocompromised patients with Fusarium onychomycosis, we suggest",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/38/17002?source=see_link\">",
"       voriconazole",
"      </a>",
"      (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H346085011\">",
"       'Onychomycosis'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H524570891\">",
"       'Primary prophylaxis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Immunocompromised patients with invasive fusariosis require aggressive antifungal therapy. In such patients, we suggest initial therapy with a lipid formulation of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/53/43863?source=see_link\">",
"       amphotericin B",
"      </a>",
"      (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Combination therapy with a lipid formulation of amphotericin B and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/38/17002?source=see_link\">",
"       voriconazole",
"      </a>",
"      should be considered in cases of severe immunosuppression",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      severe disease. The dosing of lipid formulations of amphotericin B is 3 to 5",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      IV once daily, and the dosing of voriconazole is 6",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      IV every 12 hours for two doses, followed by 4",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      IV every 12 hours. (See",
"      <a class=\"local\" href=\"#H472773663\">",
"       'Choice of antifungal therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Disseminated Fusarium infections are associated with a 60 to 80 percent mortality rate. The prognosis of fusariosis is directly related to the patient&rsquo;s immune status, with high mortality rates in persistently immunosuppressed patients, especially those who remain neutropenic. &nbsp;(See",
"      <a class=\"local\" href=\"#H5519506\">",
"       'Prognosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/42/3753/abstract/1\">",
"      Nucci M, Anaissie E. Fusarium infections in immunocompromised patients. Clin Microbiol Rev 2007; 20:695.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/42/3753/abstract/2\">",
"      Wickern GM. Fusarium allergic fungal sinusitis. J Allergy Clin Immunol 1993; 92:624.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/42/3753/abstract/3\">",
"      Nelson PE, Dignani MC, Anaissie EJ. Taxonomy, biology, and clinical aspects of Fusarium species. Clin Microbiol Rev 1994; 7:479.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/42/3753/abstract/4\">",
"      Evans J, Levesque D, de Lahunta A, Jensen HE. Intracranial fusariosis: a novel cause of fungal meningoencephalitis in a dog. Vet Pathol 2004; 41:510.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/42/3753/abstract/5\">",
"      Alastruey-Izquierdo A, Cuenca-Estrella M, Monz&oacute;n A, et al. Antifungal susceptibility profile of clinical Fusarium spp. isolates identified by molecular methods. J Antimicrob Chemother 2008; 61:805.",
"     </a>",
"    </li>",
"    <li>",
"     Torres HA, Kontoyiannis DP. Hyalohyphomycoses (Hyaline Moulds). In: Essentials of Clinical Mycology, Second edition, Kauffman C, Pappas PG, Sobel JD (Eds), Springer, New York 2011. p.281.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/42/3753/abstract/7\">",
"      D&oacute;czi I, Gyetvai T, Kredics L, Nagy E. Involvement of Fusarium spp. in fungal keratitis. Clin Microbiol Infect 2004; 10:773.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/42/3753/abstract/8\">",
"      Brilhante RS, Cordeiro RA, Medrano DJ, et al. Onychomycosis in Cear&aacute; (Northeast Brazil): epidemiological and laboratory aspects. Mem Inst Oswaldo Cruz 2005; 100:131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/42/3753/abstract/9\">",
"      Godoy P, Nunes E, Silva V, et al. Onychomycosis caused by Fusarium solani and Fusarium oxysporum in S&atilde;o Paulo, Brazil. Mycopathologia 2004; 157:287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/42/3753/abstract/10\">",
"      Ninet B, Jan I, Bontems O, et al. Molecular identification of Fusarium species in onychomycoses. Dermatology 2005; 210:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/42/3753/abstract/11\">",
"      Torres HA, Hachem RY, Chemaly RF, et al. Posaconazole: a broad-spectrum triazole antifungal. Lancet Infect Dis 2005; 5:775.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/42/3753/abstract/12\">",
"      Cuenca-Estrella M, Gomez-Lopez A, Mellado E, et al. Head-to-head comparison of the activities of currently available antifungal agents against 3,378 Spanish clinical isolates of yeasts and filamentous fungi. Antimicrob Agents Chemother 2006; 50:917.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/42/3753/abstract/13\">",
"      Espinel-Ingroff A. In vitro antifungal activities of anidulafungin and micafungin, licensed agents and the investigational triazole posaconazole as determined by NCCLS methods for 12,052 fungal isolates: review of the literature. Rev Iberoam Micol 2003; 20:121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/42/3753/abstract/14\">",
"      Paphitou NI, Ostrosky-Zeichner L, Paetznick VL, et al. In vitro activities of investigational triazoles against Fusarium species: effects of inoculum size and incubation time on broth microdilution susceptibility test results. Antimicrob Agents Chemother 2002; 46:3298.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/42/3753/abstract/15\">",
"      Arikan S, Lozano-Chiu M, Paetznick V, et al. Microdilution susceptibility testing of amphotericin B, itraconazole, and voriconazole against clinical isolates of Aspergillus and Fusarium species. J Clin Microbiol 1999; 37:3946.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/42/3753/abstract/16\">",
"      Espinel-Ingroff A, Chaturvedi V, Fothergill A, Rinaldi MG. Optimal testing conditions for determining MICs and minimum fungicidal concentrations of new and established antifungal agents for uncommon molds: NCCLS collaborative study. J Clin Microbiol 2002; 40:3776.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/42/3753/abstract/17\">",
"      Meletiadis J, Meis JF, Mouton JW, et al. Comparison of NCCLS and 3-(4,5-dimethyl-2-Thiazyl)-2, 5-diphenyl-2H-tetrazolium bromide (MTT) methods of in vitro susceptibility testing of filamentous fungi and development of a new simplified method. J Clin Microbiol 2000; 38:2949.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/42/3753/abstract/18\">",
"      Pfaller MA, Diekema DJ. Rare and emerging opportunistic fungal pathogens: concern for resistance beyond Candida albicans and Aspergillus fumigatus. J Clin Microbiol 2004; 42:4419.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/42/3753/abstract/19\">",
"      Szekely A, Johnson EM, Warnock DW. Comparison of E-test and broth microdilution methods for antifungal drug susceptibility testing of molds. J Clin Microbiol 1999; 37:1480.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/42/3753/abstract/20\">",
"      Sabatelli F, Patel R, Mann PA, et al. In vitro activities of posaconazole, fluconazole, itraconazole, voriconazole, and amphotericin B against a large collection of clinically important molds and yeasts. Antimicrob Agents Chemother 2006; 50:2009.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/42/3753/abstract/21\">",
"      Tortorano AM, Prigitano A, Dho G, et al. Species distribution and in vitro antifungal susceptibility patterns of 75 clinical isolates of Fusarium spp. from northern Italy. Antimicrob Agents Chemother 2008; 52:2683.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/42/3753/abstract/22\">",
"      Speeleveld E, Gordts B, Van Landuyt HW, et al. Susceptibility of clinical isolates of Fusarium to antifungal drugs. Mycoses 1996; 39:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/42/3753/abstract/23\">",
"      Cornely OA, Schmitz K, Aisenbrey S. The first echinocandin: caspofungin. Mycoses 2002; 45 Suppl 3:56.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/42/3753/abstract/24\">",
"      Boutati EI, Anaissie EJ. Fusarium, a significant emerging pathogen in patients with hematologic malignancy: ten years' experience at a cancer center and implications for management. Blood 1997; 90:999.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/42/3753/abstract/25\">",
"      Perfect JR. Treatment of non-Aspergillus moulds in immunocompromised patients, with amphotericin B lipid complex. Clin Infect Dis 2005; 40 Suppl 6:S401.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/42/3753/abstract/26\">",
"      Perfect JR, Marr KA, Walsh TJ, et al. Voriconazole treatment for less-common, emerging, or refractory fungal infections. Clin Infect Dis 2003; 36:1122.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/42/3753/abstract/27\">",
"      Stanzani M, Tumietto F, Vianelli N, Baccarani M. Update on the treatment of disseminated fusariosis: Focus on voriconazole. Ther Clin Risk Manag 2007; 3:1165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/42/3753/abstract/28\">",
"      Lortholary O, Obenga G, Biswas P, et al. International retrospective analysis of 73 cases of invasive fusariosis treated with voriconazole. Antimicrob Agents Chemother 2010; 54:4446.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/42/3753/abstract/29\">",
"      Raad II, Hachem RY, Herbrecht R, et al. Posaconazole as salvage treatment for invasive fusariosis in patients with underlying hematologic malignancy and other conditions. Clin Infect Dis 2006; 42:1398.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/42/3753/abstract/30\">",
"      Herbrecht R, Kessler R, Kravanja C, et al. Successful treatment of Fusarium proliferatum pneumonia with posaconazole in a lung transplant recipient. J Heart Lung Transplant 2004; 23:1451.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/42/3753/abstract/31\">",
"      Bose P, Parekh HD, Holter JL, Greenfield RA. Disseminated fusariosis occurring in two patients despite posaconazole prophylaxis. J Clin Microbiol 2011; 49:1674.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/42/3753/abstract/32\">",
"      Pujol I, Guarro J, Gen&eacute; J, Sala J. In-vitro antifungal susceptibility of clinical and environmental Fusarium spp. strains. J Antimicrob Chemother 1997; 39:163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/42/3753/abstract/33\">",
"      Ho DY, Lee JD, Rosso F, Montoya JG. Treating disseminated fusariosis: amphotericin B, voriconazole or both? Mycoses 2007; 50:227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/42/3753/abstract/34\">",
"      Vazquez JA. Clinical practice: combination antifungal therapy for mold infections: much ado about nothing? Clin Infect Dis 2008; 46:1889.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/42/3753/abstract/35\">",
"      C&oacute;rdoba S, Rodero L, Vivot W, et al. In vitro interactions of antifungal agents against clinical isolates of Fusarium spp. Int J Antimicrob Agents 2008; 31:171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/42/3753/abstract/36\">",
"      Ortoneda M, Capilla J, Javier Pastor F, et al. In vitro interactions of licensed and novel antifungal drugs against Fusarium spp. Diagn Microbiol Infect Dis 2004; 48:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/42/3753/abstract/37\">",
"      Durand-Joly I, Alfandari S, Benchikh Z, et al. Successful outcome of disseminated Fusarium infection with skin localization treated with voriconazole and amphotericin B-lipid complex in a patient with acute leukemia. J Clin Microbiol 2003; 41:4898.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/42/3753/abstract/38\">",
"      Guzman-Cottrill JA, Zheng X, Chadwick EG. Fusarium solani endocarditis successfully treated with liposomal amphotericin B and voriconazole. Pediatr Infect Dis J 2004; 23:1059.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/42/3753/abstract/39\">",
"      Tezcan G, Ozhak-Baysan B, Alastruey-Izquierdo A, et al. Disseminated fusariosis caused by Fusarium verticillioides in an acute lymphoblastic leukemia patient after allogeneic hematopoietic stem cell transplantation. J Clin Microbiol 2009; 47:278.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/42/3753/abstract/40\">",
"      Rothe A, Seibold M, Hoppe T, et al. Combination therapy of disseminated Fusarium oxysporum infection with terbinafine and amphotericin B. Ann Hematol 2004; 83:394.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/42/3753/abstract/41\">",
"      Neuburger S, Massenkeil G, Seibold M, et al. Successful salvage treatment of disseminated cutaneous fusariosis with liposomal amphotericin B and terbinafine after allogeneic stem cell transplantation. Transpl Infect Dis 2008; 10:290.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/42/3753/abstract/42\">",
"      Makowsky MJ, Warkentin DI, Savoie ML. Caspofungin and amphotericin B for disseminated Fusarium verticillioides in leukemia. Ann Pharmacother 2005; 39:1365.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/42/3753/abstract/43\">",
"      Dignani MC, Anaissie E. Human fusariosis. Clin Microbiol Infect 2004; 10 Suppl 1:67.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/42/3753/abstract/44\">",
"      Alfonso EC, Cantu-Dibildox J, Munir WM, et al. Insurgence of Fusarium keratitis associated with contact lens wear. Arch Ophthalmol 2006; 124:941.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/42/3753/abstract/45\">",
"      Bunya VY, Hammersmith KM, Rapuano CJ, et al. Topical and oral voriconazole in the treatment of fungal keratitis. Am J Ophthalmol 2007; 143:151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/42/3753/abstract/46\">",
"      Hariprasad SM, Mieler WF, Lin TK, et al. Voriconazole in the treatment of fungal eye infections: a review of current literature. Br J Ophthalmol 2008; 92:871.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/42/3753/abstract/47\">",
"      Centers for Disease Control and Prevention (CDC). Fusarium keratitis--multiple states, 2006. MMWR Morb Mortal Wkly Rep 2006; 55:400.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/42/3753/abstract/48\">",
"      Tu EY, McCartney DL, Beatty RF, et al. Successful treatment of resistant ocular fusariosis with posaconazole (SCH-56592). Am J Ophthalmol 2007; 143:222.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/42/3753/abstract/49\">",
"      Sharma N, Agarwal P, Sinha R, et al. Evaluation of intrastromal voriconazole injection in recalcitrant deep fungal keratitis: case series. Br J Ophthalmol 2011; 95:1735.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/42/3753/abstract/50\">",
"      Siatiri H, Daneshgar F, Siatiri N, Khodabande A. The effects of intrastromal voriconazole injection and topical voriconazole in the treatment of recalcitrant Fusarium keratitis. Cornea 2011; 30:872.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/42/3753/abstract/51\">",
"      Yildiz EH, Abdalla YF, Elsahn AF, et al. Update on fungal keratitis from 1999 to 2008. Cornea 2010; 29:1406.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/42/3753/abstract/52\">",
"      Tosti A, Piraccini BM, Lorenzi S, Iorizzo M. Treatment of nondermatophyte mold and Candida onychomycosis. Dermatol Clin 2003; 21:491.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/42/3753/abstract/53\">",
"      Hattori N, Shirai A, Sugiura Y, et al. Onychomycosis caused by Fusarium proliferatum. Br J Dermatol 2005; 153:647.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/42/3753/abstract/54\">",
"      Gupta AK, Baran R, Summerbell RC. Fusarium infections of the skin. Curr Opin Infect Dis 2000; 13:121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/42/3753/abstract/55\">",
"      Guilhermetti E, Takahachi G, Shinobu CS, Svidzinski TI. Fusarium spp. as agents of onychomycosis in immunocompetent hosts. Int J Dermatol 2007; 46:822.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/42/3753/abstract/56\">",
"      Baudraz-Rosselet F, Ruffieux C, Lurati M, et al. Onychomycosis insensitive to systemic terbinafine and azole treatments reveals non-dermatophyte moulds as infectious agents. Dermatology 2010; 220:164.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/42/3753/abstract/57\">",
"      Nucci M, Anaissie EJ, Queiroz-Telles F, et al. Outcome predictors of 84 patients with hematologic malignancies and Fusarium infection. Cancer 2003; 98:315.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/42/3753/abstract/58\">",
"      Almyroudis NG, Kontoyiannis DP, Sepkowitz KA, et al. Issues related to the design and interpretation of clinical trials of salvage therapy for invasive mold infection. Clin Infect Dis 2006; 43:1449.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/42/3753/abstract/59\">",
"      Dignani MC, Anaissie EJ, Hester JP, et al. Treatment of neutropenia-related fungal infections with granulocyte colony-stimulating factor-elicited white blood cell transfusions: a pilot study. Leukemia 1997; 11:1621.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/42/3753/abstract/60\">",
"      Hennequin C, Benkerrou M, Gaillard JL, et al. Role of granulocyte colony-stimulating factor in the management of infection with Fusarium oxysporum in a neutropenic child. Clin Infect Dis 1994; 18:490.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/42/3753/abstract/61\">",
"      Lupinetti FM, Giller RH, Trigg ME. Operative treatment of Fusarium fungal infection of the lung. Ann Thorac Surg 1990; 49:991.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/42/3753/abstract/62\">",
"      Velasco E, Martins CA, Nucci M. Successful treatment of catheter-related fusarial infection in immunocompromised children. Eur J Clin Microbiol Infect Dis 1995; 14:697.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/42/3753/abstract/63\">",
"      Nucci M, Anaissie E. Cutaneous infection by Fusarium species in healthy and immunocompromised hosts: implications for diagnosis and management. Clin Infect Dis 2002; 35:909.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/42/3753/abstract/64\">",
"      Anaissie EJ, Kuchar RT, Rex JH, et al. Fusariosis associated with pathogenic fusarium species colonization of a hospital water system: a new paradigm for the epidemiology of opportunistic mold infections. Clin Infect Dis 2001; 33:1871.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/42/3753/abstract/65\">",
"      Anaissie EJ, Stratton SL, Dignani MC, et al. Cleaning patient shower facilities: a novel approach to reducing patient exposure to aerosolized Aspergillus species and other opportunistic molds. Clin Infect Dis 2002; 35:E86.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/42/3753/abstract/66\">",
"      Martino P, Gastaldi R, Raccah R, Girmenia C. Clinical patterns of Fusarium infections in immunocompromised patients. J Infect 1994; 28 Suppl 1:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/42/3753/abstract/67\">",
"      Gamis AS, Gudnason T, Giebink GS, Ramsay NK. Disseminated infection with Fusarium in recipients of bone marrow transplants. Rev Infect Dis 1991; 13:1077.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/42/3753/abstract/68\">",
"      Venditti M, Micozzi A, Gentile G, et al. Invasive Fusarium solani infections in patients with acute leukemia. Rev Infect Dis 1988; 10:653.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 15674 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-183.1.191.153-6CC31590FA-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_42_3753=[""].join("\n");
var outline_f3_42_3753=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H472773705\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H472773620\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H596312049\">",
"      SPECIES PREVALENCE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H346085910\">",
"      ANTIFUNGAL SUSCEPTIBILITY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H420415640\">",
"      ANTIFUNGAL AGENTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H420415648\">",
"      Amphotericin B",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H420415655\">",
"      Azoles",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H420415662\">",
"      Echinocandins",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H420415669\">",
"      Combination therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H472773634\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5520169\">",
"      Localized disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H346085004\">",
"      - Keratitis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H346085011\">",
"      - Onychomycosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H472773641\">",
"      Invasive disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H472773663\">",
"      - Choice of antifungal therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5520317\">",
"      - Duration",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H472773691\">",
"      - Adjunctive therapies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H472773698\">",
"      PREVENTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H524570891\">",
"      Primary prophylaxis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H524570898\">",
"      Secondary prophylaxis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5519506\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H472773705\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/5/38998?source=related_link\">",
"      Amphotericin B nephrotoxicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/21/29018?source=related_link\">",
"      Antifungal susceptibility testing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/29/10712?source=related_link\">",
"      Clinical manifestations and diagnosis of Fusarium infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/18/6439?source=related_link\">",
"      Mycology, pathogenesis, and epidemiology of Fusarium infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/8/5258?source=related_link\">",
"      Onychomycosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/41/15001?source=related_link\">",
"      Pharmacology of amphotericin B",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/4/36938?source=related_link\">",
"      Pharmacology of azoles",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/59/3001?source=related_link\">",
"      Prophylaxis of infection during chemotherapy-induced neutropenia in high-risk adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/55/2937?source=related_link\">",
"      Treatment of endophthalmitis due to molds",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f3_42_3754="Synovial pathology in rheumatoid arthritis";
var content_f3_42_3754=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Synovial pathology in rheumatoid arthritis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?3/42/3754/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/42/3754/contributors\">",
"     Alisa E Koch, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?3/42/3754/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/42/3754/contributors\">",
"     RN Maini, BA, MB BChir, FRCP, FMedSci, FRS",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?3/42/3754/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/42/3754/contributors\">",
"     Paul L Romain, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?3/42/3754/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 11, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;No single histologic feature or group of features in synovium is diagnostic of rheumatoid arthritis (RA). Many of the histologic changes that are seen can also occur in other inflammatory joint diseases and even in osteoarthritis. Thus, the diagnosis of RA is made by history and physical examination of the patient, and is supported by the presence of characteristic pathologic findings in synovial tissue. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/55/6010?source=see_link\">",
"     \"Diagnosis and differential diagnosis of rheumatoid arthritis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There has been a resurgence of interest in the study of synovial tissue in RA over the past several years. Synovial tissue obtained at joint replacement surgery as well as needle and arthroscopic biopsy samples from patients with RA have been examined by molecular and immunohistochemical techniques in order to gain a better understanding of the pathogenic events in this disease. In addition, synovial biopsies are being used to assess the effects of medical interventions on the production of cytokines, joint damaging enzymes, adhesion molecules, and other inflammatory mediators.",
"   </p>",
"   <p>",
"    An overview of the histologic features of normal synovium and the changes that are characteristic of RA is presented first, which is followed by a discussion of the synovial response to treatment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     NORMAL SYNOVIUM",
"    </span>",
"    &nbsp;&mdash;&nbsp;The synovial tissue that lines the fibrous capsule of a joint is derived from cells of the embryonic mesenchyme [",
"    <a class=\"abstract\" href=\"UTD.htm?3/42/3754/abstract/1\">",
"     1",
"    </a>",
"    ]. Three types of synovium have been described: fibrous; adipose; and areolar [",
"    <a class=\"abstract\" href=\"UTD.htm?3/42/3754/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the normal state, the synovium is a thin membrane that attaches to skeletal tissues at the bone-cartilage interface, and does not encroach upon the surface of articular cartilage. The synovial membrane is divided into two layers:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The synovial intima (also termed synovial lining cell layer) is the most superficial layer of the normal synovium, and is in contact with the intraarticular cavity. It is normally composed of synovial lining cells (SLCs) arranged 1 to 3 cells thick. Although these cells form an epithelium-like unit, images obtained by transmission electron microscopy demonstrate that this is a discontinuous cellular layer without a basement membrane.",
"     </li>",
"     <li>",
"      The SLCs are loosely attached to the subintima, which contains blood vessels, lymphatics, and nerves. Capillaries and arterioles are generally located directly deep to the SLCs; venules are located closer to the joint capsule. There is a continuous transition from loose to dense connective tissue as one goes from the joint cavity toward the capsule. Most cells in normal subintimal tissues are fibroblasts and macrophages, although adipocytes and occasional lymphocytes and mast cells are present [",
"      <a class=\"abstract\" href=\"UTD.htm?3/42/3754/abstract/3\">",
"       3",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Synovial lining cells",
"    </span>",
"    &nbsp;&mdash;&nbsp;SLCs are approximately 6 to 12 &micro;m in diameter, excluding the numerous finger-like processes that extend from the main body. Classic electron microscopy studies have identified two populations of SLCs [",
"    <a class=\"abstract\" href=\"UTD.htm?3/42/3754/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The type A cell, or macrophage-like cell, contains vacuoles, a prominent Golgi apparatus, and filopodia, but little rough endoplasmic reticulum. These cells express numerous cell surface markers of the monocyte-macrophage lineage including CD11b, CD68, and CD14 [",
"      <a class=\"abstract\" href=\"UTD.htm?3/42/3754/abstract/5\">",
"       5",
"      </a>",
"      ]. Type A cells are phagocytic; in the normal joint, they may provide a mechanism by which particulate matter can be cleared from the joint cavity.",
"     </li>",
"     <li>",
"      The type B cell, or fibroblast-like synovial cell, contains fewer vacuoles and filopodia, and abundant protein synthetic organelles. These cells are responsible for the synthesis of extracellular matrix proteins of the synovium, including collagen. They also produce fibronectin [",
"      <a class=\"abstract\" href=\"UTD.htm?3/42/3754/abstract/6\">",
"       6",
"      </a>",
"      ], synovial fluid hyaluronic acid, and lubricin necessary for the normal motion of cartilage surfaces in the diarthrodial joint [",
"      <a class=\"abstract\" href=\"UTD.htm?3/42/3754/abstract/2\">",
"       2",
"      </a>",
"      ]. Finally, type B SLCs synthesize plasminogen activator which may be involved in both the degradation of fibrinogen and the activation of metalloproteinase enzymes that have been implicated in joint destruction (see below) [",
"      <a class=\"abstract\" href=\"UTD.htm?3/42/3754/abstract/7\">",
"       7",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Direct interaction between type A and type B cells in the synovial lining later is suggested by the presence of ligand-receptor pairs on the surface of each cell type. Lining macrophage-like cells express CD97, a member of the",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/49/28435?source=see_link\">",
"     secretin",
"    </a>",
"    superfamily of transmembrane receptors, and lining fibroblast-like cells express CD55, or decay accelerating factor, a specific ligand for CD97 [",
"    <a class=\"abstract\" href=\"UTD.htm?3/42/3754/abstract/8\">",
"     8",
"    </a>",
"    ]. Although the functional consequences of this ligand-receptor pair are unknown in synovium, it is noteworthy that CD55 protects cells from complement-mediated damage and it is likely that CD97 transduces signals in the macrophage. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/38/10854?source=see_link\">",
"     \"Regulators and receptors of the complement system\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Cytochemistry for uridine diphosphoglucose dehydrogenase (UDPGD) activity has been used to distinguish between the two types of cells; cells with high UDPGD activity are consistent with type B cells [",
"    <a class=\"abstract\" href=\"UTD.htm?3/42/3754/abstract/9\">",
"     9",
"    </a>",
"    ], while the expression of nonspecific esterase (NSE) activity is more typical of type A cells.",
"   </p>",
"   <p>",
"    There is still no consensus regarding the origin of SLCs. Type A and B cells may represent cells of distinct origin and lineage, or may be phenotypic variants of the same cell type. The presence of an intermediate cell type, with electron microscopic features common to both type A and B cells, has been used as an argument in favor of the latter hypothesis. As will be described below, however, there is also evidence that these cells are of different origin.",
"   </p>",
"   <p>",
"    The origin of SLCs is of some interest since they are major effector cells in the joint damage that occurs in RA (see",
"    <a class=\"local\" href=\"#H4\">",
"     'Synovial pathology in rheumatoid arthritis'",
"    </a>",
"    below). Reservoirs of mesenchymal stem cells are present in the adult in sites including bone marrow, adult periosteum, and connective tissue in and around muscle [",
"    <a class=\"abstract\" href=\"UTD.htm?3/42/3754/abstract/1\">",
"     1",
"    </a>",
"    ]. The ability of mesenchymal cells to migrate and \"fill spaces\" is critical to wound repair in the adult, but there is no definite evidence at this time that these cells repopulate the synovial tissues in adults.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     SYNOVIAL PATHOLOGY IN RHEUMATOID ARTHRITIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;As previously noted, the diagnosis of RA is clinical and cannot be made by examination of synovial tissue alone. However, characteristic histologic features of the synovium in established RA are well described (",
"    <a class=\"graphic graphic_picture graphicRef66931 \" href=\"UTD.htm?21/0/21510\">",
"     picture 1",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hyperplasia of the synovial lining cell layer",
"     </li>",
"     <li>",
"      An infiltrate of inflammatory cells in the subintima comprised predominately of lymphocytes, plasma cells, and macrophages",
"     </li>",
"     <li>",
"      Fibrin is often deposited on synovial surfaces, especially in clinically active disease.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In a synovial biopsy study, designed to compare histologic features in knee joints and small joints of patients with RA, a comparable number of macrophages, T cells, and plasma cells were demonstrated in the sublining region of the rheumatoid synovium [",
"    <a class=\"abstract\" href=\"UTD.htm?3/42/3754/abstract/10\">",
"     10",
"    </a>",
"    ]. Interestingly, numbers of Type A and Type B synovial lining layer cells in these samples did not show a significant correlation between different joints in the same patient.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Synovial lining cell hyperplasia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hyperplasia of the synovial lining cell layer is a hallmark of RA. The lining cell layer may become 6 to 10 cells thick (versus the normal of 1 to 3 cells) and there is hypertrophy of individual cells.",
"   </p>",
"   <p>",
"    Hyperplasia in established RA is primarily due to an increase in the number of type A cells [",
"    <a class=\"abstract\" href=\"UTD.htm?3/42/3754/abstract/5\">",
"     5",
"    </a>",
"    ]. Evidence for the recruitment of type A cells from the bone marrow comes from the study of radiation chimeras of normal and beige mice [",
"    <a class=\"abstract\" href=\"UTD.htm?3/42/3754/abstract/11\">",
"     11",
"    </a>",
"    ]. Beige mice carry giant secondary lysosomes in several cells including those of the monocyte-macrophage lineage. Histocompatible normal mice were irradiated and bone marrow cells were grafted from beige mice. Giant granules were subsequently noted in 1 to 7 percent of SLCs, all of which had ultrastructural features of type A cells. The absence of these granules in type B cells argues against these cells being derived from type A cells in the normal joint.",
"   </p>",
"   <p>",
"    Macrophage-like synovial lining cells do not appear to be actively proliferating in the synovial lining. However, the degree to which in situ proliferation of type B cells contributes to the hyperplasia seen in the rheumatoid joint is a matter of debate. Proliferating cell nuclear antigen (PCNA), an auxiliary protein of DNA polymerase g, plays a critical role in DNA synthesis, and its presence correlates with other indices of cellular proliferation. The presence of PCNA in RA synovial lining cells has been used as evidence that in situ proliferation of fibroblast-like synoviocytes contributes to synovial lining hyperplasia [",
"    <a class=\"abstract\" href=\"UTD.htm?3/42/3754/abstract/12\">",
"     12",
"    </a>",
"    ]. On the other hand, immunostaining for Ki-67, a marker of cell proliferation, reveals absence of this marker in the synovial tissue of patients with RA [",
"    <a class=\"abstract\" href=\"UTD.htm?3/42/3754/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    If in situ proliferation of type B cells is occurring, it may do so in episodic bursts. This could explain why few mitotic figures are present in the synovial lining layer in established RA.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Cellular infiltrate",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mononuclear cellular infiltrates are typically present in RA deep to the synovial lining layer. These infiltrates are comprised predominantly of macrophages and lymphocytes, which can form aggregates.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      CD4+ T cells are present diffusely, in aggregates, and in perivascular sites.",
"     </li>",
"     <li>",
"      CD4+, CD45RO+ differentiated memory T lymphocytes are common, especially in areas between aggregates [",
"      <a class=\"abstract\" href=\"UTD.htm?3/42/3754/abstract/14\">",
"       14",
"      </a>",
"      ]. This phenotype is consistent with cells previously exposed to antigen. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?5/58/6056?source=see_link&amp;anchor=H16#H16\">",
"       \"The adaptive cellular immune response\", section on 'Memory T cells'",
"      </a>",
"      .) Conditions in the synovial tissues may allow for an altered pool of peripheral blood T cells with limited diversity to act as proinflammatory cells [",
"      <a class=\"abstract\" href=\"UTD.htm?3/42/3754/abstract/15\">",
"       15",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      CD8+ cells are present diffusely but are less prominent.",
"     </li>",
"     <li>",
"      B lymphocytes and immunoglobulin producing plasma cells are scattered in and between aggregates and in foci; many plasma cells produce rheumatoid factor.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Most investigators find the CD4:CD8 ratio to be elevated in the synovium compared to peripheral blood, suggesting selective recruitment",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    proliferation of cells of the T-helper phenotype.",
"   </p>",
"   <p>",
"    Multinucleated cells are commonly present in the SLC layer and occasionally deep to the lining. These cells are of two types: macrophage polykaryons, and multinucleated cells with a fibroblast-like morphology. They are presumably formed by fusion of type A and type B SLCs, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?3/42/3754/abstract/16\">",
"     16",
"    </a>",
"    ]. Although common in RA, these cells can also be seen in other arthritides. The biological significance of these multinucleated cells and the factors involved in their generation are unknown.",
"   </p>",
"   <p>",
"    Other cells may also be seen in the synovium of patients with RA. Polymorphonuclear leukocytes are sometimes present, especially in acute disease flares. NK cells and mast cells have also been identified; the latter may play a role in articular damage at the cartilage-pannus junction [",
"    <a class=\"abstract\" href=\"UTD.htm?3/42/3754/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Adhesion molecules have well-defined functions in inflammation. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?35/54/36711?source=see_link\">",
"       \"Leukocyte-endothelial adhesion in the pathogenesis of inflammation\"",
"      </a>",
"      .) These molecules are expressed on endothelium and in other synovial sites in patients with RA. Adhesion molecules play a role in the activation and recruitment to the joint of circulating mononuclear cells, consistent with the observed accumulation of mononuclear cells around blood vessels. Specialized venules with a columnar endothelium, similar to the \"high endothelial venules\" described in lymph nodes, are apparent morphologically and have been specifically implicated in mononuclear cell influx into synovium.",
"      <br/>",
"      <br/>",
"      Relevant adhesion molecules include selectins, vascular cell adhesion molecule-1 (VCAM-1), intercellular adhesion molecules-1 and -2 (ICAM-1 and ICAM-2), integrins, and others [",
"      <a class=\"abstract\" href=\"UTD.htm?3/42/3754/abstract/18,19\">",
"       18,19",
"      </a>",
"      ]. Expression of VCAM-1 mRNA and protein is present in and on type B SLCs, and to a lesser extent on endothelium of small vessels beneath the lining layer [",
"      <a class=\"abstract\" href=\"UTD.htm?3/42/3754/abstract/20\">",
"       20",
"      </a>",
"      ]. Numerous endothelial cells in rheumatoid synovium are positive for E-selectin mRNA and protein, suggesting a role for this molecule in the recruitment of inflammatory cells [",
"      <a class=\"abstract\" href=\"UTD.htm?3/42/3754/abstract/19,21\">",
"       19,21",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Dendritic cells have the ability to activate resting T lymphocytes. These cells are present in RA synovial tissues and fluid. The surface molecules CD80 (B7-1) and CD86 (B7-2) are costimulatory molecules required for effective antigen presentation, and CD86 appears to be the major costimulatory molecule involved in antigen presentation by dendritic cells. The presence of CD86 on dendritic cells within T cell clusters in RA implicates these cells as antigen presenting cells within the rheumatoid joint [",
"      <a class=\"abstract\" href=\"UTD.htm?3/42/3754/abstract/22\">",
"       22",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Angiogenesis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The hypertrophied synovium is nourished by a plethora of blood vessels [",
"    <a class=\"abstract\" href=\"UTD.htm?3/42/3754/abstract/23,24\">",
"     23,24",
"    </a>",
"    ]. This growth of new blood vessels is thought to be important in the influx of inflammatory cells into the RA synovial tissue. It is also important in the growth of the RA pannus.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Pannus",
"    </span>",
"    &nbsp;&mdash;&nbsp;Destruction of cartilage and bone is a major source of morbidity in patients with established RA. The destructive process is mediated by a synovial membrane-derived tissue termed \"pannus\" (Latin for cloth). Pannus tissue adheres to the surface of articular cartilage, and cells within pannus produce proteinases, which degrade and destroy cartilage (",
"    <a class=\"graphic graphic_picture graphicRef66979 \" href=\"UTD.htm?20/53/21333\">",
"     picture 2",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?3/42/3754/abstract/25\">",
"     25",
"    </a>",
"    ]. Invasion of bone by pannus is responsible for development of the characteristic marginal erosions observed radiographically in patients with RA. This can lead to joint instability, and eventually to fibrous ankylosis.",
"   </p>",
"   <p>",
"    Multinucleated cells with the full phenotype of osteoclasts have been identified at the pannus-bone interface in bone resorption lacunae and are thus implicated as a major cell-type mediating bone resorption in RA [",
"    <a class=\"abstract\" href=\"UTD.htm?3/42/3754/abstract/26\">",
"     26",
"    </a>",
"    ]. Synovial T-cells may play an important role in osteoclastogenesis. A subset of T-cells expressing CD4 and osteoclast differentiation factor (ODF) cause peripheral blood mononuclear cells to develop into osteoclasts, an effect that is abrogated by osteoprotegerin (OPG), a soluble protein that binds to ODF [",
"    <a class=\"abstract\" href=\"UTD.htm?3/42/3754/abstract/27\">",
"     27",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/5/34906?source=see_link&amp;anchor=H593827#H593827\">",
"     \"Normal skeletal development and regulation of bone formation and resorption\", section on 'Osteoclasts'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Electron microscopic studies suggest that pannus results from synovial derived fibroblast-like cells migrating over the surface of cartilage. Deep to this fibroblast-like cell layer, ongoing destruction occurs via the invasion of cells with the electron microscopic appearance of macrophages [",
"    <a class=\"abstract\" href=\"UTD.htm?3/42/3754/abstract/28\">",
"     28",
"    </a>",
"    ]. The relationship of these macrophage-like cells to the fibroblast-like cells on the cartilage surface is unclear. One limitation of sampling synovial tissue via needle biopsy or arthroscopy is that these samples usually do not evaluate tissue at the cartilage-pannus junction.",
"   </p>",
"   <p>",
"    Over time, blood vessels as well as other cell types migrate into the pannus. Eventually, the pannus is transformed into a fibrous tissue termed \"inactive\" pannus.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Changes in early RA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Histologic changes in early RA have been studied in an attempt to better understand the pathogenetic events in this disease. Histologic examination of RA synovium in cases of up to six weeks&rsquo; disease duration has shown the following [",
"    <a class=\"abstract\" href=\"UTD.htm?3/42/3754/abstract/29\">",
"     29",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hyperplasia of the synovial lining cells; these cells are predominantly type B synoviocytes by electron microscopy (versus a predominance of type A cells in established RA).",
"     </li>",
"     <li>",
"      Cellular infiltrates composed mainly of lymphocytes. Although polymorphonuclear leukocytes are seen, they are present in smaller numbers than in other early synovial lesions in other arthritides such as reactive arthritis.",
"     </li>",
"     <li>",
"      Microvascular changes are prominent in early cases, with vascular congestion, high endothelial cells, and microvascular occlusion by platelets",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      thrombus.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    One study compared synovial tissue samples from patients with RA of less than one year duration with samples from patients with RA of more than five years duration [",
"    <a class=\"abstract\" href=\"UTD.htm?3/42/3754/abstract/30\">",
"     30",
"    </a>",
"    ]. Although synovial lining hyperplasia was present in both groups, it was more pronounced in patients with established disease. Measurements of synovial inflammation did not differ significantly between the two groups.",
"   </p>",
"   <p>",
"    Biopsies of clinically uninvolved knee joints in patients with RA have demonstrated histological evidence of synovitis [",
"    <a class=\"abstract\" href=\"UTD.htm?3/42/3754/abstract/31,32\">",
"     31,32",
"    </a>",
"    ]. These observations suggest that the synovial changes typical of RA can predate clinical signs of disease activity.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     MEDIATORS OF INFLAMMATION IN THE SYNOVIUM",
"    </span>",
"    &nbsp;&mdash;&nbsp;The analysis of synovial tissues in RA has provided information on the localization and regulation of mediators of inflammation including cytokines, enzymes, adhesion molecules, and transcription factors.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Cytokines",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cytokines are proteins that act as soluble mediators of inflammation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/8/4231?source=see_link\">",
"     \"Role of cytokines in the immune system\"",
"    </a>",
"    .) Much of what is known about the role of cytokines in RA comes from extensive studies of these proteins in serum and synovial fluid. The study of synovial tissue has provided complimentary information, including the identification of cells that produce cytokines. There is great interest in the role of macrophages and type A synovial lining cells in the initiation and perpetuation of rheumatoid synovitis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/50/10025?source=see_link\">",
"     \"Role of cytokines in rheumatic diseases\"",
"    </a>",
"    .) The dramatic clinical improvement in RA with TNF-alpha blockade has further heightened interest in synovial cytokines [",
"    <a class=\"abstract\" href=\"UTD.htm?3/42/3754/abstract/33,34\">",
"     33,34",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/19/3384?source=see_link\">",
"     \"Overview of biologic agents in the rheumatic diseases\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Dissection of the cytokine network in RA has localized several cytokines to synovial tissue and led to the notion that positive feedback loops contribute to the perpetuation of synovial inflammation Many cytokines have been immunolocalized to the RA joint, the following are illustrative [",
"    <a class=\"abstract\" href=\"UTD.htm?3/42/3754/abstract/35-40\">",
"     35-40",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      IL-1 and TNF-alpha, both of which are produced by synovial macrophages, stimulate fibroblast proliferation and increase production of IL-6, IL-8 (and other chemoattractant molecules known as chemokines), GM-CSF, and destructive enzymes such as stromelysin and collagenase (see below).",
"     </li>",
"     <li>",
"      GM-CSF, which is produced by synovial macrophages and activated fibroblasts, is a potent inducer of IL-1, TNF-alpha, and IL-8 secretion. GM-CSF, especially in combination with TNF-alpha, also activates macrophages and induces HLA-DR expression.",
"     </li>",
"     <li>",
"      TNF-alpha, IL-1-beta, IL-6, GM-CSF, and transforming growth factor-beta 1 have been identified by immunohistochemistry at the cartilage-pannus junction, mostly localized to cells expressing the macrophage marker CD68 [",
"      <a class=\"abstract\" href=\"UTD.htm?3/42/3754/abstract/40\">",
"       40",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      IL-17 is a product of a subset of T-cells. This proinflammatory cytokine has recently been implicated in synovitis and joint destruction [",
"      <a class=\"abstract\" href=\"UTD.htm?3/42/3754/abstract/41\">",
"       41",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Fibroblast-like cells produce autocrine stimulation and contribute to their own dysregulation through the elaboration of growth factors like fibroblast growth factor, as well as anti-apoptotic molecules [",
"      <a class=\"abstract\" href=\"UTD.htm?3/42/3754/abstract/42\">",
"       42",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      IL-18, which shares properties of IL-1, has other detrimental effects including induction of interferon gamma, and upregulation of inducible nitric oxide synthetase and COX-2 [",
"      <a class=\"abstract\" href=\"UTD.htm?3/42/3754/abstract/43\">",
"       43",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Lymphotoxin beta, a cytokine produced by both T and B lymphocytes, promotes the production of proinflammatory cytokines (eg, TNF-alpha) and metalloproteinases by synovial fibroblast-like synoviocytes [",
"      <a class=\"abstract\" href=\"UTD.htm?3/42/3754/abstract/44\">",
"       44",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The local production of cytokines by macrophages and fibroblasts induces angiogenesis, increases adhesion molecule expression, and recruits other inflammatory cells to the synovium [",
"      <a class=\"abstract\" href=\"UTD.htm?3/42/3754/abstract/45\">",
"       45",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Chemokines",
"    </span>",
"    &nbsp;&mdash;&nbsp;The recruitment of cells to sites of inflammation is largely directed by chemokines and their receptors. The chemokine receptors, CXCR3 and CCR5, are expressed by most T cells in the synovial fluid compared to a minority of T cells in the peripheral blood of subjects with RA, and virtually all T cells in rheumatoid synovial tissue express CXCR5. This phenotype suggests that lymphocytes are recruited to the synovium by a Th-1 type reaction [",
"    <a class=\"abstract\" href=\"UTD.htm?3/42/3754/abstract/46\">",
"     46",
"    </a>",
"    ]. Interactions between a stromal cell derived factor-1 (SDF-1) and its receptor (CXC receptor 4 [CXCR4]) may reduce the egress of T cells from the synovial compartment [",
"    <a class=\"abstract\" href=\"UTD.htm?3/42/3754/abstract/47,48\">",
"     47,48",
"    </a>",
"    ]. A number of chemokines, such as",
"    <span class=\"nowrap\">",
"     IL-8/CXCL8,",
"    </span>",
"    epithelial neutrophil derived peptide-78",
"    <span class=\"nowrap\">",
"     (ENA-78/CXCL5),",
"    </span>",
"    and",
"    <span class=\"nowrap\">",
"     GRO-alpha/CXCL1",
"    </span>",
"    have been localized to the RA synovium and may mediate neutrophil recruitment and angiogenesis in the RA joint [",
"    <a class=\"abstract\" href=\"UTD.htm?3/42/3754/abstract/49-51\">",
"     49-51",
"    </a>",
"    ]. Likewise, chemokines such as macrophage inhibitory protein-1 alpha (MIP-1",
"    <span class=\"nowrap\">",
"     alpha/CCL3)",
"    </span>",
"    or macrophage chemoattractant protein",
"    <span class=\"nowrap\">",
"     (MCP-1/CCL2),",
"    </span>",
"    may attract macrophages [",
"    <a class=\"abstract\" href=\"UTD.htm?3/42/3754/abstract/39,52\">",
"     39,52",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Cell surface proteins",
"    </span>",
"    &nbsp;&mdash;&nbsp;Direct cell-cell interactions mediated by cell surface proteins may also play a role in promoting the degradation of extracellular matrix. As an example, the leukocyte activation antigen, M6, is a potent inducer of enzymes important in degrading cartilage and bone in RA [",
"    <a class=\"abstract\" href=\"UTD.htm?3/42/3754/abstract/53\">",
"     53",
"    </a>",
"    ]. Another cell surface protein, known as the receptor activator of nuclear factor-kappaB ligand (RANKL), is expressed on activated T cells and synovial fibroblasts [",
"    <a class=\"abstract\" href=\"UTD.htm?3/42/3754/abstract/54\">",
"     54",
"    </a>",
"    ], as well as on bone lining cells. Expression of membrane bound",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    soluble RANKL could contribute to osteoclast activation and associated bone erosions [",
"    <a class=\"abstract\" href=\"UTD.htm?3/42/3754/abstract/55\">",
"     55",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/5/34906?source=see_link\">",
"     \"Normal skeletal development and regulation of bone formation and resorption\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Some carbohydrate-rich endothelial cell surface molecules, such as those of the heparan sulfate proteoglycan family, may serve to bind chemokines (see",
"    <a class=\"local\" href=\"#H12\">",
"     'Chemokines'",
"    </a>",
"    above) in the synovial microvasculature. The presence of one such heparan sulfate proteoglycan, syndecan-3, which can bind",
"    <span class=\"nowrap\">",
"     IL-8/CXCL8,",
"    </span>",
"    has been found on rheumatoid synovial endothelial cells [",
"    <a class=\"abstract\" href=\"UTD.htm?3/42/3754/abstract/56\">",
"     56",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Enzymes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several classes of enzymes have been implicated in the joint destruction that occurs in established RA. Perhaps the best studied are the family of matrix metalloproteinases (MMPs). Cytokines known to be expressed in RA synovial tissues, including IL-1-beta and TNF-alpha, are potent activators of these MMP genes.",
"   </p>",
"   <p>",
"    MMP family members are divided into three categories based upon substrate specificity.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The collagenases cleave native collagen types I, II and III, the major collagens present in bone and cartilage, respectively.",
"     </li>",
"     <li>",
"      The stromelysin group of enzymes has a broad substrate specificity, and stromelysin-1 (MMP-3) can degrade proteoglycans, gelatin, fibronectin, and laminin. Enzymes in this group may be of particular importance because of their ability to cleave MMP pro-enzymes to yield active enzymes.",
"     </li>",
"     <li>",
"      The gelatinases A (MMP-2) and B (MMP-9) degrade denatured collagen as well as basement membrane collagen and type V collagen in bone.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In situ hybridization studies have demonstrated that interstitial collagenase (MMP-1) and stromelysin-1 (MMP-3) mRNA are expressed in rheumatoid synovial lining cells (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef51875 \" href=\"UTD.htm?18/52/19268\">",
"     image 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?3/42/3754/abstract/57-59\">",
"     57-59",
"    </a>",
"    ]. Larger numbers of synovial cells producing mRNA for MMP-1 and higher levels of active metalloproteinases in synovial tissue are associated with erosive disease [",
"    <a class=\"abstract\" href=\"UTD.htm?3/42/3754/abstract/60,61\">",
"     60,61",
"    </a>",
"    ]. Gelatinases have also been identified in RA synovial tissues.",
"   </p>",
"   <p>",
"    The tissue inhibitors of metalloproteinases are naturally occurring proteins which bind in a 1:1 stoichiometry to various MMP family members, rendering them inactive. TIMP-1 and TIMP-2 have been identified in RA synovial tissues and are expressed in the synovial lining layer and in cells in the sublining [",
"    <a class=\"abstract\" href=\"UTD.htm?3/42/3754/abstract/58,59,61\">",
"     58,59,61",
"    </a>",
"    ]. The balance between metalloproteinases and TIMPs is expected to determine the rate of extracellular matrix degradation. However, it is at present difficult to make a functional interpretation of the relative intensities of their detection in tissue samples. Protease (collagenase) inhibitors may prove to have therapeutic implications for patients with rheumatoid arthritis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/22/16746?source=see_link\">",
"     \"Cytokine networks in rheumatic diseases: Implications for therapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Granzymes A and B are serine proteases present in activated natural killer (NK) cells and cytotoxic T cells. These enzymes are present in some synovial lymphocytes, particularly in NK cells in patients with RA and to a lesser extent in those with osteoarthritis [",
"    <a class=\"abstract\" href=\"UTD.htm?3/42/3754/abstract/62,63\">",
"     62,63",
"    </a>",
"    ]. The highest expression of granzyme B occurs in early RA; synovial tissue staining for granzyme B correlates with elevated serum levels of acute phase reactants [",
"    <a class=\"abstract\" href=\"UTD.htm?3/42/3754/abstract/63\">",
"     63",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Cathepsins B, D, K, L, and S are cysteine proteinases that have been identified in human rheumatoid and osteoarthritis synovium [",
"    <a class=\"abstract\" href=\"UTD.htm?3/42/3754/abstract/64-66\">",
"     64-66",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Cathepsin B colocalizes to intracellular deposits within synovial lining macrophage-like type A cells that stain for hyaluronic acid&nbsp;[",
"      <a class=\"abstract\" href=\"UTD.htm?3/42/3754/abstract/67\">",
"       67",
"      </a>",
"      ]. This observation has been interpreted to suggest that hyaluronic acid is degraded by macrophage-like type A cells following its production by fibroblast-like type B cells.",
"     </li>",
"     <li>",
"      Cathepsin K can degrade collagen of both type I (bone) and type II (articular cartilage). An increased number of cathepsin K producing cells are present in the synovium of patients with RA compared with those with OA [",
"      <a class=\"abstract\" href=\"UTD.htm?3/42/3754/abstract/66\">",
"       66",
"      </a>",
"      ]. Cathepsin K is highly expressed in osteoclasts; patients with the osteosclerotic disorder, pycnodysostosis, lack activity of this enzyme [",
"      <a class=\"abstract\" href=\"UTD.htm?3/42/3754/abstract/68\">",
"       68",
"      </a>",
"      ]. The presence of cells producing this enzyme at sites of cartilage erosion suggests a possible role in articular damage.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Transcription factors and cell signaling molecules",
"    </span>",
"    &nbsp;&mdash;&nbsp;The primary control point for the production of the proteins that mediate inflammation (eg, cytokines, enzymes, and adhesion molecules) is at the level of gene transcription. This process is regulated by transcription factors which are proteins in the nucleus of the cell that bind to specific promoter regions of DNA. There is considerable interest in understanding the role of transcription factors in the pathogenesis of RA, especially since they are potential targets for therapeutic intervention. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/27/17846?source=see_link&amp;anchor=H7#H7\">",
"     \"Principles of molecular genetics\", section on 'RNA transcription'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The term AP-1 refers to a dimeric transcription factor, typically comprising c-Jun and c-Fos, although these may be substituted by other family members (JunB, JunD; FosB, Fra1, Fra2). AP-1 activates the transcription of several genes relevant to synovitis, particularly the metalloproteinases collagenase and stromelysin. Immunohistochemical staining for c-Fos is most intense in the synovial lining layer and is found in cells with a morphology suggestive of fibroblasts [",
"    <a class=\"abstract\" href=\"UTD.htm?3/42/3754/abstract/69,70\">",
"     69,70",
"    </a>",
"    ]. In double staining experiments c-Fos is found predominantly in the CD14 negative (fibroblast-like) synovial lining cells [",
"    <a class=\"abstract\" href=\"UTD.htm?3/42/3754/abstract/71,72\">",
"     71,72",
"    </a>",
"    ]; specific Jun-B immunoreactivity and less specific Jun immunoreactivity are also present in these cells. These observations suggest that AP-1 is present in fibroblast-like synovial lining cells and may account in part for the expression of metalloproteinases in patients with RA.",
"   </p>",
"   <p>",
"    The transcription factor nuclear factor kappa B (NF-kB) is a dimer, typically of p65 (RelA) and p50 (NF-kB1); like AP-1, these may be substituted with other family members (c-Rel, RelB). NF-kB is likely to be important for the expression of a number of cytokines found in rheumatoid synovium. Immunohistochemistry has identified activated p65 and p50 in the nuclei of many deep and superficial cells in rheumatoid synovium, including endothelial cells (",
"    <a class=\"graphic graphic_picture graphicRef51926 \" href=\"UTD.htm?7/52/8002\">",
"     picture 3",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef73035 \" href=\"UTD.htm?31/23/32119\">",
"     picture 4",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?3/42/3754/abstract/71,73\">",
"     71,73",
"    </a>",
"    ]. Using double immunohistochemistry NF-kB within the synovial lining is localized predominantly, although not exclusively, in CD14 positive (macrophage-like) cells [",
"    <a class=\"abstract\" href=\"UTD.htm?3/42/3754/abstract/71\">",
"     71",
"    </a>",
"    ]. This finding is in contrast to the distribution of AP-1 in fibroblast-like cells. The immunolocalization of TNF-alpha to CD14-positive synovial lining cells in patients with RA may be attributed, at least in part, to the activity of NF-kB in these cells [",
"    <a class=\"abstract\" href=\"UTD.htm?3/42/3754/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other molecules involved in the signaling pathways have been identified in synovium [",
"    <a class=\"abstract\" href=\"UTD.htm?3/42/3754/abstract/74\">",
"     74",
"    </a>",
"    ]. Potential therapeutic targets include those of the mitogen activated protein kinase (MAPK) pathway. Three major members of this pathway include ERK, jun kinase (JNK), and p38 MAPK, all of which are expressed in active form in RA synovial tissue [",
"    <a class=\"abstract\" href=\"UTD.htm?3/42/3754/abstract/75,76\">",
"     75,76",
"    </a>",
"    ]. p38 inhibitors appear to work in a number of animal arthritis models [",
"    <a class=\"abstract\" href=\"UTD.htm?3/42/3754/abstract/77\">",
"     77",
"    </a>",
"    ]. It may be that in the context of RA, shear stress, heat stress, cytokine stress, and oxidative stress activate these signaling pathways [",
"    <a class=\"abstract\" href=\"UTD.htm?3/42/3754/abstract/78\">",
"     78",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Apoptosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Apoptosis, or programmed cell death, is a controlled means of cell removal involving segmental breakage of DNA strands. Its functions include deletion of self-reactive lymphocytes in the thymus (thereby protecting against autoimmunity), and removal of redundant cells in many other organs in the fetus and mature adult. The role of apoptosis in rheumatoid synovium is under investigation.",
"   </p>",
"   <p>",
"    Characteristic laddering of genomic DNA has been demonstrated in DNA extracted from RA and osteoarthritis (OA) synovial tissue, providing evidence that apoptosis occurs in synovium. In situ evidence of strand breaks has been shown in RA and OA synovia, and less frequently in normal synovial tissues [",
"    <a class=\"abstract\" href=\"UTD.htm?3/42/3754/abstract/79\">",
"     79",
"    </a>",
"    ]; however, the number of positive specimens was low in one study of RA synovium [",
"    <a class=\"abstract\" href=\"UTD.htm?3/42/3754/abstract/80\">",
"     80",
"    </a>",
"    ]. Apoptotic cells were mainly in the synovial lining, especially the CD68-positive macrophage-like lining cells, suggesting an orderly removal of these cells during inflammation.",
"   </p>",
"   <p>",
"    A defect in apoptosis may contribute to the abnormal accumulation of cells in the rheumatoid joint. Fragmentation of synovial DNA in RA is associated with high levels of expression of the tumor suppressor gene p53 [",
"    <a class=\"abstract\" href=\"UTD.htm?3/42/3754/abstract/81\">",
"     81",
"    </a>",
"    ]. Furthermore, somatic mutations in the p53 gene have been identified in RA synoviocytes [",
"    <a class=\"abstract\" href=\"UTD.htm?3/42/3754/abstract/82\">",
"     82",
"    </a>",
"    ]. Mutations in p53 could lead to defective apoptosis since p53 induces the expression of bax, a member of the bcl-2 proto-oncogene family and a key regulator of apoptosis. Expression of bcl-2 itself has been examined in RA synovial tissue and is largely restricted to lymphocyte aggregates deep to the synovial lining layer [",
"    <a class=\"abstract\" href=\"UTD.htm?3/42/3754/abstract/80\">",
"     80",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     SYNOVIAL TISSUE RESPONSE TO THERAPY AND CORRELATION WITH DISEASE ACTIVITY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The advantage of synovial biopsy over measurements of peripheral blood to assess the response to therapeutic interventions was highlighted in a report of two patients with RA treated with the monoclonal antibody",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/25/26008?source=see_link\">",
"     alemtuzumab",
"    </a>",
"    (Campath-1H) [",
"    <a class=\"abstract\" href=\"UTD.htm?3/42/3754/abstract/83\">",
"     83",
"    </a>",
"    ]. The study subjects developed a prolonged depletion of circulating lymphocytes in response to the drug despite persistence of clinical synovitis. Synovial tissue analysis revealed significant T lymphocytic infiltrates at a time when circulating T lymphocytes were markedly depleted, suggesting that peripheral blood analysis may not accurately reflect the synovial tissue response to therapy. In contrast, synovial T cell depletion and reconstitution did correlate with changes in clinical disease activity in a series of seven patients who had synovial biopsies before and after autologous stem cell transplantation [",
"    <a class=\"abstract\" href=\"UTD.htm?3/42/3754/abstract/84\">",
"     84",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Quantitative analysis of synovial tissue enables the response to a therapeutic intervention to be measured at the target organ.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Quantitative immunohistochemical analysis of sequential synovial biopsy specimens has been used to measure the response at four weeks to intravenous anti-TNF-alpha monoclonal antibodies. One study of 14 patients with RA found significant reductions in staining for E-selectin, VCAM-1 and T lymphocytes after such treatment compared to controls [",
"      <a class=\"abstract\" href=\"UTD.htm?3/42/3754/abstract/85\">",
"       85",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Treatment of 16 patients with a chemokine receptor CCR1 antagonist resulted in a decrease in the number of synovial tissue macrophages and CCR1+ cells after therapy, as assessed by synovial biopsy [",
"      <a class=\"abstract\" href=\"UTD.htm?3/42/3754/abstract/86\">",
"       86",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In situ hybridization for metalloproteinase mRNA has been used to quantitatively assess the synovial response to drugs. Intraarticular glucocorticoids decreased the synovial lining layer expression of collagenase mRNA in three patients with RA in one report [",
"      <a class=\"abstract\" href=\"UTD.htm?3/42/3754/abstract/58\">",
"       58",
"      </a>",
"      ]. In a pilot clinical trial of N-[4-hydroxyphenyl] retinamide, however, there was no decrease in mRNA for collagenase or stromelysin [",
"      <a class=\"abstract\" href=\"UTD.htm?3/42/3754/abstract/87\">",
"       87",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Variability and the representative nature of small synovial biopsies are important issues dictating that sampling be done in a controlled manner. The availability of small arthroscopes has facilitated the selection of biopsy sites under direct vision. One report found that multiple synovial samples taken from within a rheumatoid joint are histologically very similar, even when specimens are taken from maximally and minimally inflamed areas [",
"    <a class=\"abstract\" href=\"UTD.htm?3/42/3754/abstract/88\">",
"     88",
"    </a>",
"    ]. Another group has taken sequential arthroscopic biopsies from adjacent areas, in an attempt to reduce potential variability [",
"    <a class=\"abstract\" href=\"UTD.htm?3/42/3754/abstract/89,90\">",
"     89,90",
"    </a>",
"    ]. Using this method, intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/25/31129?source=see_link\">",
"     methylprednisolone",
"    </a>",
"    decreased the immunostaining for E-selectin and ICAM-1 and TNF-alpha within 24 hours.",
"   </p>",
"   <p>",
"    Samples from different joints (wrist or metacarpophalangeal versus knee) of the same patient taken at the same time show a good correlation between the numbers of sublining macrophages, T cells, and plasma cells [",
"    <a class=\"abstract\" href=\"UTD.htm?3/42/3754/abstract/10\">",
"     10",
"    </a>",
"    ]. Interestingly, numbers of Type A and Type B synovial lining layer cells in these samples did not show a significant correlation, suggesting that in biopsy studies, cells within the lining layer should not be used to assess therapeutic responses.",
"   </p>",
"   <p>",
"    Correlations between synovial histology and clinical disease activity have been difficult to demonstrate. An important problem is the presence of overlap in the histologic findings in clinically normal and inflamed joints. One study, for example, found that normal synovium collected at arthroscopy from four healthy volunteers had perivascular and scattered lymphocytes, findings previously thought indicative of synovitis [",
"    <a class=\"abstract\" href=\"UTD.htm?3/42/3754/abstract/91\">",
"     91",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a study comparing early disease (RA of less than 1 year) and longstanding disease (RA of greater than 5 years), there was no change in immunohistological features with disease duration, although knee pain in the subjects correlated with macrophage numbers, IL-6 and, TNF-alpha expression in the synovial biopsies [",
"    <a class=\"abstract\" href=\"UTD.htm?3/42/3754/abstract/92\">",
"     92",
"    </a>",
"    ]. Knee pain did not correlate with scores for CD4+ T cells.",
"   </p>",
"   <p>",
"    However, there is a correlation between synovial lining hyperplasia and the Ritchie index, which provides a measure of the number and severity of clinically affected joints [",
"    <a class=\"abstract\" href=\"UTD.htm?3/42/3754/abstract/87\">",
"     87",
"    </a>",
"    ]. In addition, there appears to be a correlation between lymphocyte numbers and clinical measures of disease activity [",
"    <a class=\"abstract\" href=\"UTD.htm?3/42/3754/abstract/93-95\">",
"     93-95",
"    </a>",
"    ]. As an example, one study of 24 patients with RA measured a clinical index of disease activity and T cell infiltrates in the synovium before and after one year of standard antirheumatic drug therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?3/42/3754/abstract/94\">",
"     94",
"    </a>",
"    ]. Clinical improvement was noted in 16 patients (group A), while the remainder had deterioration or no improvement (group B). Group A patients had a decrease in intensity of the synovial T cell infiltrate, ratio of T helper to T suppressor cells, and number of biopsy samples containing type B cells following treatment, compared to no changes in group B.",
"   </p>",
"   <p>",
"    Prospective studies have demonstrated that synovial lining layer depth and sublining macrophage density correlate significantly with radiologic deterioration at one and six years [",
"    <a class=\"abstract\" href=\"UTD.htm?3/42/3754/abstract/96,97\">",
"     96,97",
"    </a>",
"    ]. There was no correlation between lymphocytic infiltration and progression of erosions in these reports. The observation that radiologic scores deteriorated at six years despite clinical improvement in disease activity supports the concept that erosion and inflammation may involve separate cellular processes within the synovium [",
"    <a class=\"abstract\" href=\"UTD.htm?3/42/3754/abstract/97\">",
"     97",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The synovial response to therapeutic interventions may yield information regarding the pathogenesis of RA which cannot be obtained by other means. In addition, future studies should expand our understanding of the relationship between synovial histologic features and clinical disease activity.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H895962782\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The synovial tissue that lines the fibrous capsule of a joint is derived from cells of the embryonic mesenchyme. In the normal state, the synovium is a thin membrane that attaches to skeletal tissues at the bone-cartilage interface and does not encroach upon the surface of articular cartilage. The synovial membrane is divided into two layers: the intima or synovial lining cell (SLC) layer, which is the more superficial layer; and the subintima, which contains primarily fibroblasts, macrophages, blood vessels, lymphatics, and nerves and which is adjacent to the joint capsule. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Normal synovium'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There are two types of SLC: the type A, macrophage-like cell, and the type B, fibroblast-like cell. These cells appear to directly interact and are major effector cells in the joint damage that occurs in rheumatoid arthritis (RA). Mononuclear cellular infiltrates are typically present in RA deep to the synovial lining layer. These infiltrates are comprised predominantly of macrophages and lymphocytes, which can form aggregates. The hypertrophied synovium is nourished by a plethora of blood vessels, which is thought to be important in the influx of inflammatory cells into the RA synovial tissue and in the growth of the RA pannus, a synovial membrane-derived tissue which adheres to the surface of articular cartilage. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Synovial lining cells'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H4\">",
"       'Synovial pathology in rheumatoid arthritis'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H5\">",
"       'Synovial lining cell hyperplasia'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H6\">",
"       'Cellular infiltrate'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H7\">",
"       'Angiogenesis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The destruction of cartilage and bone in RA is mediated by pannus; cells within pannus produce proteinases, which degrade and destroy cartilage. Invasion of bone by pannus is responsible for development of the characteristic marginal erosions observed radiographically in patients with RA and can lead to joint instability and, eventually, to fibrous ankylosis. Histologic changes in early RA include SLC hyperplasia, lymphocytic cellular infiltrates, some numbers of polymorphonuclear leukocytes, and microvascular changes. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Pannus'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H9\">",
"       'Changes in early RA'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The analysis of synovial tissues in RA has provided information on the localization and regulation of mediators of inflammation including cytokines, chemokines, enzymes, adhesion molecules, and transcription factors. A defect in apoptosis may contribute to the abnormal accumulation of cells in the rheumatoid joint. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Mediators of inflammation in the synovium'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Peripheral blood analysis may not accurately reflect the synovial tissue response to therapy, as indicated by studies designed to assess the response to therapeutic interventions. However, the synovial response to therapeutic interventions may yield information regarding the pathogenesis of RA which cannot be obtained by other means. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Synovial tissue response to therapy and correlation with disease activity'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/42/3754/abstract/1\">",
"      Caplan AI. Mesenchymal stem cells. J Orthop Res 1991; 9:641.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/42/3754/abstract/2\">",
"      Henderson B, Pettipher ER. The synovial lining cell: biology and pathobiology. Semin Arthritis Rheum 1985; 15:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/42/3754/abstract/3\">",
"      Lydyard PM, Edwards JC. The pathophysiology of rheumatoid arthritis. Clin Exp Rheumatol 1994; 12 Suppl 11:S55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/42/3754/abstract/4\">",
"      BARLAND P, NOVIKOFF AB, HAMERMAN D. Electron microscopy of the human synovial membrane. J Cell Biol 1962; 14:207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/42/3754/abstract/5\">",
"      Athanasou NA, Quinn J. Immunocytochemical analysis of human synovial lining cells: phenotypic relation to other marrow derived cells. Ann Rheum Dis 1991; 50:311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/42/3754/abstract/6\">",
"      Waller HA, Butler MG, McClean JG, et al. Localisation of fibronectin mRNA in the rheumatoid synovium by in situ hybridisation. Ann Rheum Dis 1992; 51:735.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/42/3754/abstract/7\">",
"      Andersen RB, Gormsen J. Fibrinolytic and fibrin stabilizing activity of synovial membranes. Ann Rheum Dis 1970; 29:287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/42/3754/abstract/8\">",
"      Hamann J, Wishaupt JO, van Lier RA, et al. Expression of the activation antigen CD97 and its ligand CD55 in rheumatoid synovial tissue. Arthritis Rheum 1999; 42:650.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/42/3754/abstract/9\">",
"      Wilkinson LS, Pitsillides AA, Worrall JG, Edwards JC. Light microscopic characterization of the fibroblast-like synovial intimal cell (synoviocyte). Arthritis Rheum 1992; 35:1179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/42/3754/abstract/10\">",
"      Kraan MC, Reece RJ, Smeets TJ, et al. Comparison of synovial tissues from the knee joints and the small joints of rheumatoid arthritis patients: Implications for pathogenesis and evaluation of treatment. Arthritis Rheum 2002; 46:2034.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/42/3754/abstract/11\">",
"      Edwards JC, Willoughby DA. Demonstration of bone marrow derived cells in synovial lining by means of giant intracellular granules as genetic markers. Ann Rheum Dis 1982; 41:177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/42/3754/abstract/12\">",
"      Qu Z, Garcia CH, O'Rourke LM, et al. Local proliferation of fibroblast-like synoviocytes contributes to synovial hyperplasia. Results of proliferating cell nuclear antigen/cyclin, c-myc, and nucleolar organizer region staining. Arthritis Rheum 1994; 37:212.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/42/3754/abstract/13\">",
"      Lalor PA, Mapp PI, Hall PA, Revell PA. Proliferative activity of cells in the synovium as demonstrated by a monoclonal antibody, Ki67. Rheumatol Int 1987; 7:183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/42/3754/abstract/14\">",
"      Koch AE, Robinson PG, Radosevich JA, Pope RM. Distribution of CD45RA and CD45RO T-lymphocyte subsets in rheumatoid arthritis synovial tissue. J Clin Immunol 1990; 10:192.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/42/3754/abstract/15\">",
"      Weyand CM, Goronzy JJ. T-cell responses in rheumatoid arthritis: systemic abnormalities-local disease. Curr Opin Rheumatol 1999; 11:210.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/42/3754/abstract/16\">",
"      Wilkinson LS, Pitsillides AA, Edwards JC. Giant cells in arthritic synovium. Ann Rheum Dis 1993; 52:182.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/42/3754/abstract/17\">",
"      Wooley DE. Mast cells in the rheumatoid lesion--ringleaders or innocent bystanders? Ann Rheum Dis 1995; 54:533.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/42/3754/abstract/18\">",
"      Hale LP, Martin ME, McCollum DE, et al. Immunohistologic analysis of the distribution of cell adhesion molecules within the inflammatory synovial microenvironment. Arthritis Rheum 1989; 32:22.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/42/3754/abstract/19\">",
"      Koch AE, Burrows JC, Haines GK, et al. Immunolocalization of endothelial and leukocyte adhesion molecules in human rheumatoid and osteoarthritic synovial tissues. Lab Invest 1991; 64:313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/42/3754/abstract/20\">",
"      Kriegsmann J, Keyszer GM, Geiler T, et al. Expression of vascular cell adhesion molecule-1 mRNA and protein in rheumatoid synovium demonstrated by in situ hybridization and immunohistochemistry. Lab Invest 1995; 72:209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/42/3754/abstract/21\">",
"      Kriegsmann J, Keyszer GM, Geiler T, et al. Expression of E-selectin messenger RNA and protein in rheumatoid arthritis. Arthritis Rheum 1995; 38:750.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/42/3754/abstract/22\">",
"      Thomas R, Lipsky PE. Presentation of self peptides by dendritic cells: possible implications for the pathogenesis of rheumatoid arthritis. Arthritis Rheum 1996; 39:183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/42/3754/abstract/23\">",
"      Koch AE. Angiogenesis as a target in rheumatoid arthritis. Ann Rheum Dis 2003; 62 Suppl 2:ii60.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/42/3754/abstract/24\">",
"      Koch AE. Review: angiogenesis: implications for rheumatoid arthritis. Arthritis Rheum 1998; 41:951.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/42/3754/abstract/25\">",
"      Ishikawa H, Hirata S, Andoh Y, et al. An immunohistochemical and immunoelectron microscopic study of adhesion molecules in synovial pannus formation in rheumatoid arthritis. Rheumatol Int 1996; 16:53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/42/3754/abstract/26\">",
"      Gravallese EM, Harada Y, Wang JT, et al. Identification of cell types responsible for bone resorption in rheumatoid arthritis and juvenile rheumatoid arthritis. Am J Pathol 1998; 152:943.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/42/3754/abstract/27\">",
"      Kotake S, Udagawa N, Hakoda M, et al. Activated human T cells directly induce osteoclastogenesis from human monocytes: possible role of T cells in bone destruction in rheumatoid arthritis patients. Arthritis Rheum 2001; 44:1003.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/42/3754/abstract/28\">",
"      Shiozawa S, Tokuhisa T. Contribution of synovial mesenchymal cells to the pathogenesis of rheumatoid arthritis. Semin Arthritis Rheum 1992; 21:267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/42/3754/abstract/29\">",
"      Schumacher HR Jr, Bautista BB, Krauser RE, et al. Histological appearance of the synovium in early rheumatoid arthritis. Semin Arthritis Rheum 1994; 23:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/42/3754/abstract/30\">",
"      Tak PP, Thurkow EW, Daha MR, et al. Expression of adhesion molecules in early rheumatoid synovial tissue. Clin Immunol Immunopathol 1995; 77:236.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/42/3754/abstract/31\">",
"      Soden M, Rooney M, Cullen A, et al. Immunohistological features in the synovium obtained from clinically uninvolved knee joints of patients with rheumatoid arthritis. Br J Rheumatol 1989; 28:287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/42/3754/abstract/32\">",
"      Pando JA, Duray P, Yarboro C, et al. Synovitis occurs in some clinically normal and asymptomatic joints in patients with early arthritis. J Rheumatol 2000; 27:1848.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/42/3754/abstract/33\">",
"      Elliott MJ, Maini RN, Feldmann M, et al. Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis. Lancet 1994; 344:1105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/42/3754/abstract/34\">",
"      Moreland LW, Baumgartner SW, Schiff MH, et al. Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein. N Engl J Med 1997; 337:141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/42/3754/abstract/35\">",
"      Chu CQ, Field M, Feldmann M, Maini RN. Localization of tumor necrosis factor alpha in synovial tissues and at the cartilage-pannus junction in patients with rheumatoid arthritis. Arthritis Rheum 1991; 34:1125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/42/3754/abstract/36\">",
"      Wood NC, Dickens E, Symons JA, Duff GW. In situ hybridization of interleukin-1 in CD14-positive cells in rheumatoid arthritis. Clin Immunol Immunopathol 1992; 62:295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/42/3754/abstract/37\">",
"      Wood NC, Symons JA, Dickens E, Duff GW. In situ hybridization of IL-6 in rheumatoid arthritis. Clin Exp Immunol 1992; 87:183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/42/3754/abstract/38\">",
"      Deleuran B, Lemche P, Kristensen M, et al. Localisation of interleukin 8 in the synovial membrane, cartilage-pannus junction and chondrocytes in rheumatoid arthritis. Scand J Rheumatol 1994; 23:2.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/42/3754/abstract/39\">",
"      Koch AE, Kunkel SL, Harlow LA, et al. Enhanced production of monocyte chemoattractant protein-1 in rheumatoid arthritis. J Clin Invest 1992; 90:772.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/42/3754/abstract/40\">",
"      Chu CQ, Field M, Allard S, et al. Detection of cytokines at the cartilage/pannus junction in patients with rheumatoid arthritis: implications for the role of cytokines in cartilage destruction and repair. Br J Rheumatol 1992; 31:653.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/42/3754/abstract/41\">",
"      Toh ML, Miossec P. The role of T cells in rheumatoid arthritis: new subsets and new targets. Curr Opin Rheumatol 2007; 19:284.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/42/3754/abstract/42\">",
"      Franz JK, Pap T, Hummel KM, et al. Expression of sentrin, a novel antiapoptotic molecule, at sites of synovial invasion in rheumatoid arthritis. Arthritis Rheum 2000; 43:599.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/42/3754/abstract/43\">",
"      Gracie JA, Forsey RJ, Chan WL, et al. A proinflammatory role for IL-18 in rheumatoid arthritis. J Clin Invest 1999; 104:1393.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/42/3754/abstract/44\">",
"      Braun A, Takemura S, Vallejo AN, et al. Lymphotoxin beta-mediated stimulation of synoviocytes in rheumatoid arthritis. Arthritis Rheum 2004; 50:2140.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/42/3754/abstract/45\">",
"      Sarkissian M, Lafyatis R. Integrin engagement regulates proliferation and collagenase expression of rheumatoid synovial fibroblasts. J Immunol 1999; 162:1772.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/42/3754/abstract/46\">",
"      Qin S, Rottman JB, Myers P, et al. The chemokine receptors CXCR3 and CCR5 mark subsets of T cells associated with certain inflammatory reactions. J Clin Invest 1998; 101:746.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/42/3754/abstract/47\">",
"      Bradfield PF, Amft N, Vernon-Wilson E, et al. Rheumatoid fibroblast-like synoviocytes overexpress the chemokine stromal cell-derived factor 1 (CXCL12), which supports distinct patterns and rates of CD4+ and CD8+ T cell migration within synovial tissue. Arthritis Rheum 2003; 48:2472.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/42/3754/abstract/48\">",
"      Burman A, Haworth O, Hardie DL, et al. A chemokine-dependent stromal induction mechanism for aberrant lymphocyte accumulation and compromised lymphatic return in rheumatoid arthritis. J Immunol 2005; 174:1693.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/42/3754/abstract/49\">",
"      Koch AE, Polverini PJ, Kunkel SL, et al. Interleukin-8 as a macrophage-derived mediator of angiogenesis. Science 1992; 258:1798.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/42/3754/abstract/50\">",
"      Koch AE, Kunkel SL, Harlow LA, et al. Epithelial neutrophil activating peptide-78: a novel chemotactic cytokine for neutrophils in arthritis. J Clin Invest 1994; 94:1012.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/42/3754/abstract/51\">",
"      Koch AE, Kunkel SL, Shah MR, et al. Growth-related gene product alpha. A chemotactic cytokine for neutrophils in rheumatoid arthritis. J Immunol 1995; 155:3660.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/42/3754/abstract/52\">",
"      Koch AE, Kunkel SL, Harlow LA, et al. Macrophage inflammatory protein-1 alpha. A novel chemotactic cytokine for macrophages in rheumatoid arthritis. J Clin Invest 1994; 93:921.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/42/3754/abstract/53\">",
"      Konttinen YT, Li TF, Mandelin J, et al. Increased expression of extracellular matrix metalloproteinase inducer in rheumatoid synovium. Arthritis Rheum 2000; 43:275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/42/3754/abstract/54\">",
"      Crotti TN, Smith MD, Weedon H, et al. Receptor activator NF-kappaB ligand (RANKL) expression in synovial tissue from patients with rheumatoid arthritis, spondyloarthropathy, osteoarthritis, and from normal patients: semiquantitative and quantitative analysis. Ann Rheum Dis 2002; 61:1047.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/42/3754/abstract/55\">",
"      Pettit AR, Ji H, von Stechow D, et al. TRANCE/RANKL knockout mice are protected from bone erosion in a serum transfer model of arthritis. Am J Pathol 2001; 159:1689.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/42/3754/abstract/56\">",
"      Patterson AM, Gardner L, Shaw J, et al. Induction of a CXCL8 binding site on endothelial syndecan-3 in rheumatoid synovium. Arthritis Rheum 2005; 52:2331.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/42/3754/abstract/57\">",
"      Gravallese EM, Darling JM, Ladd AL, et al. In situ hybridization studies of stromelysin and collagenase messenger RNA expression in rheumatoid synovium. Arthritis Rheum 1991; 34:1076.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/42/3754/abstract/58\">",
"      Firestein GS, Paine MM, Littman BH. Gene expression (collagenase, tissue inhibitor of metalloproteinases, complement, and HLA-DR) in rheumatoid arthritis and osteoarthritis synovium. Quantitative analysis and effect of intraarticular corticosteroids. Arthritis Rheum 1991; 34:1094.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/42/3754/abstract/59\">",
"      McCachren SS. Expression of metalloproteinases and metalloproteinase inhibitor in human arthritic synovium. Arthritis Rheum 1991; 34:1085.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/42/3754/abstract/60\">",
"      Goldbach-Mansky R, Lee JM, Hoxworth JM, et al. Active synovial matrix metalloproteinase-2 is associated with radiographic erosions in patients with early synovitis. Arthritis Res 2000; 2:145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/42/3754/abstract/61\">",
"      Nawrocki B, Polette M, Clavel C, et al. Expression of stromelysin 3 and tissue inhibitors of matrix metallo-proteinases, TIMP-1 and TIMP-2, in rheumatoid arthritis. Pathol Res Pract 1994; 190:690.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/42/3754/abstract/62\">",
"      M&uuml;ller-Ladner U, Kriegsmann J, Tschopp J, et al. Demonstration of granzyme A and perforin messenger RNA in the synovium of patients with rheumatoid arthritis. Arthritis Rheum 1995; 38:477.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/42/3754/abstract/63\">",
"      Tak PP, Kummer JA, Hack CE, et al. Granzyme-positive cytotoxic cells are specifically increased in early rheumatoid synovial tissue. Arthritis Rheum 1994; 37:1735.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/42/3754/abstract/64\">",
"      Trabandt A, Aicher WK, Gay RE, et al. Expression of the collagenolytic and Ras-induced cysteine proteinase cathepsin L and proliferation-associated oncogenes in synovial cells of MRL/I mice and patients with rheumatoid arthritis. Matrix 1990; 10:349.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/42/3754/abstract/65\">",
"      Trabandt A, Gay RE, Fassbender HG, Gay S. Cathepsin B in synovial cells at the site of joint destruction in rheumatoid arthritis. Arthritis Rheum 1991; 34:1444.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/42/3754/abstract/66\">",
"      Hou WS, Li W, Keyszer G, et al. Comparison of cathepsins K and S expression within the rheumatoid and osteoarthritic synovium. Arthritis Rheum 2002; 46:663.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/42/3754/abstract/67\">",
"      Asari A, Kuriyama S, Kominami E, Uchiyama Y. Cytochemical localization of hyaluronic acid in human synovium with special reference to its possible process of degradation. Arch Histol Cytol 1995; 58:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/42/3754/abstract/68\">",
"      Gelb BD, Shi GP, Chapman HA, Desnick RJ. Pycnodysostosis, a lysosomal disease caused by cathepsin K deficiency. Science 1996; 273:1236.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/42/3754/abstract/69\">",
"      Sano H, Forough R, Maier JA, et al. Detection of high levels of heparin binding growth factor-1 (acidic fibroblast growth factor) in inflammatory arthritic joints. J Cell Biol 1990; 110:1417.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/42/3754/abstract/70\">",
"      Trabandt A, Aicher WK, Gay RE, et al. Spontaneous expression of immediately-early response genes c-fos and egr-1 in collagenase-producing rheumatoid synovial fibroblasts. Rheumatol Int 1992; 12:53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/42/3754/abstract/71\">",
"      Handel ML, McMorrow LB, Gravallese EM. Nuclear factor-kappa B in rheumatoid synovium. Localization of p50 and p65. Arthritis Rheum 1995; 38:1762.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/42/3754/abstract/72\">",
"      Kinne RW, Boehm S, Iftner T, et al. Synovial fibroblast-like cells strongly express jun-B and C-fos proto-oncogenes in rheumatoid- and osteoarthritis. Scand J Rheumatol Suppl 1995; 101:121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/42/3754/abstract/73\">",
"      Marok R, Winyard PG, Coumbe A, et al. Activation of the transcription factor nuclear factor-kappaB in human inflamed synovial tissue. Arthritis Rheum 1996; 39:583.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/42/3754/abstract/74\">",
"      Hammaker D, Sweeney S, Firestein GS. Signal transduction networks in rheumatoid arthritis. Ann Rheum Dis 2003; 62 Suppl 2:ii86.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/42/3754/abstract/75\">",
"      Schett G, Tohidast-Akrad M, Smolen JS, et al. Activation, differential localization, and regulation of the stress-activated protein kinases, extracellular signal-regulated kinase, c-JUN N-terminal kinase, and p38 mitogen-activated protein kinase, in synovial tissue and cells in rheumatoid arthritis. Arthritis Rheum 2000; 43:2501.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/42/3754/abstract/76\">",
"      Han Z, Boyle DL, Aupperle KR, et al. Jun N-terminal kinase in rheumatoid arthritis. J Pharmacol Exp Ther 1999; 291:124.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/42/3754/abstract/77\">",
"      Badger AM, Griswold DE, Kapadia R, et al. Disease-modifying activity of SB 242235, a selective inhibitor of p38 mitogen-activated protein kinase, in rat adjuvant-induced arthritis. Arthritis Rheum 2000; 43:175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/42/3754/abstract/78\">",
"      Schett G, Tohidast-Akrad M, Steiner G, Smolen J. The stressed synovium. Arthritis Res 2001; 3:80.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/42/3754/abstract/79\">",
"      Firestein GS, Yeo M, Zvaifler NJ. Apoptosis in rheumatoid arthritis synovium. J Clin Invest 1995; 96:1631.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/42/3754/abstract/80\">",
"      Sugiyama M, Tsukazaki T, Yonekura A, et al. Localisation of apoptosis and expression of apoptosis related proteins in the synovium of patients with rheumatoid arthritis. Ann Rheum Dis 1996; 55:442.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/42/3754/abstract/81\">",
"      Firestein GS, Nguyen K, Aupperle KR, et al. Apoptosis in rheumatoid arthritis: p53 overexpression in rheumatoid arthritis synovium. Am J Pathol 1996; 149:2143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/42/3754/abstract/82\">",
"      Firestein GS, Echeverri F, Yeo M, et al. Somatic mutations in the p53 tumor suppressor gene in rheumatoid arthritis synovium. Proc Natl Acad Sci U S A 1997; 94:10895.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/42/3754/abstract/83\">",
"      Ruderman EM, Weinblatt ME, Thurmond LM, et al. Synovial tissue response to treatment with Campath-1H. Arthritis Rheum 1995; 38:254.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/42/3754/abstract/84\">",
"      Verburg RJ, Flierman R, Sont JK, et al. Outcome of intensive immunosuppression and autologous stem cell transplantation in patients with severe rheumatoid arthritis is associated with the composition of synovial T cell infiltration. Ann Rheum Dis 2005; 64:1397.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/42/3754/abstract/85\">",
"      Tak PP, Taylor PC, Breedveld FC, et al. Decrease in cellularity and expression of adhesion molecules by anti-tumor necrosis factor alpha monoclonal antibody treatment in patients with rheumatoid arthritis. Arthritis Rheum 1996; 39:1077.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/42/3754/abstract/86\">",
"      Haringman JJ, Kraan MC, Smeets TJ, et al. Chemokine blockade and chronic inflammatory disease: proof of concept in patients with rheumatoid arthritis. Ann Rheum Dis 2003; 62:715.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/42/3754/abstract/87\">",
"      Gravallese EM, Handel ML, Coblyn J, et al. N-[4-hydroxyphenyl] retinamide in rheumatoid arthritis: a pilot study. Arthritis Rheum 1996; 39:1021.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/42/3754/abstract/88\">",
"      Rooney M, Condell D, Quinlan W, et al. Analysis of the histologic variation of synovitis in rheumatoid arthritis. Arthritis Rheum 1988; 31:956.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/42/3754/abstract/89\">",
"      Youssef PP, Triantafillou S, Parker A, et al. Effects of pulse methylprednisolone on cell adhesion molecules in the synovial membrane in rheumatoid arthritis. Reduced E-selectin and intercellular adhesion molecule 1 expression. Arthritis Rheum 1996; 39:1970.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/42/3754/abstract/90\">",
"      Youssef PP, Haynes DR, Triantafillou S, et al. Effects of pulse methylprednisolone on inflammatory mediators in peripheral blood, synovial fluid, and synovial membrane in rheumatoid arthritis. Arthritis Rheum 1997; 40:1400.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/42/3754/abstract/91\">",
"      Lindblad S, Hedfors E. The synovial membrane of healthy individuals--immunohistochemical overlap with synovitis. Clin Exp Immunol 1987; 69:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/42/3754/abstract/92\">",
"      Tak PP, Smeets TJ, Daha MR, et al. Analysis of the synovial cell infiltrate in early rheumatoid synovial tissue in relation to local disease activity. Arthritis Rheum 1997; 40:217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/42/3754/abstract/93\">",
"      Rooney M, Whelan A, Feighery C, Bresnihan B. The immunohistologic features of synovitis, disease activity and in vitro IgM rheumatoid factor synthesis by blood mononuclear cells in rheumatoid arthritis. J Rheumatol 1989; 16:459.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/42/3754/abstract/94\">",
"      Rooney M, Whelan A, Feighery C, Bresnihan B. Changes in lymphocyte infiltration of the synovial membrane and the clinical course of rheumatoid arthritis. Arthritis Rheum 1989; 32:361.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/42/3754/abstract/95\">",
"      Walters MT, Stevenson FK, Goswami R, et al. Comparison of serum and synovial fluid concentrations of beta 2-microglobulin and C reactive protein in relation to clinical disease activity and synovial inflammation in rheumatoid arthritis. Ann Rheum Dis 1989; 48:905.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/42/3754/abstract/96\">",
"      Yanni G, Whelan A, Feighery C, Bresnihan B. Synovial tissue macrophages and joint erosion in rheumatoid arthritis. Ann Rheum Dis 1994; 53:39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/42/3754/abstract/97\">",
"      Mulherin D, Fitzgerald O, Bresnihan B. Synovial tissue macrophage populations and articular damage in rheumatoid arthritis. Arthritis Rheum 1996; 39:115.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7500 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-203.80.222.8-CDD449C725-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_42_3754=[""].join("\n");
var outline_f3_42_3754=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H895962782\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      NORMAL SYNOVIUM",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Synovial lining cells",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      SYNOVIAL PATHOLOGY IN RHEUMATOID ARTHRITIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Synovial lining cell hyperplasia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Cellular infiltrate",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Angiogenesis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Pannus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Changes in early RA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      MEDIATORS OF INFLAMMATION IN THE SYNOVIUM",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Cytokines",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Chemokines",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Cell surface proteins",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Enzymes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Transcription factors and cell signaling molecules",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Apoptosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      SYNOVIAL TISSUE RESPONSE TO THERAPY AND CORRELATION WITH DISEASE ACTIVITY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H895962782\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"RHEUM/7500\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"RHEUM/7500|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?18/52/19268\" title=\"diagnostic image 1\">",
"      Stromelysin in synovium of RA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"RHEUM/7500|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?21/0/21510\" title=\"picture 1\">",
"      Synovial tissue in RA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?20/53/21333\" title=\"picture 2\">",
"      Pannus invading cartilage in RA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?7/52/8002\" title=\"picture 3\">",
"      p65 subunit of NF kB in RA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?31/23/32119\" title=\"picture 4\">",
"      p50 subunit of NF kB CD14 cells",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/22/16746?source=related_link\">",
"      Cytokine networks in rheumatic diseases: Implications for therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/55/6010?source=related_link\">",
"      Diagnosis and differential diagnosis of rheumatoid arthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/54/36711?source=related_link\">",
"      Leukocyte-endothelial adhesion in the pathogenesis of inflammation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/5/34906?source=related_link\">",
"      Normal skeletal development and regulation of bone formation and resorption",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/19/3384?source=related_link\">",
"      Overview of biologic agents in the rheumatic diseases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/27/17846?source=related_link\">",
"      Principles of molecular genetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/38/10854?source=related_link\">",
"      Regulators and receptors of the complement system",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/50/10025?source=related_link\">",
"      Role of cytokines in rheumatic diseases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/8/4231?source=related_link\">",
"      Role of cytokines in the immune system",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/58/6056?source=related_link\">",
"      The adaptive cellular immune response",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f3_42_3755="Indications exercise testing";
var content_f3_42_3755=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F78644&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F78644&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Indications for pediatric exercise testing",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td>",
"       Evaluate specific symptoms or signs that may be induced or aggravated by exercise",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Identify abnormal adaptive responses occurring in children with cardiac or other disorders",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Assess the effectiveness of specific medical and surgical treatments",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Estimate levels of functional capacity for vocational, recreational, and athletic recommendations",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Improve the safety of vocational, recreational, and athletic recommendations",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Estimate prognosis for a given disease (eg, cystic fibrosis)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Evaluate fitness levels",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Establish baseline data and follow up on effectiveness of cardiac rehabilitation",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_42_3755=[""].join("\n");
var outline_f3_42_3755=null;
var title_f3_42_3756="WHO discharge criteria";
var content_f3_42_3756=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F79197&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F79197&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Criteria for discharge from non-residential care",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Criteria",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Child",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Weight-for-height has reached -1 SD (90 percent) of NCHS/WHO median reference values",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Eating an adequate amount of a nutritious diet that the mother can prepare at home",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Gaining weight at a normal or increased rate (about 10 to 15 g/kg per day)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        All vitamin and mineral deficiencies have been treated",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        All infections and other conditions have been or are being treated, including anaemia, diarrhoea, intestinal parasitic infections, malaria, tuberculosis and otitis media",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Full immunization programme started",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Mother or carer",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Able and willing to look after the child",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Knows how to prepare appropriate foods and to feed the child",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Knows how to make appropriate toys and to play with the child",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Knows how to give home treatment for diarrhoea, fever and acute respiratory infections, and how to recognize the signs that mean she must seek medical assistance",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Health worker",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Able to ensure follow-up of the child and support for the mother",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Management of Severe Malnutrition: A Manual for Physicians and other Senior Health Workers. World Health Organization, Geneva, 1999. Copyright &copy; 1999 World Health Organization.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_42_3756=[""].join("\n");
var outline_f3_42_3756=null;
var title_f3_42_3757="Comparison pharm stress agents";
var content_f3_42_3757=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F71371&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F71371&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Comparison of major pharmacologic agents used for stress testing",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup span=\"5\" width=\"20%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\">",
"        Dipyridamole",
"       </td>",
"       <td class=\"subtitle1\">",
"        Adenosine",
"       </td>",
"       <td class=\"subtitle1\">",
"        Regadenoson",
"       </td>",
"       <td class=\"subtitle1\">",
"        Dobutamine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Chemical",
"        </strong>",
"       </td>",
"       <td>",
"        Pyrimidine derivative",
"       </td>",
"       <td>",
"        Endogenous vasodilator of purine derivative",
"       </td>",
"       <td>",
"        Purine derivative",
"       </td>",
"       <td>",
"        Synthetic catecholamine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Onset and duration of action, half-life",
"        </strong>",
"       </td>",
"       <td>",
"        Effect peaks at 7 to 15 minutes, half-life 30 to 45 minutes",
"       </td>",
"       <td>",
"        Immediate onset, half-life less than five seconds, effects disappear rapidly after infusion",
"       </td>",
"       <td>",
"        <p>",
"         Peak 1 to 4 minutes after injection",
"        </p>",
"        Half-life of &cong;30 minutes",
"       </td>",
"       <td>",
"        Onset 1 to 2 minutes, half-life 2 minutes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Mechanism of action",
"        </strong>",
"       </td>",
"       <td>",
"        Blocks reuptake of endogenous adenosine causing coronary vasodilation",
"       </td>",
"       <td>",
"        Stimulation of adenosine receptor A2A causing coronary vasodilation",
"       </td>",
"       <td>",
"        Stimulates A2A adenosine receptor causes coronary vasodilation",
"       </td>",
"       <td>",
"        Alpha-1, beta-1, and beta-2 stimulation increases myocardial O2 demand and secondary vasodilatation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Dose",
"        </strong>",
"       </td>",
"       <td>",
"        140 mcg/kg per min for 4 minutes (maximum 0.56 mg/kg)",
"       </td>",
"       <td>",
"        140 mcg/kg per min for 4 to 6 minutes",
"       </td>",
"       <td>",
"        Regadenoson 0.4 mg/5 mL",
"       </td>",
"       <td>",
"        5 to 40 mcg/kg per min, depending upon heart rate response",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Radionuclide injection",
"        </strong>",
"       </td>",
"       <td>",
"        7 to 9 minutes after initiation of infusion",
"       </td>",
"       <td>",
"        3 minutes into infusion; infusion continued for further 1 to 3 minutes",
"       </td>",
"       <td>",
"        10 to 20 seconds after regadenoson",
"       </td>",
"       <td>",
"        At peak stress",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Hemodynamics",
"        </strong>",
"       </td>",
"       <td>",
"        Slight increase in heart rate and slight decrease in blood pressure (BP)",
"       </td>",
"       <td>",
"        Slight increase in heart rate and slight decrease in BP (adenosine more than dipyridamole)",
"       </td>",
"       <td>",
"        Slight increase in heart rate and slight decrease in BP",
"       </td>",
"       <td>",
"        Target heart rate 85 percent of maximum predicted heart rate",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Side effects",
"        </strong>",
"       </td>",
"       <td>",
"        Occur frequently, but minor",
"       </td>",
"       <td>",
"        Same as dipyridamole but resolve rapidly; heart block more common",
"       </td>",
"       <td>",
"        Dyspnea, headache and flushing",
"       </td>",
"       <td>",
"        Most common chest pain, most serious nonsustained ventricular tachycardia, nonfatal myocardial infarction",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Contraindications",
"        </strong>",
"       </td>",
"       <td>",
"        Bronchospasm, second or third degree AV block or sick sinus syndrome (unless protected by a functioning pacemaker)",
"       </td>",
"       <td>",
"        Same as dipyridamole",
"       </td>",
"       <td>",
"        <p>",
"         Second- or third-degree AV block or sinus node dysfunction",
"        </p>",
"        Caution for bronchospasm",
"       </td>",
"       <td>",
"        Recent acute coronary syndrome, hemodynamic and electrophysiologic instability",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_42_3757=[""].join("\n");
var outline_f3_42_3757=null;
var title_f3_42_3758="Neonatal HSV SSx";
var content_f3_42_3758=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F67814&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F67814&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 598px\">",
"   <div class=\"ttl\">",
"    Signs and symptoms of neonatal herpes simplex virus infection",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 578px; height: 405px; background-image: url(data:image/gif;base64,R0lGODlhQgKVAdUAAP////8AAAAzmSBzOcDAwICAgAAAABhWKr8AAEBAQAAZTH8AAAAmcoBAQBEREVVVVYiIiMzMzDMzM+7u7hA5HKqqqggcDgAMJkBNZkRERHd3dyIiIt3d3T8AAJmZmWZmZru7u2BgYDAwMCAgIKCgoAYVCtDQ0ODg4BAQEHBwcPDw8C8AAAwrFR8AAAAJHAATOQAGE18AAAIHA5CQkBJAIAQOB0BJXCAQEFAwMI8AAAADCYBwcF9AQAAAAAAAAAAAACH5BAAAAAAALAAAAABCApUBAAb/QIBwSCwaj8ikcslsOp/QqHRKrVqv2Kx2y+16v+CweEwum8/otHrNbrvf8Lh8Tq/b7/i8fs/v+/+AgYKDhIWGh4iJiouMjY6PkJGSk5SVlpeYmZqbnJ2en6ChoqOkpaanqKmqq6ytrq+wsVEECbK2t7iytLm8vb6iu7/Cw8SRwcXIycqAx8vOz9BvzdHU1dZe09fa29xN2d3g4dzf4uXmzgQtC+vs7e7v8PHy8/T19vf4+fr3MQTn/64IdAhAsKDBgwgTKlzIsKHDhxAjSpwIEYE/gBhTCaTIsaPHjyBDdrSYsaSpjSJTqlzJsmUAkiZjhkLpsqbNmzhhytzJiSbO/59Ag1LUybPoJZ9Ckypd+vKi0aeUkDKdSrUlUahYHUmtyrXrSKdZwy7a6rWsWYZXxaotRPas27dp18plZqCu3bt3C+jdy7ev37+AAwseTLiw4cOIE+s9MbexIAIXBEieTFmyAseYwz24C8HNBAMOpkCuTFrA5cyotW2uACCDAdaPI5emfDq17WirAWgwAGF3BgcGHgiBYLezBAMRIoDWbeC3gQ+bHUQA4AF4cACfHbiWDsBBaOJ1N8BWMnr25Nq30yvLfTzC7s7AIxDXAGCDAQ7tlYd+3/2+h+fKSQDAfNkNeJ13RBCXAREENOhggzPIZp5p6lWYzGbhecCccchhaP9XBfktxx9wE1QQ3HwAmChBgSYKh2AFrtUl4BAJ1GhjjSJIaB56FvbYS25D8NcecR8QcVwF+m3YX4nBBWigBiweGBpwIDi5RHkT8ujjlrYAKYSQyBloVwQmNicib0u2SJ11RUbp4ncyGjAjeTrOpiWXePqI5Y55skKCYoAGKuigiDF2zp529rlKAiEQ6uijkCI2AljiEOACA5hmqimmLyiqSgKUtgLqPwSI8OCpD3qayqixsGoOOaqKGiorrpYDa6yLzporqbXgKourBASqayS1Vtqrr7C4WkAH+3RQQCQoElFsOLcie4qyC1C0wLNHKGdXBrC114WaTVipRLQ0Drv/TbXWloKtttwa4SR+BoAgh7lJoCvEtOCw2+4o7060LRJWmrjgZskdV1fCY06AoXjZubYBBPYJp9wDEYM2nYcZcGDdaw6Hx9p/oBlAn7TqauPvv6EELNHA3cophJMIH6ehEDYPsRoHBmxQIJH13Xfxz9fpzJuVO/es3AZPFsFvNyuz/InLEcEsr8wpXocwyXJOwPWKH9dFNH0hYrycmhTbpYGVYb92nb4APD3OsVKv6lQB2QocbxHzHmcvwkPkjLMBHmx2M3bLoVi2m0nOt7QQhg8Bgsxwy70u3XVfe3feL+9NhLd1ZTAdAAh/XKTp2HnowNgALH621nHSh2EFIde1/1/sTqd8TdSZb0I1RFZbYrnKmPdOirLM6uNsJsPvXrzxogArLPO6W8M79Jc0b4r21VyPfSXcH199989/70n4AI9PjffmS4J+9OpHw377kLzfcvzQzE+/I/aD0v8y+tsfI6QHKPwh4n/KCKAAFaGsCyjggRCMoAQheAHPUQKBySDACCLFwQ568IOBMWA1lKWACdnJgkPgQIwcwIH+CKhAAPhAeKCkBwwioy1vyeFPUGgOEpqwNArg4QQ24ADWVMBFdYFAgfijwtHhwYbFwKEOp+gSHpbDhz+sTBCR8J8iEcE7REzSZjJAwz1AkRhSpKIaU2JFcWAxi+fhIX++6ID/bP8HABGwj4xamIczDiONawykR9oYjjfC0TQ8BBodW2O7IUxAA67pTB9FCMCBCPKSKyEkOAwJxy0eYYhFTNGbsAOc0DxAkjI83B38KAxAYvKVDtFkNziZRU8eQYW2ayGCDPQdDDlAkpMklSVhSUyOyJIbtPyhLYVHyQQOs5jQhMgxt9HACVpTghWknjCjyc2HTFMbBFRMMwnByl+4spvF/OY1yslMUq0AAfCMpzznSc962vOe+MynPvfJz376858IUKc12Am+cd7QVKhKqEIXytCGOvShEI2oRCcaUUNlhKAXNGgUy7fA7GlUExi1xMcmBjm7CCeGdlElEhTY0UOE1H3/H+UEiRgpyTlGEgAqnMCVONrSjP4qppuY6QR2ycSeQYGlPSWnU4JVQG3eYqZLUhK5jACYEPA0qcS6mwUowNWuevWrXbWAQF0KVE0I1QFMU9LjjlDVq2L1EcqiwADmSte62pWuFLAiBKyztv6ozVuStM/JnljWTMz0pkqiKU4zoFPyuPWtjYjrXSdr17wigVwfgI8BGovH8IhpsKssLCZGejMPnVSGdVHpEZAK2T9IlrKwtewRiCOBvgoBqp0FDsWAA1o7vPQWrG1tH14L28nK1ggTiBFoWBM2JMkpOnCrw29tEVzhmvFuci2ucQkJgTFGdWZyUk5mTVZD0fKiutYN/6YQCpBd7VZWjjTs4nc7O6fo0mG6unhsesk6BPa6967HLUIFdlMXL4ZtbVhrmnpfpd/9FoK4/51rgAvKKwfDtL9bBauGvSpWpzLYwlkdAlPF6WFbNRjEgcAv/8ybC/SiWA4qjiyLceHiF8MhxgOcMXBPbOPh6rh+P85vjwfYKBAa+ciGmVSFh6yIPyH5yVD+i0VNzOQqa4THVs5yVLCs5S4/osZeDrMfwCzmMueBzGZOMx3QrOY2S4PLbo6zHtgs5zqbgc52znMY8KznPnOBz34O9BUALehCS4EAN2iAohfN6EY7+tGQjrSkJ03pSkN6B4bu6DnR2ZAGZHqBm+b0Qv88/en9hVrUCSF1qdt3alQfRNWr/l6rXV0QWMcaerOmdQBsfeve5ZrWvO513X7t6mALm2XERrWxj92uZIt62cxGVjr2Qe1qW9vaOKCotrfN7W57+9sONUG02WCpTZn73OhOt7rXze52u/vd8I63vOdN73rbG942+DQumwNMIsBwDIg6pMAHTvCCG/zgCE+4whfO8Nlg4NPigpE06tTwilv84hjPuMY3PqGHZxo4mR1CBGLUse6ERmF1GTCa4rObBzgASg8bTxICzvGa2/zmOM95xT1uaK41pz6rk+8uDSScESGHwCZLWlrppPOmO/3pUH86zzPtHvuAxy4C2qUdv7T/8qOjya924Sxe7kLxqJv97GhPexanHujk3uw4HCAiH28bGhUFibws/3rknEBztfv974BvOtsDDUkZsWbkJjU52HkT9+bkXZK1W86Vyh74ylv+8gwf/LjL0HfMe/7zoDeP5jcPcMqH/vSox/zoSb9n06f+9bBH++pZ/wUCyMACuM897hMQ5d77/vfAD/5fSED7MxDAApQda/GPffzkL//5K0X+ZJUP/Vg3f/rVz74Qrn9X6ms/09y3q/e/X+jw13X85A+0+emK/vT3ef1zbb/78wz/Ach//nUmQA02fH/8x5nQ/mdmABiAYjaABOhlBniAWpaACmhlDNiATPaAENhj/xI4gS9WgRYIYhiYgQ62gRyYXqUCbiIogh9oLQTwTgCVgioIUDFQgtL2TN20AC7oK85mFjI4g7FSg2VxgzjoKTroFTzYg33yg10RhEKIJ0TIFUZ4hFuShFWxhEzYI05IFVAYhRUyhVNRhVaYHljIFFq4hbZBAGM3hmRYhmZ4hmhohry3F2DYhK4Hev3XhomAWoTzBHZHBbnxb0SgJrkxVU/QeaEXh3JoCDeVU2bgJUyAiIf2hp8niIM4CDyzdDOjMB2TMdLhLQISIicXHEmUOsWBdSZnIkwzOQ9wMVcnARezJo00ebE3GY74iIHgh0A3AZOzIolzHU6iia1TL5NjSv9fRzqvQXe7CAIyVCWwc3jBkR1z119/EQKM6HmvCIt/sFbg9UJi8zoWIzO62B4FgltAgiBE4gACkoq5kYp0eFLr1YzPiHnRKI1+UIiMRUS02DXYSF+76FybGAEFshnAtHe7ZB2dQY51mIpCMFT3wYqtKADt6I59QIcaEgGUyAFuYo9lckfcuByRhyTAkXWhwRxplYoRsJEXAzq/xASACIcMKQsGwwzreHkLmZKNcBzc8Qcn2YgwyYUwcE06uZM82ZM+qZMhMIIPNWU3mT8lcABImZRKuZRM2ZRO+ZRQGZVSOZVU6ZQvWZSkUH8RtpVc2ZVe+ZXdh5XrI31gWZZmeZb/aGl/Yik/ZJmWbvmWcHl+a5k/bRmXdnmXX3mVc/kJWomXfvmX4reX6FCXgFmYhqmXgtkThGmYjImXiJmYmtCXjTmZaPmYkIkJkkmZmpmXl3lDR1mVoBmaojmapNmUltmZlRCCQrmarAluRImaveCBsImEcDabPSWbtqkntZmboLabvGlqvvmbrBacwilrxFmcuHacyOlryrmcw9aczolsGyR81Fmd1nmdjuKOXahr3BlIXxiF29md4qlD38mE4Tme6GmD2gmD6dmetFaeR3ie7jmfSwGfQiif9JmfQGGfPYif+vmfNcGfOOifAFqgKiGgM0igBrqgH4GgLqigDBqh/wKjnSi4ghZ6oRiaoRq6oRzaoRvagtJIADn5kyRaoiZ6oiiaoiq6oizqky8wA63pbdrZkglZozrHAEHWgKCzMGRQkzb6ozmHo4KJLz1Ko0B6pBknpHuJL4jXHBywG0VCHEoUc7uoiEbgo0iapRinpHO5o6Ehj100VF/qixUQibuYcszoF86opWwapDmqgOayozKzGTJEH20zAeJCBFVlpG3apwXHpWuJL3JHBJPDo3s3OE7EdH66qFv6pgfIpMp1UsdxUpGXj97Ap4yaqRMCqNFpBViqqaC6qY7amZ8aqqZaGZzaqVRAADpwAa76qrAaq7I6q7Raq7Z6q7eKAbq6q/+82qu++qvAGqzCOqzEWqzGeqy6agPipqqD9pml+azQ6pQswKyvspib6ZYUQK22Yq3XipbZqq3Uwq3dapbfCq5QI67jCpblaq7rgq7p6pXryq67467vypXxKq/dQ6/1GmH3iq9sua/Y6q8qo68Aq139KrDo4KzRurDROq0I2z0IFaMSy1APSz4VC5wXSz+4mbE7sbEcGxMe+7ElEbIiixEkW7JLhrKZc7IqS2Ut+5wvO2yJZmk0W7M2e7M4m7M6u7M827OLxgMIC6ESyk0OKpxCO7TQVLS/ebRIS0xKy5tM27Sv9LS5GbVSe0lUa5tWe7XeGbTsybVNm7WzubVgS0X/YgubZFu25Om1asu1Z4ua03Ztcju3dFu3dnu3eBsPHbBQRyiLPXop9xa4gju4hFu4hnu46dYp/melRNCHRWN8mHqqkmtwd/J9jGs0RvS4dxa5k9u5h1S52oeIVwcBp6gix7EiYCccpisBuOQdmxUf3SGJK8W5nlu7WRKAXoIi9sEBjrsgiCUE9gECZfJcXfdIJvMf/Ta7tru8DQe62eclHpJyjlt0aIJ0r0EusEsiS/MbnAUAZUi7zBu+FLK4wTgcz9G4dagm76EgwFgB5OIazLVZwHi+Jgm+4ru8zlt90SscV4ccISkn6ssbeAoaR0IuECknM1UmiTpz9nu/tZu//9I4OWm1kpfqwBb8uWI5vKgoBPDLdw18wZILwVX7wSBsqiKstbeneyq8wizcwi78wjAcwzFcAkWGnTaMZNSamQVblgcwqjGrCDq8w1/Zwz8cC0EsxF1JxEX8CkeMxFupxEvcCk3sxP8FxVG8ClNMxdplxVesEQSrxe7FxV18ClkMxpQlxmNcCmVsxneFxmk8CmvMxnXlxm88E/u3YXicx3q8x3zcxxrGAj5cxzQJnYL8FCxbyABEyIjME4e8yDekyI4MspAcySM7yZRsspZ8ySmryVyYyZzssp98G6o5saRcyqZ8yqicyg6iAuBZoR76yrAcy7I8y7TcoTkQyMKWtv9tK7Vx8aBfu8vAnBO43Gu6HMwS2sslWMzGzKDI/IHKvMwG2swc+MzQDKDSnIHUXM36ec0WmM3aTJ/cPIHe/M3uGc4QOM7knJ7m3IBimIbu/M7wHM/yPM/0XM/2fM/4nM/xXMOAsj96uAaAM2gkXMIE/XQnrCogUhcP4AF66LdY4NAB7akDXdAUjXMHrShDlVYQ8AH/rAYRXQWlWtEibXYX3Sf6oQE3UyCRlIqT2omBU4eukRwk10JIV4q4qFwho49UWh2rqKgj/dOWV9J9QocCDBoyFJDX4Te9uIdO+nNg+hx32FnCEUZGEwFKp4xUpY5AvdWBJ9SK4gG7sTp2wUL/Ur2L+ih5Q2AfMuRcd7EiygUBI5lgwPi/dzEB56inWs3Vep12Xs0lRzQdHuMzyyUzLI0c/wweaTWoAqY010HVJWXVdVgEBrmMqzXRe33ZBNfXW/KkelSJyyFDH1DYZ92RjqRbMxOppQuSOI0wlUqSyVvZmB3bTqfZxGzZsn3bfOJ+IY3bvJ3Z8yeiLRrcwj3cxF3cxn3cyJ3cCnABqtzcCsXK0qawDDvd1F3d1n3d2J3d2r3d3I3dNDDMI/vFcjze5F3e5k2ZdJwncXze7N3e7v3eWwzeGbHe8F3f9n3fbJzeSCje+N3f/v3f+6rfXELfAF7gBn7gcCngTcjfCN7g/w7+4Eks3ybL4BBe4RZ+4QquJxR+4Rze4QWe4VK44R4+4iT+3iBuIQQg3d294ize4i7+4jAe4zKelN9tghHr3Die4zq+4zze4z6+yiboyaHcL0I+5HNj5GFY5EjuPEuOGo3c5Eas5FAuP1I+5c/w5FYuxTf+41ze5V7+5WAe5mIuUdBNYyhwI2ie5mq+5myO5iggAm0e53Ie5wYw53Z+5zUyAiOA53we52/e54Cu5nUe6ISe53te6IT+54ge6IO+6H2u544O6Cgg4YiQgDhWBAbABnrBBpdOBJm+Bpu+Bp0+BJ+uBqGuBqPeCJY+zKWeBqeeBqnuvZp+mvvC6rPO6f+Ufgirzgatjgavjgax3utn8OtnEOy3Luq5bgi7vgbCbgbEbgbGDuq0Hje2Lu24fl5Vni68fuyoXu2mPu3R/u3X3mLZXuvbbu3Ifu7inu7Mzu2wnuxsUe7Uru6uDu7eXu/jrgbNXgbPXgaxvggmkAJskALLiupsQALEtwYEz+kHn/BqsPCi3vADX/BZXvEWf/EYn/Eav/E9CB6oawYSAEwx4kVgkFwyolP0EtlgUKg/JyYfLwaTI0kjPwZ69HMpr1pdAAIKY75dEwY8cxctNPNigCEbfPNikPIn4/HdywUeYy84pTA3I/SsoBzTUVtlUKiSRDET4DEy1wU5NUSd8QD/qiu/Y8D1VN86veUF/9sZWs/1YrABqiT2WbP0TE+/nVX1af8FFDMgPuP2YFABZC0BRSL3JkL3WyD3cedceK/3deH0hL9ZbR9KrAABMwIBC2IGGSBJD3AymV8GId8dsFEvZKAcHED5w3H5YOAxHkBSm8/Br80FesS6oC8Eog8GkJQglY/6YTBUGtL6rfH6WsAzndH5kl/7XyABJ7X5pj8gut8FtV/8IOD7nT/5l7/3mC/zMk/yYbD8ta/yYGB1zD8cssv0JEVS058B2l/yyO+9Tu/9XeAcclL61T/+XqABM3L+6d8FYi8Bsg8EBhAAYPAQkUnlkrkEbQwGhwaSIUI2/03tdikkeoueDISY+XDRafWa3eZCJFermw4YEx+aMrmu/kgmiBwqvob61CY2PODkDrk8oiIh8vYc1aoABgsttR74JD4YATA5tTjAKO34SpVEGTWLDFmbHCBc52aRwGCFUu9ygYPdIgwiACT0hJd+sSY4YIM5QJMeHgAqDAKFQwGeIYiNkZWTNsianwmFQTImJiTIqq+zleECkcGPk5UfcM+hgSE44ADgD4B42LSNy+BgAj5xwlBZQ+gv3TiLF5FAiAIII4hIWexEOaMM0sduEqIcIQnFgLVRGxOOK1dG5DhpUdidTGnxAc5AGg1wVObRGJIMNRVuNHbTiE2lV2AGA/9q4AxTlUepYtS6lWtXr1/BhhU7lmxZs2fRplW7lm1bt2/hxpU7l25du3fx5tW7l29fv38BBxY8mHBhw4cRJ1a8mHFjx48hR5Y8mXJly5cxZ9a8mXNnz59BhxY9mnRp06dRp1a9mnVr169hx5Y9m3Zt27dx59a9m3dv37+BBxc+nHhx44Wntow5q2fF48+hN9aoZ7qw5tGxZz9cHZs1DyytaWg5ZULPKBXKR9mAXspRBxGmxtE+nz7f6h8MfAtK0Ij4KBp6WqW5UzaYQIqXrLmuvgUZpCs5cyL5Tzw+HJhHkAizObA7gwxwrsEPQUSrOiSIkY+ICfHID4meVALAQAdY5EmwqRBprFGsEZH4ThIUXTSvw/SiYEjDlgCIoEITbUxSySWZbNLJJ6GMUsopqazSyiuxzFLLLbns0ssvwQxTzDHJLNPMM9FMU8012WzTzTfhjFPOOUULAgA7);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Signs and symptoms of neonatal herpes simplex virus infection at diagnosis and initiation of therapy.",
"    <div class=\"footnotes\">",
"     SEM: skin, eyes, or mouth; CNS: central nervous system; DIC: disseminated intravascular coagulopathy.",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Kimberlin DW, Lin C-Y, Jacobs RF, et al. Natural history of neonatal herpes simplex virus infections in the acyclovir era. Pediatrics 2001; 108:223.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_42_3758=[""].join("\n");
var outline_f3_42_3758=null;
var title_f3_42_3759="Contents: Depressive disorders";
var content_f3_42_3759=[" <script type=\"text/javascript\">",
"  $$.inlineInitCustomer(",
"	false);",
"	var quirksmode = document.compatMode == \"CSS1Compat\";",
"	if (quirksmode) {",
"		$(\"html\").addClass(\"ie-standards\");",
"	}",
" </script>",
" <div id=\"message-wrap\">",
"  <div id=\"message-bg\">",
"  </div>",
"  <iframe id=\"message-bk\">",
"  </iframe>",
"  <dl id=\"message-container\">",
"   <dt id=\"message-title\">",
"   </dt>",
"   <dd id=\"message-body\">",
"   </dd>",
"   <dd id=\"message-controls\">",
"   </dd>",
"  </dl>",
" </div>",
" <div id=\"topPanel\">",
"  <div id=\"header\">",
"   <div id=\"header_container\">",
"    <h2 id=\"logo\">",
"     <a href=\"./toc\">",
"      Wolters Kluwer Health UpToDate",
"     </a>",
"    </h2>",
"    <div id=\"header_right\">",
"     <div id=\"searchpanel\">",
"      <a href=\"/login\" id=\"loginbutton\">",
"       Log in",
"      </a>",
"      <div id=\"cmsSearchBox\">",
"       <div class=\"header-search\">",
"        <form action=\"./search\" id=\"cmssearch\" method=\"get\" name=\"SearchForm\">",
"         <div class=\"header-search-left\">",
"          <input autocomplete=\"off\" class=\"searchfield\" id=\"cmsTxtBox\" name=\"search\" placeholder=\"Search UpToDate\" type=\"text\"/>",
"         </div>",
"         <div class=\"header-search-right\">",
"          <input alt=\"Search\" id=\"cmsSearchSubmit\" src=\"/sites/all/themes/uptodate/images/search_button.png\" type=\"image\"/>",
"         </div>",
"         <div class=\"clear\">",
"         </div>",
"        </form>",
"       </div>",
"      </div>",
"      <div id=\"cms_lang_dropdown\">",
"       <form accept-charset=\"UTF-8\" action=\"/\" id=\"lang-dropdown-form\" method=\"post\">",
"        <div class=\"form-item form-type-select form-item-lang-dropdown-select\">",
"         <select class=\"lang-dropdown-select-element form-select\" id=\"edit-lang-dropdown-select\" name=\"lang_dropdown_select\" style=\"width:100px\">",
"          <option selected=\"selected\" value=\"en\">",
"           English",
"          </option>",
"          <option value=\"ja\">",
"           ���������������������������",
"          </option>",
"         </select>",
"        </div>",
"        <input name=\"lang_dropdown_type\" type=\"hidden\" value=\"language\">",
"         <input name=\"en\" type=\"hidden\" value=\"/\">",
"          <input name=\"ja\" type=\"hidden\" value=\"/ja\">",
"           <noscript>",
"            <div>",
"             <input class=\"form-submit\" id=\"edit-submit\" name=\"op\" type=\"submit\" value=\"Go\"/>",
"            </div>",
"           </noscript>",
"           <input name=\"form_build_id\" type=\"hidden\" value=\"form-on4lUWpxHun_wp6revUkjCG6rK2IBuCGME9Cw0HXeok\">",
"            <input name=\"form_id\" type=\"hidden\" value=\"lang_dropdown_form\">",
"            </input>",
"           </input>",
"          </input>",
"         </input>",
"        </input>",
"       </form>",
"      </div>",
"      <div class=\"clear\">",
"      </div>",
"     </div>",
"     <ul id=\"utility\">",
"      <li class=\"first\">",
"       <a href=\"/home/about-us\">",
"        About Us",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/news-events\">",
"        News &amp; Events",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/contact-us\">",
"        Contact Us",
"       </a>",
"      </li>",
"      <li class=\"last\">",
"       <a href=\"/help\">",
"        Help",
"       </a>",
"      </li>",
"     </ul>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"nav\">",
"    <ul>",
"     <li id=\"productTab\">",
"      <a href=\"/home/product\">",
"       Product",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"editoralTab\">",
"      <a href=\"/home/editorial\">",
"       Editorial",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"whyUptodateTab\">",
"      <a href=\"/home/why-uptodate\">",
"       Why UpToDate",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"supscriptionOptionsTab\">",
"      <a href=\"/home/subscription-options\">",
"       Subscription Options",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"/store\">",
"       Subscribe",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"wkhcsTab\">",
"      <a href=\"/home/wolters-kluwer-health-clinical-solutions\">",
"       Wolters Kluwer Health Clinical Solutions",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"    </ul>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"greyBar\">",
"    <div id=\"greyBarTitle\">",
"     <span class=\"emphasis\">",
"      <a href=\"UTD.htm?3/3/3134\">",
"       Contents",
"      </a>",
"     </span>",
"     <img src=\"./../images/space_arrows.myextg\">",
"      <a href=\"UTD.htm?41/24/42381\">",
"       Psychiatry",
"      </a>",
"      <img src=\"./../images/space_arrows.myextg\">",
"       Depressive disorders",
"      </img>",
"     </img>",
"    </div>",
"    <div id=\"greyBarButtons\">",
"     <div id=\"printGB\">",
"      <a class=\"icontxt\" href=\"?view=print\">",
"       <img align=\"middle\" alt=\"Print this page\" border=\"0\" height=\"20\" src=\"./../images/icn_print.myextg\" width=\"24\"/>",
"      </a>",
"      <a class=\"icontxt\" href=\"?view=print\" title=\"Print this page\">",
"       Print",
"      </a>",
"     </div>",
"    </div>",
"   </div>",
"   <!-- menuMessage.jsp -->",
"   <!-- /menuMessage.jsp -->",
"  </div>",
"  <!-- header -->",
" </div>",
" <!-- topPanel -->",
" <div id=\"leftPanel\">",
"  <ul>",
"   <li>",
"    <a href=\"UTD.htm?3/45/3806\">",
"     Specialties",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?18/22/18798\">",
"     Patient Information",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?3/13/3294\">",
"     What's New",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/37/606\">",
"     Calculators",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/40/654\">",
"     Authors and Editors",
"    </a>",
"   </li>",
"  </ul>",
" </div>",
" <!-- leftPanel -->",
" <div id=\"rightPanel\">",
"  <noscript>",
"   <div id=\"javascriptDisabled\">",
"    It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"   </div>",
"  </noscript>",
"  <div id=\"printHeader\">",
"   <div id=\"printHeaderLogo\">",
"    <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"    </img>",
"   </div>",
"   <div id=\"printHeaderText\">",
"    Official reprint from UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"    <a href=\"file://www.uptodate.com\">",
"     www.uptodate.com",
"    </a>",
"    <br>",
"     &copy;2013 UpToDate",
"     <sup>",
"      &reg;",
"     </sup>",
"    </br>",
"   </div>",
"   <div id=\"printHeaderLinks\">",
"    <a href=\"#\" id=\"printHeaderPrint\" rel=\"\" title=\"Click here to print\">",
"     Print",
"    </a>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"     Back",
"    </a>",
"   </div>",
"  </div>",
"  <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" id=\"tocTable\" width=\"100%\">",
"   <trs>",
"    <tds>",
"     <h1>",
"      Contents:",
"			Depressive disorders",
"     </h1>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds valign=\"top\">",
"     <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">",
"      <trs>",
"       <tds>",
"        <strong>",
"         Antidepressant medication",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?25/33/26135\">",
"           Antidepressant medication in adults: Switching and discontinuing medication",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?5/18/5417\">",
"           Atypical antidepressants: Pharmacology, administration, and side effects",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?42/48/43783\">",
"           Effect of antidepressants on suicide risk in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?7/25/7574\">",
"           Monoamine oxidase inhibitors (MAOIs) for treating depressed adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?5/0/5129\">",
"           Serotonin modulators: Pharmacology, administration, and side effects",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?5/28/5578\">",
"           Serotonin-norepinephrine reuptake inhibitors (SNRIs): Pharmacology, administration, and side effects",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?1/63/2039\">",
"           Sexual dysfunction associated with selective serotonin reuptake inhibitor (SSRI) antidepressants",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?30/56/31626\">",
"           Unipolar depression in adults and selective serotonin reuptake inhibitors (SSRIs): Pharmacology, administration, and side effects",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?35/20/36169\">",
"           Unipolar depression in adults and tricyclic and tetracyclic drugs: Pharmacology, administration, and side effects",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?17/3/17464\">",
"           Unipolar depression in adults: Anxiolytics",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?26/34/27175\">",
"           Unipolar depression in adults: Augmentation of antidepressants with thyroid hormone",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?9/39/9850\">",
"           Unipolar depression in adults: Continuation and maintenance treatment",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?37/53/38745\">",
"           Use of psychotropic medications in breastfeeding women",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Bipolar disorder",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?42/3/43065\">",
"           Bipolar disorder in adults and lithium: Pharmacology, administration, and side effects",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?19/11/19639\">",
"           Bipolar disorder in adults: Epidemiology and diagnosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/9/27802\">",
"           Bipolar disorder in adults: Maintenance treatment",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?43/3/44088\">",
"           Bipolar disorder in adults: Pharmacotherapy for acute depression",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?37/8/38026\">",
"           Bipolar disorder in adults: Pharmacotherapy for acute mania, mixed episodes, and hypomania",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Depression",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?4/57/5017\">",
"           Catatonia in adults: Epidemiology, clinical features, assessment, and diagnosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?42/57/43928\">",
"           Catatonia in adults: Treatment and prognosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?11/13/11481\">",
"           Clinical manifestations and diagnosis of depression",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/42/28328\">",
"           Depression in adults: Psychodynamic psychotherapy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?16/13/16601\">",
"           Depression in adults: Supportive psychotherapy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?29/2/29735\">",
"           Depression in pregnant women: Clinical features and consequences",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?28/0/28682\">",
"           Depression in pregnant women: Management",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?38/37/39514\">",
"           Diagnosis and management of late-life depression",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?17/38/18025\">",
"           Family and couples therapy for treating depressed adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?30/29/31190\">",
"           Grief and bereavement",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?39/8/40074\">",
"           Initial treatment of depression in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?17/16/17674\">",
"           Interpersonal Psychotherapy (IPT) for depressed adults: Indications, theoretical foundation, general concepts, and efficacy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?4/20/4425\">",
"           Interpersonal Psychotherapy (IPT) for depressed adults: Specific interventions and techniques",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?8/24/8584\">",
"           Mindfulness based cognitive therapy as maintenance treatment for unipolar major depression",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?40/21/41305\">",
"           Overview of electroconvulsive therapy (ECT) for adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?26/38/27242\">",
"           Overview of idiopathic environmental intolerance (multiple chemical sensitivity)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?20/11/20666\">",
"           Postpartum blues and depression",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?22/25/22936\">",
"           Seasonal affective disorder",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?10/8/10377\">",
"           Suicidal ideation and behavior in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?12/52/13128\">",
"           Technique for performing electroconvulsive therapy (ECT) in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?26/61/27609\">",
"           Treatment of resistant depression in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?36/38/37481\">",
"           Unipolar depression in adults: Epidemiology, pathogenesis, and neurobiology",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?6/30/6633\">",
"           Unipolar depression in adults: Overview of neuromodulation procedures",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?37/19/38201\">",
"           Unipolar depression in adults: Prognosis and course of illness",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?16/50/17192\">",
"           Unipolar depression in adults: Treatment with lithium",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?31/15/31993\">",
"           Unipolar depression in adults: Treatment with second-generation antipsychotics",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?4/62/5097\">",
"           Unipolar depression in adults: Treatment with surgical approaches",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?16/18/16682\">",
"           Unipolar depression in adults: Treatment with transcranial magnetic stimulation (TMS)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?40/28/41416\">",
"           Unipolar major depression in adults: Indications for and efficacy of electroconvulsive therapy (ECT)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?4/0/4105\">",
"           Unipolar major depression with psychotic features: Acute treatment",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?5/15/5368\">",
"           Unipolar major depression with psychotic features: Epidemiology, clinical features, assessment, and diagnosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?7/55/8055\">",
"           Unipolar major depression with psychotic features: Maintenance treatment and prognosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?25/26/26025\">",
"           Unipolar minor depression in adults: Epidemiology, clinical presentation, and diagnosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?34/12/35015\">",
"           Unipolar minor depression in adults: Management and treatment",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?4/40/4745\">",
"           Using scales to monitor symptoms and treatment of depression (measurement based care)",
"          </a>",
"         </li>",
"        </ul>",
"       </tds>",
"      </trs>",
"     </div>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"     <img height=\"10\" src=\"./../images/spacer.myextg\" width=\"1\"/>",
"    </tds>",
"   </trs>",
"  </div>",
"  <div id=\"footer\">",
"   <div id=\"footerNav\">",
"    <ul>",
"     <li>",
"      <a href=\"file://www.wolterskluwerhealth.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Wolters Kluwer Health",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.factsandcomparisons.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Facts &amp; Comparisons&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medispan.com\" rel=\"nofollow\" target=\"_blank\">",
"       Medi-Span&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationordersets.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Order Sets",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationmedical.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Medical",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://pharmacyonesource.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Pharmacy OneSource&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medicom.com.cn/\" rel=\"nofollow\" target=\"_blank\">",
"       Medicom",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.lexi.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Lexicomp",
"      </a>",
"     </li>",
"     <li class=\"last\">",
"      <a href=\"/home/privacy-policy\">",
"       Privacy Policy",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"   <div id=\"footerLogo\">",
"    <a href=\"./toc\">",
"     Wolters Kluwer Health | UpToDate",
"    </a>",
"   </div>",
"   <div id=\"supportFooter\">",
"    <span class=\"sfInfo\">",
"     &copy; 2013 UpToDate, Inc. All rights reserved.",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Release: 21.3 - C21.34",
"    </span>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <span class=\"sfInfo\">",
"     <a href=\"/home/terms-use\">",
"      Terms of Use",
"     </a>",
"    </span>",
"    <br/>",
"    <span class=\"sfInfo\">",
"     Licensed to:",
"     <span class=\"emphasis\">",
"      UpToDate Marketing Professional",
"     </span>",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Support Tag: [0605-95.154.198.148-DE53DA4769-14]",
"     <br/>",
"    </span>",
"   </div>",
"  </div>",
" </div>",
" <!-- rightPanel -->",
"</body>"].join("\n");
var script_f3_42_3759=[""].join("\n");
var outline_f3_42_3759=null;
